semisynthetic derivative - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	semisynthetic derivative	go back to main search page
Accession:	CHEBI:72588	browse the term
Definition:	Any organic molecular entity derived from a natural product by partial chemical synthesis.
Synonyms:	related_synonym:	semi-synthetic compound; semi-synthetic compounds; semi-synthetic derivative; semi-synthetic derivatives; semisynthetic compound; semisynthetic compounds; semisynthetic derivatives
	xref:	Wikipedia:Semisynthesis

show annotations for term's descendants Sort by:
Rat (1648) Mouse (1653) Human (1677) Chinchilla (0) Bonobo (0) Dog (3) Squirrel (0) Pig (9) Green Monkey (0) Naked Mole-rat (0) All
Genes (1648)

(E)-roxithromycin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2, apoptosis regulator

decreases expression

Roxithromycin results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases activity

Roxithromycin results in decreased activity of CYP2B6 protein

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
decreases expression
decreases activity

Roxithromycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]
Roxithromycin results in decreased expression of CYP3A4 mRNA
Roxithromycin results in decreased activity of CYP3A4 protein

PMID:16416302 PMID:16837568 PMID:17164692

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

Fas ligand

increases expression

Roxithromycin results in increased expression of FASLG protein

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Roxithromycin results in increased expression of FOS mRNA; Roxithromycin results in increased expression of FOS protein

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

interleukin 1 beta

multiple interactions

Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of IL1B mRNA]; Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of IL1B protein]
Roxithromycin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

PMID:17524151 PMID:18197913

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of IL6 mRNA]; Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit beta 4

decreases expression

Roxithromycin results in decreased expression of ITGB4 protein

NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012

G

laminin subunit gamma 2

decreases expression

Roxithromycin results in decreased expression of LAMC2 protein

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

Roxithromycin inhibits the reaction [Lipopolysaccharides results in increased expression of MUC5AC mRNA]; Roxithromycin inhibits the reaction [Lipopolysaccharides results in increased expression of MUC5AC protein]

NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475

G

nuclear factor kappa B subunit 1

multiple interactions

Roxithromycin inhibits the reaction [Diethylnitrosamine results in increased activity of [NFKB1 protein binds to RELA protein]]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 2

multiple interactions

Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of NOS2 protein]
Roxithromycin inhibits the reaction [Diethylnitrosamine results in increased activity of NOS2 protein]

PMID:16061884 PMID:17524151

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Roxithromycin inhibits the reaction [Diethylnitrosamine results in increased activity of [NFKB1 protein binds to RELA protein]]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

tumor necrosis factor

multiple interactions

Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of TNF mRNA]; Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of TNF protein]
Roxithromycin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

PMID:17524151 PMID:18197913

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

artemether

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

[Artemether co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

nuclear receptor subfamily 1, group I, member 3

affects expression
multiple interactions

artemether affects the expression of NR1I3 mRNA alternative form
[Artemether co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA; Artemether binds to and results in increased activity of NR1I3 protein alternative form

PMID:24721719 PMID:31312845

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

prolactin

increases secretion

Artemether results in increased secretion of PRL protein

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

artesunate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions
decreases expression

Deferoxamine inhibits the reaction [Artesunate results in decreased expression of ACTA2 mRNA]
Artesunate results in decreased expression of ACTA2 mRNA; Artesunate results in decreased expression of ACTA2 protein
Artesunate inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

apoptosis inducing factor, mitochondria associated 1

affects localization

artesunate affects the localization of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

androgen receptor

multiple interactions

artesunate binds to and results in decreased activity of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

autophagy related 12

increases expression

Artesunate results in increased expression of ATG12 mRNA

NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418

G

autophagy related 3

increases expression

Artesunate results in increased expression of ATG3 mRNA

NCBI chr11:55,624,914...55,653,249
Ensembl chr11:55,624,917...55,653,224

G

autophagy related 5

increases expression

Artesunate results in increased expression of ATG5 mRNA

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

Artesunate results in increased expression of BAX protein
[1,2-Dimethylhydrazine co-treated with artesunate] results in increased expression of BAX protein

PMID:24704559 PMID:29031619 PMID:33002460

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

Artesunate results in decreased expression of BCL2 protein
3-methyladenine inhibits the reaction [Artesunate results in decreased expression of BCL2 protein]; acadesine promotes the reaction [Artesunate results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [Artesunate results in decreased expression of BCL2 protein]; dorsomorphin inhibits the reaction [Artesunate results in decreased expression of BCL2 protein]; Sirolimus promotes the reaction [Artesunate results in decreased expression of BCL2 protein]
[1,2-Dimethylhydrazine co-treated with artesunate] results in decreased expression of BCL2 protein

PMID:24704559 PMID:29031619 PMID:33002460

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone marrow stromal cell antigen 1

increases response to substance

BST1 mRNA results in increased susceptibility to artesunate

NCBI chr14:67,253,706...67,270,203
Ensembl chr14:67,252,998...67,270,180

G

caspase 3

increases activity
increases cleavage
multiple interactions

artesunate results in increased activity of CASP3 protein
Artesunate results in increased cleavage of CASP3 protein
3-methyladenine inhibits the reaction [Artesunate results in increased cleavage of CASP3 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Artesunate results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Artesunate results in increased cleavage of CASP3 protein]

PMID:19513562 PMID:24704559 PMID:33002460

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

affects expression

artesunate affects the expression of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

increases expression
decreases response to substance

artesunate results in increased expression of CAT protein
CAT protein results in decreased susceptibility to artesunate

PMID:19513562 PMID:20144594

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin D1

decreases expression

Artesunate results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

decreases expression

Artesunate results in decreased expression of CCNE1 protein

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

chaperonin containing TCP1 subunit 2

decreases response to substance

CCT2 mRNA results in decreased susceptibility to artesunate

NCBI chr 7:52,692,725...52,705,478
Ensembl chr 7:52,692,725...52,706,944

G

cyclin dependent kinase 2

decreases expression

Artesunate results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression

Artesunate results in decreased expression of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

checkpoint kinase 1

multiple interactions
increases phosphorylation

APOBEC3C protein promotes the reaction [Artesunate results in increased phosphorylation of CHEK1 protein]

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

checkpoint kinase 2

multiple interactions
increases phosphorylation

APOBEC3C protein promotes the reaction [Artesunate results in increased phosphorylation of CHEK2 protein]

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

CAP-GLY domain containing linker protein family, member 4

increases response to substance

CLIP4 mRNA results in increased susceptibility to artesunate

NCBI chr 6:23,616,280...23,697,625
NCBI chr 6:23,718,580...23,729,231
NCBI chr 6:23,597,729...23,601,000
Ensembl chr 6:23,616,281...23,677,874

G

coenzyme Q8A

decreases response to substance

COQ8A mRNA results in decreased susceptibility to artesunate

NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431

G

catenin beta 1

multiple interactions

artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CTNNB1 protein]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

dopamine beta-hydroxylase

increases response to substance

DBH mRNA results in increased susceptibility to artesunate

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

desmin

multiple interactions
decreases expression

Deferoxamine inhibits the reaction [Artesunate results in decreased expression of DES mRNA]
Artesunate results in decreased expression of DES mRNA; Artesunate results in decreased expression of DES protein

NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699

G

estrogen receptor 1

multiple interactions

artesunate binds to and results in decreased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

Fas cell surface death receptor

increases expression

artesunate results in increased expression of FAS protein

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

filamin A

increases response to substance

FLNA mRNA results in increased susceptibility to artesunate

NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052

G

fibronectin 1

multiple interactions
decreases expression

Deferoxamine inhibits the reaction [Artesunate results in decreased expression of FN1 mRNA]
Artesunate results in decreased expression of FN1 mRNA; Artesunate results in decreased expression of FN1 protein

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

ferritin heavy chain 1

decreases expression
multiple interactions

Artesunate results in decreased expression of FTH1 mRNA; Artesunate results in decreased expression of FTH1 protein
Chloroquine inhibits the reaction [Artesunate results in decreased expression of FTH1 mRNA]

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

frizzled class receptor 7

increases response to substance

FZD7 mRNA results in increased susceptibility to artesunate

NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781

G

glutamate-cysteine ligase, catalytic subunit

affects response to substance
decreases response to substance

GCLC mRNA affects the susceptibility to artesunate
GCLC mRNA results in decreased susceptibility to artesunate

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

decreases response to substance

GCLM mRNA results in decreased susceptibility to artesunate

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glutathione peroxidase 4

decreases activity
multiple interactions

Artesunate results in decreased activity of GPX4 protein
Artesunate inhibits the reaction [Carbon Tetrachloride results in increased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glutathione S-transferase mu 4

affects response to substance

GSTM4 mRNA affects the susceptibility to artesunate

NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323

G

glutathione S-transferase pi 1

decreases expression

artesunate results in decreased expression of GSTP1 protein

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 2

affects response to substance

GSTT2 mRNA affects the susceptibility to artesunate

NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288

G

glutathione S-transferase zeta 1

affects response to substance

GSTZ1 mRNA affects the susceptibility to artesunate

NCBI chr 6:106,794,594...106,805,284
Ensembl chr 6:106,794,074...106,805,284

G

H2A.X variant histone

multiple interactions
increases phosphorylation

APOBEC3C protein promotes the reaction [Artesunate results in increased phosphorylation of H2AX protein]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

interleukin 1 beta

multiple interactions

Artesunate inhibits the reaction [Ethanol results in increased expression of IL1B protein]; Artesunate inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Artesunate inhibits the reaction [Glucose results in increased secretion of IL1B protein]

PMID:27474069 PMID:30031708

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Artesunate inhibits the reaction [Ethanol results in increased expression of IL6 protein]; Artesunate inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; Artesunate inhibits the reaction [Glucose results in increased secretion of IL6 protein]

PMID:27474069 PMID:30031708

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit beta 1

increases response to substance

ITGB1 mRNA results in increased susceptibility to artesunate

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases lipidation

3-methyladenine inhibits the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]; acadesine promotes the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]; Acetylcysteine inhibits the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]; dorsomorphin inhibits the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

microsomal glutathione S-transferase 3

affects response to substance

MGST3 mRNA affects the susceptibility to artesunate

NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411

G

marker of proliferation Ki-67

multiple interactions

artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of MKI67 protein]

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 9

multiple interactions
decreases expression

artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of MMP9 protein]
Chloroquine inhibits the reaction [Artesunate results in decreased expression of MMP9 mRNA]

PMID:29031619 PMID:30551460

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions

artesunate inhibits the reaction [Ethanol results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

decreases response to substance

MTHFD2 mRNA results in decreased susceptibility to artesunate

NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608

G

mechanistic target of rapamycin kinase

multiple interactions
decreases phosphorylation

acadesine promotes the reaction [Artesunate results in decreased phosphorylation of MTOR protein]; Acetylcysteine inhibits the reaction [Artesunate results in decreased phosphorylation of MTOR protein]; dorsomorphin inhibits the reaction [Artesunate results in decreased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

MYD88, innate immune signal transduction adaptor

multiple interactions

artesunate inhibits the reaction [Glucose results in increased expression of MYD88 protein]

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

nascent polypeptide associated complex subunit alpha

decreases response to substance

NACA mRNA results in decreased susceptibility to artesunate

NCBI chr 7:468,862...481,992
Ensembl chr 7:469,723...481,992

G

NCK-associated protein 1

increases response to substance

NCKAP1 mRNA results in increased susceptibility to artesunate

NCBI chr 3:65,417,450...65,491,769
Ensembl chr 3:65,417,453...65,492,217

G

nuclear receptor coactivator 4

multiple interactions
decreases expression

Chloroquine inhibits the reaction [Artesunate results in decreased expression of NCOA4 mRNA]
Artesunate results in decreased expression of NCOA4 mRNA; Artesunate results in decreased expression of NCOA4 protein

NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641
Ensembl chr16:7,366,542...7,409,641

G

NFE2 like bZIP transcription factor 2

affects localization

artesunate affects the localization of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NLR family, pyrin domain containing 3

multiple interactions

artesunate inhibits the reaction [Glucose results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

Artesunate results in increased cleavage of PARP1 protein
3-methyladenine inhibits the reaction [Artesunate results in increased cleavage of PARP1 protein]; acadesine promotes the reaction [Artesunate results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [Artesunate results in increased cleavage of PARP1 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Artesunate results in increased cleavage of PARP1 protein]; dorsomorphin inhibits the reaction [Artesunate results in increased cleavage of PARP1 protein]; Sirolimus promotes the reaction [Artesunate results in increased cleavage of PARP1 protein]

PMID:24704559 PMID:33002460

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

proliferating cell nuclear antigen

multiple interactions

artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PCNA protein]

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

progesterone receptor

multiple interactions

artesunate binds to and results in increased activity of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[Carbon Tetrachloride results in increased susceptibility to Artesunate] which results in increased expression of PTGS2 mRNA; [Carbon Tetrachloride results in increased susceptibility to Artesunate] which results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

artesunate inhibits the reaction [Ethanol results in increased expression of RELA protein]; artesunate inhibits the reaction [Glucose results in increased phosphorylation of RELA protein]

PMID:27474069 PMID:30031708

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

replication protein A2

increases phosphorylation

Artesunate results in increased phosphorylation of RPA2 protein

NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350

G

ribosomal protein L41

decreases response to substance

RPL41 mRNA results in decreased susceptibility to artesunate

NCBI chr 7:977,885...978,965

G

ribosomal protein L6

decreases response to substance

RPL6 mRNA results in decreased susceptibility to artesunate

NCBI chr12:35,347,493...35,352,011
Ensembl chr12:35,347,497...35,351,921

G

ribosomal protein L7

decreases response to substance

RPL7 mRNA results in decreased susceptibility to artesunate

NCBI chr 5:3,217,184...3,220,192

G

ribosomal protein S12

decreases response to substance

RPS12 mRNA results in decreased susceptibility to artesunate

NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014

G

ribosomal protein S15a

decreases response to substance

RPS15A mRNA results in decreased susceptibility to artesunate

NCBI chr 1:172,420,151...172,427,021
Ensembl chr 1:172,419,761...172,426,995

G

ribosomal protein S6

decreases response to substance

RPS6 mRNA results in decreased susceptibility to artesunate

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

solute carrier family 25 member 19

decreases response to substance

SLC25A19 mRNA results in decreased susceptibility to artesunate

NCBI chr10:100,853,554...100,867,517
Ensembl chr10:100,847,168...100,867,447

G

Sp1 transcription factor

decreases expression

artesunate results in decreased expression of SP1 protein

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

sequestosome 1

multiple interactions
decreases expression

Chloroquine inhibits the reaction [Artesunate results in decreased expression of SQSTM1 protein]
Artesunate results in decreased expression of SQSTM1 mRNA; Artesunate results in decreased expression of SQSTM1 protein

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

serine and arginine rich splicing factor 2

decreases response to substance

SRSF2 mRNA results in decreased susceptibility to artesunate

NCBI chr10:102,052,158...102,055,365
Ensembl chr10:102,052,314...102,055,338

G

TIMP metallopeptidase inhibitor 1

increases expression
multiple interactions

Artesunate results in increased expression of TIMP1 mRNA
Chloroquine inhibits the reaction [Artesunate results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

toll-like receptor 4

multiple interactions

artesunate inhibits the reaction [Glucose results in increased expression of TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

artesunate inhibits the reaction [Ethanol results in increased expression of TNF protein]; artesunate inhibits the reaction [Glucose results in increased expression of TNF mRNA]; artesunate inhibits the reaction [Glucose results in increased secretion of TNF protein]

PMID:27474069 PMID:30031708

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

increases expression
multiple interactions

Artesunate results in increased expression of TP53 protein
Artesunate inhibits the reaction [TPT1 protein binds to TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein, translationally-controlled 1

affects response to substance
multiple interactions

TPT1 protein affects the susceptibility to artesunate
Artesunate binds to and results in decreased expression of TPT1 protein; Artesunate inhibits the reaction [TPT1 protein binds to TP53 protein]

PMID:15878303 PMID:33259807

NCBI chr15:51,156,728...51,159,629
Ensembl chr15:51,146,154...51,159,625

G

Tu translation elongation factor, mitochondrial

decreases response to substance

TUFM mRNA results in decreased susceptibility to artesunate

NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395

G

unc-51 like autophagy activating kinase 1

increases phosphorylation
multiple interactions

Artesunate results in increased phosphorylation of ULK1 protein
acadesine promotes the reaction [Artesunate results in increased phosphorylation of ULK1 protein]; Acetylcysteine inhibits the reaction [Artesunate results in increased phosphorylation of ULK1 protein]; dorsomorphin inhibits the reaction [Artesunate results in increased phosphorylation of ULK1 protein]

NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966

G

vascular endothelial growth factor A

multiple interactions

artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

YY1 transcription factor

decreases expression

artesunate results in decreased expression of YY1 protein

NCBI chr 6:127,706,739...127,736,499
Ensembl chr 6:127,707,596...127,732,747

G

zinc finger and BTB domain containing 4

increases response to substance

ZBTB4 mRNA results in increased susceptibility to artesunate

NCBI chr10:54,480,698...54,501,492
Ensembl chr10:54,485,071...54,501,492

caspofungin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

histamine N-methyltransferase

decreases activity

caspofungin results in decreased activity of HNMT protein

NCBI chr 3:6,591,804...6,623,821
Ensembl chr 3:6,591,463...6,624,012

cefaloridine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylacetamide deacetylase

increases expression

Cephaloridine results in increased expression of AADAC mRNA

NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734

G

aminoadipate-semialdehyde synthase

decreases expression

Cephaloridine results in decreased expression of AASS mRNA

NCBI chr 4:51,606,461...51,663,136
Ensembl chr 4:51,606,462...51,663,136

G

ATP-binding cassette, sub-family B member 1B

increases expression

Cephaloridine results in increased expression of ABCB1B mRNA

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily C member 2

increases expression

Cephaloridine results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

aminocarboxymuconate semialdehyde decarboxylase

decreases expression

Cephaloridine results in decreased expression of ACMSD mRNA

NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209

G

acyl-CoA thioesterase 9

increases expression

Cephaloridine results in increased expression of ACOT9 mRNA

NCBI chr X:40,073,197...40,123,573
Ensembl chr X:40,064,810...40,123,559

G

acyl-CoA synthetase medium-chain family member 5

decreases expression

Cephaloridine results in decreased expression of ACSM5 mRNA

NCBI chr 1:173,870,873...173,896,838
Ensembl chr 1:173,863,041...173,898,588

G

ADAM metallopeptidase domain 8

decreases expression

Cephaloridine results in decreased expression of ADAM8 mRNA

NCBI chr 1:194,776,559...194,789,330
Ensembl chr 1:194,770,060...194,788,801

G

adhesion G protein-coupled receptor E1

increases expression

Cephaloridine results in increased expression of ADGRE1 mRNA

NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000

G

adenosine A2a receptor

increases expression

Cephaloridine results in increased expression of ADORA2A mRNA

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

adrenoceptor alpha 1D

increases expression

Cephaloridine results in increased expression of ADRA1D mRNA

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

aftiphilin

decreases expression

Cephaloridine results in decreased expression of AFTPH mRNA

NCBI chr14:94,871,429...94,925,625
Ensembl chr14:94,871,429...94,925,376

G

aldo-keto reductase family 1 member B1

increases expression

Cephaloridine results in increased expression of AKR1B1 mRNA

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1, member D1

increases expression

Cephaloridine results in increased expression of AKR1D1 mRNA

NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372

G

5'-aminolevulinate synthase 1

increases expression

Cephaloridine results in increased expression of ALAS1 mRNA

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

aldehyde dehydrogenase 3 family, member A1

increases expression

Cephaloridine results in increased expression of ALDH3A1 mRNA

NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681

G

aldehyde dehydrogenase 3 family, member B1

increases expression

Cephaloridine results in increased expression of ALDH3B1 mRNA

NCBI chr 1:201,145,309...201,162,675
Ensembl chr 1:201,145,309...201,163,921

G

aldolase, fructose-bisphosphate A

affects expression

Cephaloridine affects the expression of ALDOA mRNA

NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182

G

APC membrane recruitment protein 2

decreases expression

Cephaloridine results in decreased expression of AMER2 mRNA

NCBI chr15:34,525,352...34,535,660
Ensembl chr15:34,524,542...34,528,455

G

adhesion molecule with Ig like domain 2

increases expression

Cephaloridine results in increased expression of AMIGO2 mRNA

NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695

G

adenosine monophosphate deaminase 1

increases expression

Cephaloridine results in increased expression of AMPD1 mRNA

NCBI chr 2:190,598,707...190,619,938
Ensembl chr 2:190,598,700...190,619,938

G

adenosine monophosphate deaminase 3

increases expression

Cephaloridine results in increased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887

G

angiopoietin-like 4

increases expression

Cephaloridine results in increased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

anillin, actin binding protein

decreases expression

Cephaloridine results in decreased expression of ANLN mRNA

NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538

G

annexin A13

decreases expression

Cephaloridine results in decreased expression of ANXA13 mRNA

NCBI chr 7:89,884,356...89,936,907
Ensembl chr 7:89,884,356...89,936,907

G

annexin A7

increases expression

Cephaloridine results in increased expression of ANXA7 mRNA

NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385

G

amyloid P component, serum

decreases expression

Cephaloridine results in decreased expression of APCS mRNA

NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298

G

apolipoprotein A4

increases expression

Cephaloridine results in increased expression of APOA4 mRNA

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein B

increases expression

Cephaloridine results in increased expression of APOB mRNA

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C2

increases expression

Cephaloridine results in increased expression of APOC2 mRNA

NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476

G

apolipoprotein L domain containing 1

decreases expression

Cephaloridine results in decreased expression of APOLD1 mRNA

NCBI chr 4:167,768,437...167,825,706
Ensembl chr 4:167,818,271...167,825,706

G

ARFGEF family member 3

decreases expression

Cephaloridine results in decreased expression of ARFGEF3 mRNA

NCBI chr 1:13,245,578...13,404,319
Ensembl chr 1:13,244,830...13,404,084

G

Rho GTPase activating protein 35

decreases expression

Cephaloridine results in decreased expression of ARHGAP35 mRNA

NCBI chr 1:77,202,436...77,319,298
Ensembl chr 1:77,202,436...77,319,298

G

AT-rich interaction domain 5A

increases expression

Cephaloridine results in increased expression of ARID5A mRNA

NCBI chr 9:38,534,612...38,549,467
Ensembl chr 9:38,534,590...38,547,597

G

anti-silencing function 1B histone chaperone

increases expression

Cephaloridine results in increased expression of ASF1B mRNA

NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549

G

ASH1 like histone lysine methyltransferase

decreases expression

Cephaloridine results in decreased expression of ASH1L mRNA

NCBI chr 2:174,346,267...174,483,057
Ensembl chr 2:174,346,150...174,483,055

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

Cephaloridine results in increased expression of ASNS mRNA

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

ATPase family, AAA domain containing 1

increases expression

Cephaloridine results in increased expression of ATAD1 mRNA

NCBI chr 1:230,544,227...230,610,524
Ensembl chr 1:230,544,047...230,596,548

G

ATPase family, AAA domain containing 2

increases expression

Cephaloridine results in increased expression of ATAD2 mRNA

NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738

G

activating transcription factor 3

decreases expression

Cephaloridine results in decreased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

atlastin GTPase 1

increases expression

Cephaloridine results in increased expression of ATL1 mRNA

NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204

G

ATPase phospholipid transporting 11C

decreases expression

Cephaloridine results in decreased expression of ATP11C mRNA

NCBI chr X:138,564,459...138,752,116
Ensembl chr X:138,565,836...138,751,204

G

ATPase H+/K+ transporting non-gastric alpha2 subunit

increases expression

Cephaloridine results in increased expression of ATP12A mRNA

NCBI chr15:30,443,571...30,468,229
Ensembl chr15:30,443,571...30,468,229

G

aurora kinase B

decreases expression

Cephaloridine results in decreased expression of AURKB mRNA

NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837

G

Beta-1,3-galactosyltransferase 2

decreases expression

Cephaloridine results in decreased expression of B3GALT2 mRNA

NCBI chr13:55,389,406...55,398,419
Ensembl chr13:55,389,406...55,398,419

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7

decreases expression

Cephaloridine results in decreased expression of B3GNT7 mRNA

NCBI chr 9:86,956,220...86,960,171
Ensembl chr 9:86,956,220...86,960,170

G

BAG cochaperone 3

increases expression

Cephaloridine results in increased expression of BAG3 mRNA

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

BCL2-antagonist/killer 1

increases expression

Cephaloridine results in increased expression of BAK1 mRNA

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BRCA1 associated RING domain 1

increases expression

Cephaloridine results in increased expression of BARD1 mRNA

NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265

G

basic leucine zipper ATF-like transcription factor

increases expression

Cephaloridine results in increased expression of BATF mRNA

NCBI chr 6:105,353,715...105,376,051
Ensembl chr 6:105,353,715...105,376,051

G

Bcl2-like 1

affects expression

Cephaloridine affects the expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

brain expressed X-linked 2

increases expression

Cephaloridine results in increased expression of BEX1 mRNA

NCBI chr X:99,019,847...99,021,375
Ensembl chr X:99,019,000...99,021,503

G

brain expressed, X-linked 4

increases expression

Cephaloridine results in increased expression of BEX4 mRNA

NCBI chr X:99,131,985...99,133,417
Ensembl chr X:99,131,942...99,133,531

G

basic helix-loop-helix family, member e41

increases expression

Cephaloridine results in increased expression of BHLHE41 mRNA

NCBI chr 4:178,834,264...178,838,618
Ensembl chr 4:178,834,271...178,838,468

G

baculoviral IAP repeat-containing 3

increases expression

Cephaloridine results in increased expression of BIRC3 mRNA

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

biliverdin reductase B

increases expression

Cephaloridine results in increased expression of BLVRB mRNA

NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375

G

bactericidal/permeability-increasing protein

increases expression

Cephaloridine results in increased expression of BPI mRNA

NCBI chr 3:146,909,626...146,936,487
Ensembl chr 3:146,909,629...146,936,221

G

BRCA1 interacting DNA helicase 1

increases expression

Cephaloridine results in increased expression of BRIP1 mRNA

NCBI chr10:70,907,266...71,031,502
Ensembl chr10:70,907,371...71,030,324

G

barttin CLCNK type accessory subunit beta

increases expression

Cephaloridine results in increased expression of BSND mRNA

NCBI chr 5:121,251,774...121,260,571
Ensembl chr 5:121,251,774...121,260,571

G

BTG anti-proliferation factor 2

decreases expression

Cephaloridine results in decreased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

BUB1 mitotic checkpoint serine/threonine kinase B

decreases expression

Cephaloridine results in decreased expression of BUB1B mRNA

NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547

G

similar to human chromosome 16 open reading frame 89

increases expression

Cephaloridine results in increased expression of C10H16ORF89 mRNA

NCBI chr10:10,361,909...10,371,046
Ensembl chr10:10,361,948...10,371,046

G

C1q and TNF related 1

increases expression

Cephaloridine results in increased expression of C1QTNF1 mRNA

NCBI chr10:103,660,319...103,681,662
Ensembl chr10:103,660,327...103,681,660

G

complement C5

decreases expression

Cephaloridine results in decreased expression of C5 mRNA

NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994

G

complement C6

increases expression

Cephaloridine results in increased expression of C6 mRNA

NCBI chr 2:53,846,028...53,921,279
Ensembl chr 2:53,851,985...53,921,275

G

calcium voltage-gated channel subunit alpha1 H

increases expression

Cephaloridine results in increased expression of CACNA1H mRNA

NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376

G

calcium voltage-gated channel auxiliary subunit gamma 3

increases expression

Cephaloridine results in increased expression of CACNG3 mRNA

NCBI chr 1:177,201,361...177,297,019
Ensembl chr 1:177,201,288...177,297,024

G

calbindin 1

increases expression

Cephaloridine results in increased expression of CALB1 mRNA

NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431

G

calbindin 2

decreases expression

Cephaloridine results in decreased expression of CALB2 mRNA

NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438

G

calreticulin

increases expression

Cephaloridine results in increased expression of CALR mRNA

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

CaM kinase-like vesicle-associated

increases expression

Cephaloridine results in increased expression of CAMKV mRNA

NCBI chr 8:108,626,821...108,641,169
Ensembl chr 8:108,626,821...108,641,169

G

calnexin

increases expression

Cephaloridine results in increased expression of CANX mRNA

NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821

G

catalase

affects expression

Cephaloridine affects the expression of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil domain containing 113

increases expression

Cephaloridine results in increased expression of CCDC113 mRNA

NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923

G

C-C motif chemokine ligand 17

increases expression

Cephaloridine results in increased expression of CCL17 mRNA

NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819

G

C-C motif chemokine ligand 19

increases expression

Cephaloridine results in increased expression of CCL19 mRNA

NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308

G

C-C motif chemokine ligand 20

increases expression

Cephaloridine results in increased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 28

increases expression

Cephaloridine results in increased expression of CCL28 mRNA

NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997

G

C-C motif chemokine ligand 3

decreases expression

Cephaloridine results in decreased expression of CCL3 mRNA

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

decreases expression

Cephaloridine results in decreased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

cellular communication network factor 2

decreases expression

Cephaloridine results in decreased expression of CCN2 mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin A2

decreases expression

Cephaloridine results in decreased expression of CCNA2 mRNA

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

decreases expression

Cephaloridine results in decreased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin B2

decreases expression

Cephaloridine results in decreased expression of CCNB2 mRNA

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

cyclin E1

increases expression

Cephaloridine results in increased expression of CCNE1 mRNA

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin E2

increases expression

Cephaloridine results in increased expression of CCNE2 mRNA

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

CD52 molecule

decreases expression

Cephaloridine results in decreased expression of CD52 mRNA

NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348

G

Cd72 molecule

increases expression

Cephaloridine results in increased expression of CD72 mRNA

NCBI chr 5:57,697,361...57,704,980
Ensembl chr 5:57,697,367...57,704,725

G

CD86 molecule

increases expression

Cephaloridine results in increased expression of CD86 mRNA

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cell division cycle 42

decreases expression

Cephaloridine results in decreased expression of CDC42 mRNA

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

cell division cycle 45

increases expression

Cephaloridine results in increased expression of CDC45 mRNA

NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619

G

cell division cycle 6

increases expression

Cephaloridine results in increased expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cell division cycle associated 2

decreases expression

Cephaloridine results in decreased expression of CDCA2 mRNA

NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611

G

cyclin-dependent kinase 1

decreases expression

Cephaloridine results in decreased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase like 1

decreases expression

Cephaloridine results in decreased expression of CDKL1 mRNA

NCBI chr 6:88,224,154...88,273,434
Ensembl chr 6:88,224,143...88,270,276

G

cyclin-dependent kinase inhibitor 1A

decreases expression

Cephaloridine results in decreased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

decreases expression

Cephaloridine results in decreased expression of CDKN1B mRNA

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

chromatin licensing and DNA replication factor 1

increases expression

Cephaloridine results in increased expression of CDT1 mRNA

NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659

G

CEA cell adhesion molecule 16, tectorial membrane component

increases expression

Cephaloridine results in increased expression of CEACAM16 mRNA

NCBI chr 1:79,514,975...79,524,871
Ensembl chr 1:79,514,975...79,524,871

G

centromere protein K

increases expression

Cephaloridine results in increased expression of CENPK mRNA

NCBI chr 2:35,360,390...35,421,372
Ensembl chr 2:35,360,132...35,385,706

G

centromere protein Q

increases expression

Cephaloridine results in increased expression of CENPQ mRNA

NCBI chr 9:19,957,122...19,972,807
Ensembl chr 9:19,957,048...19,972,789

G

carboxylesterase-like 1

decreases expression

Cephaloridine results in decreased expression of CESL1 mRNA

NCBI chr19:22,670,709...23,006,329
Ensembl chr19:22,670,712...22,712,608

G

chromatin assembly factor 1 subunit A

increases expression

Cephaloridine results in increased expression of CHAF1A mRNA

NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654

G

chromatin assembly factor 1 subunit B

increases expression

Cephaloridine results in increased expression of CHAF1B mRNA

NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070

G

chromodomain helicase DNA binding protein 4

decreases expression

Cephaloridine results in decreased expression of CHD4 mRNA

NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541

G

chromodomain helicase DNA binding protein 6

decreases expression

Cephaloridine results in decreased expression of CHD6 mRNA

NCBI chr 3:149,596,509...149,757,765
Ensembl chr 3:149,596,509...149,757,755

G

checkpoint kinase 1

increases expression

Cephaloridine results in increased expression of CHEK1 mRNA

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

carbohydrate sulfotransferase 7

decreases expression

Cephaloridine results in decreased expression of CHST7 mRNA

NCBI chr X:2,396,260...2,432,828
Ensembl chr X:2,393,874...2,432,840

G

chromosome transmission fidelity factor 18

increases expression

Cephaloridine results in increased expression of CHTF18 mRNA

NCBI chr10:14,743,006...14,751,044
Ensembl chr10:14,742,621...14,751,050

G

cartilage intermediate layer protein

decreases expression

Cephaloridine results in decreased expression of CILP mRNA

NCBI chr 8:65,777,281...65,792,251
Ensembl chr 8:65,777,281...65,792,251

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

increases expression

Cephaloridine results in increased expression of CITED2 mRNA

NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897

G

cytoskeleton associated protein 2

decreases expression

Cephaloridine results in decreased expression of CKAP2 mRNA

NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913

G

claudin 14

increases expression

Cephaloridine results in increased expression of CLDN14 mRNA

NCBI chr11:33,232,281...33,329,440
Ensembl chr11:33,232,220...33,329,171

G

calsyntenin 2

decreases expression

Cephaloridine results in decreased expression of CLSTN2 mRNA

NCBI chr 8:98,020,406...98,637,232
Ensembl chr 8:98,021,666...98,637,731

G

c-Maf-inducing protein

decreases expression

Cephaloridine results in decreased expression of CMIP mRNA

NCBI chr19:45,304,597...45,510,653
Ensembl chr19:45,304,031...45,508,709

G

carnosine dipeptidase 1

decreases expression

Cephaloridine results in decreased expression of CNDP1 mRNA

NCBI chr18:77,984,886...78,030,837
Ensembl chr18:77,984,907...78,007,765

G

collagen type IV alpha 4 chain

decreases expression

Cephaloridine results in decreased expression of COL4A4 mRNA

NCBI chr 9:83,833,173...83,875,436
Ensembl chr 9:83,755,515...83,875,876

G

collagen type VII alpha 1 chain

increases expression

Cephaloridine results in increased expression of COL7A1 mRNA

NCBI chr 8:109,604,877...109,637,249
Ensembl chr 8:109,604,861...109,637,252

G

carnitine palmitoyltransferase 1B

increases expression

Cephaloridine results in increased expression of CPT1B mRNA

NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404

G

cellular retinoic acid binding protein 1

increases expression

Cephaloridine results in increased expression of CRABP1 mRNA

NCBI chr 8:55,138,363...55,159,360
Ensembl chr 8:55,151,285...55,159,360

G

CREB binding protein

decreases expression

Cephaloridine results in decreased expression of CREBBP mRNA

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

cryptochrome circadian regulator 1

increases expression

Cephaloridine results in increased expression of CRY1 mRNA

NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091

G

C-X-C motif chemokine ligand 1

decreases expression

Cephaloridine results in decreased expression of CXCL1 mRNA

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 10

increases expression

Cephaloridine results in increased expression of CXCL10 mRNA

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 13

increases expression

Cephaloridine results in increased expression of CXCL13 mRNA

NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933

G

C-X-C motif chemokine ligand 14

increases expression

Cephaloridine results in increased expression of CXCL14 mRNA

NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839

G

CXXC finger protein 4

decreases expression

Cephaloridine results in decreased expression of CXXC4 mRNA

NCBI chr 2:222,664,148...222,689,365
Ensembl chr 2:222,664,771...222,689,365

G

cytochrome b5 type A

increases expression

Cephaloridine results in increased expression of CYB5A mRNA

NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression

Cephaloridine results in increased expression of CYP1B1 mRNA

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 24, subfamily a, polypeptide 1

decreases expression

Cephaloridine results in decreased expression of CYP24A1 mRNA

NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383

G

cytochrome P450, subfamily 2, polypeptide 11

decreases expression

Cephaloridine results in decreased expression of CYP2C mRNA

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450 family 7 subfamily B member 1

increases expression

Cephaloridine results in increased expression of CYP7B1 mRNA

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

dCTP pyrophosphatase 1

increases expression

Cephaloridine results in increased expression of DCTPP1 mRNA

NCBI chr 1:181,877,440...181,880,833
Ensembl chr 1:181,877,437...181,880,839

G

dCTP pyrophosphatase 1, pseudogene 2

increases expression

Cephaloridine results in increased expression of DCTPP1-PS2 mRNA

NCBI chr16:1,392,967...1,393,868

G

dopa decarboxylase

decreases expression

Cephaloridine results in decreased expression of DDC mRNA

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

DNA-damage-inducible transcript 4

decreases expression

Cephaloridine results in decreased expression of DDIT4 mRNA

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

DNA-damage-inducible transcript 4-like

increases expression

Cephaloridine results in increased expression of DDIT4L mRNA

NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375

G

DExD-box helicase 39A

increases expression

Cephaloridine results in increased expression of DDX39A mRNA

NCBI chr19:24,418,743...24,427,422
Ensembl chr19:24,418,114...24,426,954

G

DEAD-box helicase 6

decreases expression

Cephaloridine results in decreased expression of DDX6 mRNA

NCBI chr 8:44,931,127...44,967,773
Ensembl chr 8:44,931,974...44,964,405

G

2,4-dienoyl-CoA reductase 2

decreases expression

Cephaloridine results in decreased expression of DECR2 mRNA

NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479

G

dehydrogenase/reductase member 2 like 1

increases expression

Cephaloridine results in increased expression of DHRS2L1 mRNA

NCBI chr15:28,635,197...28,638,087
Ensembl chr15:28,635,197...28,638,087

G

DLG associated protein 1

increases expression

Cephaloridine results in increased expression of DLGAP1 mRNA

NCBI chr 9:109,857,500...110,726,817
Ensembl chr 9:110,167,448...110,726,817

G

dynein, axonemal, heavy chain 7

decreases expression

Cephaloridine results in decreased expression of DNAH7 mRNA

NCBI chr 9:54,960,235...55,266,529
Ensembl chr 9:54,960,440...55,262,297

G

dynein, axonemal, heavy chain 9

decreases expression

Cephaloridine results in decreased expression of DNAH9 mRNA

NCBI chr10:50,496,174...50,864,909
Ensembl chr10:50,497,688...50,864,949

G

deoxyribonuclease 1L3

increases expression

Cephaloridine results in increased expression of DNASE1L3 mRNA

NCBI chr15:16,922,335...16,948,322
Ensembl chr15:16,922,335...16,948,317

G

2'-deoxynucleoside 5'-phosphate N-hydrolase 1

increases expression

Cephaloridine results in increased expression of DNPH1 mRNA

NCBI chr 9:14,481,296...14,484,034
Ensembl chr 9:14,481,066...14,484,022

G

DNA replication fork stabilization factor DONSON

increases expression

Cephaloridine results in increased expression of DONSON mRNA

NCBI chr11:30,919,834...30,933,150
Ensembl chr11:30,923,239...30,932,889

G

double PHD fingers 1

increases expression

Cephaloridine results in increased expression of DPF1 mRNA

NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950

G

DNA replication and sister chromatid cohesion 1

increases expression

Cephaloridine results in increased expression of DSCC1 mRNA

NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212

G

desmoglein 2

increases expression

Cephaloridine results in increased expression of DSG2 mRNA

NCBI chr18:11,846,207...11,904,630
Ensembl chr18:11,846,183...11,904,156

G

deltex E3 ubiquitin ligase 4

increases expression

Cephaloridine results in increased expression of DTX4 mRNA

NCBI chr 1:209,457,719...209,545,163
Ensembl chr 1:209,460,735...209,492,818

G

dual specificity phosphatase 6

affects expression

Cephaloridine affects the expression of DUSP6 mRNA

NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185

G

dual specificity phosphatase 7

decreases expression

Cephaloridine results in decreased expression of DUSP7 mRNA

NCBI chr 8:107,009,369...107,016,404
Ensembl chr 8:107,008,528...107,016,404

G

dual specificity phosphatase 9

increases expression

Cephaloridine results in increased expression of DUSP9 mRNA

NCBI chr X:151,351,897...151,355,822
Ensembl chr X:151,351,897...151,355,821

G

E2F transcription factor 8

increases expression

Cephaloridine results in increased expression of E2F8 mRNA

NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098

G

erythroid differentiation regulatory factor 1

decreases expression

Cephaloridine results in decreased expression of EDRF1 mRNA

NCBI chr 1:188,441,514...188,478,743
Ensembl chr 1:188,441,634...188,478,701

G

eukaryotic translation elongation factor 2

increases expression

Cephaloridine results in increased expression of EEF2 mRNA

NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183

G

early growth response 1

decreases expression

Cephaloridine results in decreased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 2

decreases expression

Cephaloridine results in decreased expression of EGR2 mRNA

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

eukaryotic translation initiation factor 4H

increases expression

Cephaloridine results in increased expression of EIF4H mRNA

NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876

G

E74 like ETS transcription factor 3

increases expression

Cephaloridine results in increased expression of ELF3 mRNA

NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481

G

embigin

increases expression

Cephaloridine results in increased expression of EMB mRNA

NCBI chr 2:49,070,509...49,125,042
Ensembl chr 2:49,069,087...49,125,050

G

essential meiotic structure-specific endonuclease 1

decreases expression

Cephaloridine results in decreased expression of EME1 mRNA

NCBI chr10:79,586,718...79,595,515
Ensembl chr10:79,586,729...79,595,435

G

ectodermal-neural cortex 1

increases expression

Cephaloridine results in increased expression of ENC1 mRNA

NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713

G

enolase 2

increases expression

Cephaloridine results in increased expression of ENO2 mRNA

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

endosomal transmembrane epsin interactor 1

increases expression

Cephaloridine results in increased expression of ENTREP1 mRNA

NCBI chr 1:221,592,500...221,646,603
Ensembl chr 1:221,592,503...221,646,758

G

extra spindle pole bodies like 1, separase

decreases expression

Cephaloridine results in decreased expression of ESPL1 mRNA

NCBI chr 7:133,424,027...133,450,984
Ensembl chr 7:133,424,130...133,450,984

G

exonuclease 1

increases expression

Cephaloridine results in increased expression of EXO1 mRNA

NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654

G

coagulation factor XIII B chain

decreases expression

Cephaloridine results in decreased expression of F13B mRNA

NCBI chr13:51,130,908...51,156,383
Ensembl chr13:51,130,920...51,156,381

G

FAM111 trypsin like peptidase A

decreases expression

Cephaloridine results in decreased expression of FAM111A mRNA

NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547

G

FA complementation group D2

increases expression

Cephaloridine results in increased expression of FANCD2 mRNA

NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412

G

fibulin 1

increases expression

Cephaloridine results in increased expression of FBLN1 mRNA

NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075

G

fructose-bisphosphatase 2

increases expression

Cephaloridine results in increased expression of FBP2 mRNA

NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698

G

F-box protein 5

increases expression

Cephaloridine results in increased expression of FBXO5 mRNA

NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437

G

Fc gamma receptor 2A

increases expression

Cephaloridine results in increased expression of FCGR2A mRNA

NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967

G

Fc gamma receptor 2B

increases expression

Cephaloridine results in increased expression of FCGR2B mRNA

NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778

G

Fc gamma receptor 3A

increases expression

Cephaloridine results in increased expression of FCGR3A mRNA

NCBI chr13:83,249,905...83,259,921
Ensembl chr13:83,249,872...83,259,921

G

ficolin B

increases expression

Cephaloridine results in increased expression of FCNB mRNA

NCBI chr 3:11,393,713...11,402,198
Ensembl chr 3:11,393,739...11,402,151

G

flap structure-specific endonuclease 1

increases expression

Cephaloridine results in increased expression of FEN1 mRNA

NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003

G

fibrinogen beta chain

increases expression

Cephaloridine results in increased expression of FGB mRNA

NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979

G

fibroblast growth factor 17

increases expression

Cephaloridine results in increased expression of FGF17 mRNA

NCBI chr15:45,711,498...45,717,622
Ensembl chr15:45,711,998...45,717,063

G

fibrinogen-like 2

increases expression

Cephaloridine results in increased expression of FGL2 mRNA

NCBI chr 4:13,710,566...13,716,207
Ensembl chr 4:13,710,575...13,716,207

G

FH2 domain containing 1

increases expression

Cephaloridine results in increased expression of FHDC1 mRNA

NCBI chr 2:169,790,917...169,829,580
Ensembl chr 2:169,790,947...169,827,896

G

filamin A interacting protein 1

decreases expression

Cephaloridine results in decreased expression of FILIP1 mRNA

NCBI chr 8:80,761,283...80,956,556
Ensembl chr 8:80,764,604...80,922,549

G

folate hydrolase 1

decreases expression

Cephaloridine results in decreased expression of FOLH1 mRNA

NCBI chr 1:140,428,101...140,501,563
Ensembl chr 1:140,428,101...140,501,379

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression

Cephaloridine results in decreased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box E1

decreases expression

Cephaloridine results in decreased expression of FOXE1 mRNA

NCBI chr 5:60,630,027...60,632,835
Ensembl chr 5:60,630,027...60,632,835

G

forkhead box Q1

increases expression

Cephaloridine results in increased expression of FOXQ1 mRNA

NCBI chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377

G

FYVE and coiled-coil domain autophagy adaptor 1

decreases expression

Cephaloridine results in decreased expression of FYCO1 mRNA

NCBI chr 8:123,412,105...123,479,315
Ensembl chr 8:123,412,112...123,479,021

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

Cephaloridine results in decreased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glucose-6-phosphate dehydrogenase

increases expression

Cephaloridine results in increased expression of G6PD mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

growth arrest and DNA-damage-inducible, alpha

increases expression

Cephaloridine results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

polypeptide N-acetylgalactosaminyltransferase 13

increases expression

Cephaloridine results in increased expression of GALNT13 mRNA

NCBI chr 3:38,903,695...39,560,683
Ensembl chr 3:38,974,490...39,558,803

G

glucosidase, alpha; neutral C

decreases expression

Cephaloridine results in decreased expression of GANC mRNA

NCBI chr 3:107,353,369...107,406,104
Ensembl chr 3:107,353,369...107,405,241

G

golgi associated RAB2 interactor family member 4

increases expression

Cephaloridine results in increased expression of GARIN4 mRNA

NCBI chr13:102,742,988...102,745,168
Ensembl chr13:102,742,988...102,745,168

G

glucosylceramidase beta 3

decreases expression

Cephaloridine results in decreased expression of GBA3 mRNA

NCBI chr14:60,574,974...60,721,411
Ensembl chr14:60,574,976...60,721,653

G

guanine deaminase

increases expression

Cephaloridine results in increased expression of GDA mRNA

NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416

G

growth differentiation factor 15

decreases expression

Cephaloridine results in decreased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

GDNF family receptor alpha 2

decreases expression

Cephaloridine results in decreased expression of GFRA2 mRNA

NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714

G

GINS complex subunit 2

increases expression

Cephaloridine results in increased expression of GINS2 mRNA

NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339

G

GINS complex subunit 4

increases expression

Cephaloridine results in increased expression of GINS4 mRNA

NCBI chr16:68,787,572...68,799,938
Ensembl chr16:68,767,339...68,802,273

G

geminin, DNA replication inhibitor

increases expression

Cephaloridine results in increased expression of GMNN mRNA

NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054

G

G protein subunit alpha 14

increases expression

Cephaloridine results in increased expression of GNA14 mRNA

NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423

G

glycoprotein nmb

increases expression

Cephaloridine results in increased expression of GPNMB mRNA

NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367

G

G protein-coupled receptor 135

decreases expression

Cephaloridine results in decreased expression of GPR135 mRNA

NCBI chr 6:90,627,533...90,630,661
Ensembl chr 6:90,629,178...90,630,551

G

G protein-coupled receptor 19

increases expression

Cephaloridine results in increased expression of GPR19 mRNA

NCBI chr 4:167,710,944...167,739,232
Ensembl chr 4:167,710,666...167,741,036

G

glutathione peroxidase 2

increases expression

Cephaloridine results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutamate ionotropic receptor AMPA type subunit 3

decreases expression

Cephaloridine results in decreased expression of GRIA3 mRNA

NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096

G

glutathione-disulfide reductase

increases expression

Cephaloridine results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 2

increases expression

Cephaloridine results in increased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase alpha 5

increases expression

Cephaloridine results in increased expression of GSTA5 mRNA

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

glutathione S-transferase mu 1

increases expression

Cephaloridine results in increased expression of GSTM1 mRNA

PMID:18172885 PMID:18500788

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase pi 1

increases expression

Cephaloridine results in increased expression of GSTP1 mRNA

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glucoside xylosyltransferase 1

decreases expression

Cephaloridine results in decreased expression of GXYLT1 mRNA

NCBI chr 7:124,400,896...124,434,682
Ensembl chr 7:124,400,896...124,434,699

G

H1.1 linker histone, cluster member

increases expression

Cephaloridine results in increased expression of H1F1 mRNA

NCBI chr17:41,366,268...41,367,011
Ensembl chr17:41,366,268...41,367,011

G

hydroxyacyl-CoA dehydrogenase

decreases expression

Cephaloridine results in decreased expression of HADH mRNA

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

HAUS augmin-like complex, subunit 8

increases expression

Cephaloridine results in increased expression of HAUS8 mRNA

NCBI chr16:17,930,819...17,945,254
Ensembl chr16:17,930,820...17,945,237

G

hepatitis A virus cellular receptor 1

increases expression

Cephaloridine results in increased expression of HAVCR1 mRNA

PMID:18500788 PMID:20305092

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

HCK proto-oncogene, Src family tyrosine kinase

increases expression

Cephaloridine results in increased expression of HCK mRNA

NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693

G

heme binding protein 1

increases expression

Cephaloridine results in increased expression of HEBP1 mRNA

NCBI chr 4:167,974,316...168,003,854
Ensembl chr 4:167,974,319...168,003,854

G

heme binding protein 2

increases expression

Cephaloridine results in increased expression of HEBP2 mRNA

NCBI chr 1:13,194,982...13,201,777
Ensembl chr 1:13,194,982...13,201,777

G

helicase, lymphoid specific

increases expression

Cephaloridine results in increased expression of HELLS mRNA

NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844

G

HEPACAM family member 2

increases expression

Cephaloridine results in increased expression of HEPACAM2 mRNA

NCBI chr 4:31,446,195...31,480,859
Ensembl chr 4:31,446,169...31,480,953

G

hemojuvelin BMP co-receptor

decreases expression

Cephaloridine results in decreased expression of HJV mRNA

NCBI chr 2:184,065,944...184,069,851
Ensembl chr 2:184,065,970...184,069,850

G

H2.0-like homeobox

decreases expression

Cephaloridine results in decreased expression of HLX mRNA

NCBI chr13:96,280,335...96,285,750
Ensembl chr13:96,280,339...96,285,750

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

decreases expression

Cephaloridine results in decreased expression of HMGCS2 mRNA

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

increases expression

Cephaloridine results in increased expression of HMOX1 mRNA

PMID:18172885 PMID:18500788

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

H6 family homeobox 3

increases expression

Cephaloridine results in increased expression of HMX3 mRNA

NCBI chr 1:186,313,237...186,315,201
Ensembl chr 1:186,313,063...186,315,201

G

heterogeneous nuclear ribonucleoprotein A1

increases expression

Cephaloridine results in increased expression of HNRNPA1 mRNA

NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609

G

heterogeneous nuclear ribonucleoprotein A1, pseudogene 28

increases expression

Cephaloridine results in increased expression of HNRNPA1-PS28 mRNA

NCBI chr X:107,752,105...107,759,183

G

histidine-rich glycoprotein

decreases expression

Cephaloridine results in decreased expression of HRG mRNA

NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389

G

hydroxysteroid (17-beta) dehydrogenase 2

decreases expression

Cephaloridine results in decreased expression of HSD17B2 mRNA

NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

increases expression

Cephaloridine results in increased expression of HSD3B1 mRNA

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

heat shock protein 90 alpha family class A member 1

increases expression

Cephaloridine results in increased expression of HSP90AA1 mRNA

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein family A (Hsp70) member 1A

increases expression

Cephaloridine results in increased expression of HSPA1A mRNA

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 1B

increases expression

Cephaloridine results in increased expression of HSPA1B mRNA

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

heat shock protein family H (Hsp110) member 1

increases expression

Cephaloridine results in increased expression of HSPH1 mRNA

NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224

G

HIV-1 Tat interactive protein 2

increases expression

Cephaloridine results in increased expression of HTATIP2 mRNA

NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629

G

5-hydroxytryptamine (serotonin) receptor 5B

increases expression

Cephaloridine results in increased expression of HTR5B mRNA

NCBI chr13:32,686,911...32,699,835
Ensembl chr13:32,687,042...32,699,835

G

intercellular adhesion molecule 1

increases expression

Cephaloridine results in increased expression of ICAM1 mRNA

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

isopentenyl-diphosphate delta isomerase 2 like 3

decreases expression

Cephaloridine results in decreased expression of IDI2L3 mRNA

NCBI chr17:61,518,138...61,535,484
Ensembl chr17:61,519,390...61,531,603

G

immediate early response 3

decreases expression

Cephaloridine results in decreased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

interferon induced transmembrane protein 10

increases expression

Cephaloridine results in increased expression of IFITM10 mRNA

NCBI chr 1:197,507,501...197,524,180
Ensembl chr 1:197,507,503...197,525,151

G

interleukin 18

increases expression

Cephaloridine results in increased expression of IL18 mRNA

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

decreases expression

Cephaloridine results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 20 receptor subunit alpha

decreases expression

Cephaloridine results in decreased expression of IL20RA mRNA

NCBI chr 1:14,424,215...14,494,226
Ensembl chr 1:14,451,228...14,493,602

G

inhibin subunit beta B

decreases expression

Cephaloridine results in decreased expression of INHBB mRNA

NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832

G

inositol-trisphosphate 3-kinase A

increases expression

Cephaloridine results in increased expression of ITPKA mRNA

NCBI chr 3:106,726,036...106,734,601
Ensembl chr 3:106,726,036...106,734,600

G

inositol-trisphosphate 3-kinase B

increases expression

Cephaloridine results in increased expression of ITPKB mRNA

NCBI chr13:92,069,160...92,164,281
Ensembl chr13:92,069,216...92,162,004

G

jade family PHD finger 2

decreases expression

Cephaloridine results in decreased expression of JADE2 mRNA

NCBI chr10:36,075,239...36,124,210
Ensembl chr10:36,078,917...36,116,984

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Cephaloridine results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

decreases expression
increases expression

Cephaloridine results in decreased expression of JUNB mRNA
Cephaloridine results in increased expression of JUNB mRNA

PMID:18172885 PMID:18500788

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

kelch repeat and BTB domain containing 11

decreases expression

Cephaloridine results in decreased expression of KBTBD11 mRNA

NCBI chr16:74,618,291...74,638,010
Ensembl chr16:74,615,792...74,637,736

G

potassium voltage-gated channel subfamily H member 1

increases expression

Cephaloridine results in increased expression of KCNH1 mRNA

NCBI chr13:103,722,140...104,024,762
Ensembl chr13:103,722,245...104,024,740

G

potassium inwardly-rectifying channel, subfamily J, member 15

decreases expression

Cephaloridine results in decreased expression of KCNJ15 mRNA

NCBI chr11:34,577,397...34,621,725
Ensembl chr11:34,577,363...34,621,952

G

potassium channel tetramerization domain containing 1

increases expression

Cephaloridine results in increased expression of KCTD1 mRNA

NCBI chr18:6,122,390...6,316,434
Ensembl chr18:6,122,390...6,317,393

G

alpha-ketoglutarate dehydrogenase subunit 4

increases expression

Cephaloridine results in increased expression of KGD4 mRNA

NCBI chr 2:31,870,549...31,878,335
Ensembl chr 2:31,870,551...31,880,730

G

kinesin family member 18A

decreases expression

Cephaloridine results in decreased expression of KIF18A mRNA

NCBI chr 3:95,764,388...95,824,756
Ensembl chr 3:95,764,388...95,824,582

G

kinesin family member 2C

decreases expression

Cephaloridine results in decreased expression of KIF2C mRNA

NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637

G

KLF transcription factor 7

decreases expression

Cephaloridine results in decreased expression of KLF7 mRNA

NCBI chr 9:65,433,683...65,526,372
Ensembl chr 9:65,437,167...65,526,261

G

kelch-like family member 25

decreases expression

Cephaloridine results in decreased expression of KLHL25 mRNA

NCBI chr 1:129,724,894...129,750,142
Ensembl chr 1:129,722,026...129,750,227

G

kinetochore-localized astrin/SPAG5 binding protein

decreases expression

Cephaloridine results in decreased expression of KNSTRN mRNA

NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715

G

kinetochore associated 1

increases expression

Cephaloridine results in increased expression of KNTC1 mRNA

NCBI chr12:32,769,020...32,839,617
Ensembl chr12:32,769,020...32,839,561

G

laminin subunit alpha 2

decreases expression

Cephaloridine results in decreased expression of LAMA2 mRNA

NCBI chr 1:17,672,675...18,320,641
Ensembl chr 1:17,672,536...18,320,530

G

laminin subunit beta 3

increases expression

Cephaloridine results in increased expression of LAMB3 mRNA

NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405

G

leucyl-tRNA synthetase 1

decreases expression

Cephaloridine results in decreased expression of LARS1 mRNA

NCBI chr18:34,201,555...34,256,003
Ensembl chr18:34,201,549...34,255,931

G

ligand dependent nuclear receptor corepressor

decreases expression

Cephaloridine results in decreased expression of LCOR mRNA

NCBI chr 1:240,298,565...240,405,627
Ensembl chr 1:240,298,563...240,402,448

G

leukocyte cell-derived chemotaxin 2

decreases expression

Cephaloridine results in decreased expression of LECT2 mRNA

NCBI chr17:8,044,759...8,050,983
Ensembl chr17:8,044,759...8,050,983

G

galectin 2

increases expression

Cephaloridine results in increased expression of LGALS2 mRNA

NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802

G

galectin 3

increases expression

Cephaloridine results in increased expression of LGALS3 mRNA

NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025

G

LIM homeobox 3

decreases expression

Cephaloridine results in decreased expression of LHX3 mRNA

NCBI chr 3:9,026,432...9,035,122
Ensembl chr 3:9,027,425...9,034,480

G

DNA ligase 1

increases expression

Cephaloridine results in increased expression of LIG1 mRNA

NCBI chr 1:74,165,688...74,204,400
Ensembl chr 1:74,165,842...74,204,413

G

lamin B1

decreases expression

Cephaloridine results in decreased expression of LMNB1 mRNA

NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502

G

LRAT domain containing 1

increases expression

Cephaloridine results in increased expression of LRATD1 mRNA

NCBI chr 6:36,916,969...36,922,143
Ensembl chr 6:36,913,469...36,922,319

G

leucine rich repeat neuronal 3

decreases expression

Cephaloridine results in decreased expression of LRRN3 mRNA

NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330

G

MAF bZIP transcription factor

decreases expression

Cephaloridine results in decreased expression of MAF mRNA

NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365

G

mitogen-activated protein kinase kinase kinase 1

increases expression

Cephaloridine results in increased expression of MAP3K1 mRNA

NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463

G

mitogen activated protein kinase kinase kinase 12

decreases expression

Cephaloridine results in decreased expression of MAP3K12 mRNA

NCBI chr 7:133,630,267...133,648,464
Ensembl chr 7:133,630,835...133,640,789

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation
increases activity

Thymic Factor, Circulating inhibits the reaction [Cephaloridine results in increased phosphorylation of MAPK1 protein]
Cephaloridine results in increased activity of MAPK1 protein

PMID:16154539 PMID:16272694

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases activity
multiple interactions
increases phosphorylation

Cephaloridine results in increased activity of MAPK3 protein
Thymic Factor, Circulating inhibits the reaction [Cephaloridine results in increased phosphorylation of MAPK3 protein]

PMID:16154539 PMID:16272694

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8 interacting protein 3

increases expression

Cephaloridine results in increased expression of MAPK8IP3 mRNA

NCBI chr10:13,918,417...13,958,335
Ensembl chr10:13,918,400...13,958,273

G

MBL associated serine protease 2

increases expression

Cephaloridine results in increased expression of MASP2 mRNA

NCBI chr 5:159,035,892...159,049,561
Ensembl chr 5:159,035,911...159,049,580

G

minichromosome maintenance complex component 2

increases expression

Cephaloridine results in increased expression of MCM2 mRNA

NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847

G

minichromosome maintenance complex component 3

increases expression

Cephaloridine results in increased expression of MCM3 mRNA

NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314

G

minichromosome maintenance complex component 5

increases expression

Cephaloridine results in increased expression of MCM5 mRNA

NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389

G

minichromosome maintenance complex component 6

increases expression

Cephaloridine results in increased expression of MCM6 mRNA

NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960

G

minichromosome maintenance complex component 7

increases expression

Cephaloridine results in increased expression of MCM7 mRNA

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

G

minichromosome maintenance 8 homologous recombination repair factor

increases expression

Cephaloridine results in increased expression of MCM8 mRNA

NCBI chr 3:120,086,741...120,117,008
Ensembl chr 3:120,086,763...120,117,008

G

mesoderm posterior bHLH transcription factor 1

decreases expression

Cephaloridine results in decreased expression of MESP1 mRNA

NCBI chr 1:133,738,357...133,739,875
Ensembl chr 1:133,738,357...133,739,875

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

Cephaloridine results in increased expression of MET mRNA

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

monoglyceride lipase

decreases expression

Cephaloridine results in decreased expression of MGLL mRNA

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

G

marker of proliferation Ki-67

decreases expression

Cephaloridine results in decreased expression of MKI67 mRNA

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 12

increases expression

Cephaloridine results in increased expression of MMP12 mRNA

NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611

G

matrix metallopeptidase 16

increases expression

Cephaloridine results in increased expression of MMP16 mRNA

NCBI chr 5:31,312,280...31,556,276
Ensembl chr 5:31,312,280...31,548,388

G

meiotic nuclear divisions 1

increases expression

Cephaloridine results in increased expression of MND1 mRNA

NCBI chr 2:169,433,523...169,496,081
Ensembl chr 2:169,433,540...169,496,096

G

meiosis-specific nuclear structural 1

decreases expression

Cephaloridine results in decreased expression of MNS1 mRNA

NCBI chr 8:73,148,877...73,169,570
Ensembl chr 8:73,148,877...73,176,925

G

mercaptopyruvate sulfurtransferase

decreases expression

Cephaloridine results in decreased expression of MPST mRNA

NCBI chr 7:109,955,581...109,963,155
Ensembl chr 7:109,955,675...109,963,141

G

MPV17 mitochondrial inner membrane protein like

decreases expression

Cephaloridine results in decreased expression of MPV17L mRNA

NCBI chr10:1,988,451...2,025,300
Ensembl chr10:1,988,136...2,007,649

G

metallothionein 1

decreases expression

Cephaloridine results in decreased expression of MT1A mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

increases expression

Cephaloridine results in increased expression of MTHFD1L mRNA

NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

increases expression

Cephaloridine results in increased expression of MTHFD2 mRNA

NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608

G

myomesin 3

increases expression

Cephaloridine results in increased expression of MYOM3 mRNA

NCBI chr 5:147,992,737...148,043,282
Ensembl chr 5:147,992,737...148,043,274

G

nuclear receptor co-repressor 2

decreases expression

Cephaloridine results in decreased expression of NCOR2 mRNA

NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319

G

NIMA-related kinase 6

increases expression

Cephaloridine results in increased expression of NEK6 mRNA

NCBI chr 3:22,284,269...22,356,302
Ensembl chr 3:22,284,279...22,395,990

G

nuclear factor, interleukin 3 regulated

increases expression

Cephaloridine results in increased expression of NFIL3 mRNA

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

NFKB inhibitor alpha

decreases expression

Cephaloridine results in decreased expression of NFKBIA mRNA

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NFKB inhibitor zeta

decreases expression

Cephaloridine results in decreased expression of NFKBIZ mRNA

NCBI chr11:44,782,676...44,810,722
Ensembl chr11:44,782,676...44,810,723

G

nerve growth factor receptor

increases expression

Cephaloridine results in increased expression of NGFR mRNA

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

NHP2 ribonucleoprotein

increases expression

Cephaloridine results in increased expression of NHP2 mRNA

NCBI chr10:35,877,057...35,880,399
Ensembl chr10:35,877,054...35,882,545

G

ninjurin 2

increases expression

Cephaloridine results in increased expression of NINJ2 mRNA

NCBI chr 4:153,306,439...153,408,618
Ensembl chr 4:153,306,553...153,408,617

G

nipsnap homolog 3A (C. elegans)

increases expression

Cephaloridine results in increased expression of NIPSNAP3B mRNA

NCBI chr 5:67,613,993...67,625,067
Ensembl chr 5:67,614,036...67,669,700

G

NME/NM23 nucleoside diphosphate kinase 4

decreases expression

Cephaloridine results in decreased expression of NME4 mRNA

NCBI chr10:15,114,624...15,118,479
Ensembl chr10:15,002,926...15,118,479

G

NOP56 ribonucleoprotein

increases expression

Cephaloridine results in increased expression of NOP56 mRNA

NCBI chr 3:117,476,963...117,481,847
Ensembl chr 3:117,477,053...117,481,841

G

NAD(P)H quinone dehydrogenase 1

increases expression

Cephaloridine results in increased expression of NQO1 mRNA

PMID:18172885 PMID:18500788

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group D, member 1

increases expression

Cephaloridine results in increased expression of NR1D1 mRNA

NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705

G

nurim

increases expression

Cephaloridine results in increased expression of NRM mRNA

NCBI chr20:2,888,321...2,892,804
Ensembl chr20:2,877,567...2,891,802

G

nudix hydrolase 11

increases expression

Cephaloridine results in increased expression of NUDT10 mRNA; Cephaloridine results in increased expression of NUDT11 mRNA

NCBI chr X:16,326,775...16,333,396
Ensembl chr X:16,326,598...16,333,145

G

opioid related nociceptin receptor 1

increases expression

Cephaloridine results in increased expression of OPRL1 mRNA

NCBI chr 3:168,831,934...168,839,920
Ensembl chr 3:168,834,003...168,839,920

G

olfactory receptor family 2 subfamily W member 6

increases expression

Cephaloridine results in increased expression of OR2W6 mRNA

NCBI chr17:42,906,458...42,907,396
Ensembl chr17:42,904,951...42,919,599

G

olfactory receptor family 52 subfamily B member 2

increases expression

Cephaloridine results in increased expression of OR52B2 mRNA

NCBI chr 1:159,695,507...159,696,475
Ensembl chr 1:159,694,964...159,701,227

G

olfactory receptor family 52 subfamily K member 1

decreases expression

Cephaloridine results in decreased expression of OR52K1 mRNA

NCBI chr 1:157,037,381...157,038,325
Ensembl chr 1:157,037,381...157,038,325

G

origin recognition complex, subunit 6

increases expression

Cephaloridine results in increased expression of ORC6 mRNA

NCBI chr19:21,757,867...21,765,638
Ensembl chr19:21,757,866...21,765,662

G

oxysterol binding protein-like 8

decreases expression

Cephaloridine results in decreased expression of OSBPL8 mRNA

NCBI chr 7:46,596,944...46,749,888
Ensembl chr 7:46,596,983...46,749,888

G

oncostatin M receptor

increases expression

Cephaloridine results in increased expression of OSMR mRNA

NCBI chr 2:55,907,119...55,961,373
Ensembl chr 2:55,907,132...55,961,262

G

oxoglutarate receptor 1

increases expression

Cephaloridine results in increased expression of OXGR1 mRNA

NCBI chr15:97,145,947...97,146,960
Ensembl chr15:97,144,293...97,166,612

G

peptidyl arginine deiminase 6

increases expression

Cephaloridine results in increased expression of PADI6 mRNA

NCBI chr 5:153,021,855...153,037,443
Ensembl chr 5:153,021,965...153,037,414

G

partner and localizer of BRCA2

increases expression

Cephaloridine results in increased expression of PALB2 mRNA

NCBI chr 1:176,665,076...176,689,053
Ensembl chr 1:176,665,076...176,688,990

G

PAS domain containing serine/threonine kinase

increases expression

Cephaloridine results in increased expression of PASK mRNA

NCBI chr 9:93,844,275...93,886,036
Ensembl chr 9:93,844,278...93,885,111

G

PDZ binding kinase

decreases expression

Cephaloridine results in decreased expression of PBK mRNA

NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014

G

protocadherin 7

decreases expression

Cephaloridine results in decreased expression of PCDH7 mRNA

NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051
Ensembl chr14:52,475,610...52,902,051

G

protocadherin 9

decreases expression

Cephaloridine results in decreased expression of PCDH9 mRNA

NCBI chr15:69,340,108...70,237,531
Ensembl chr15:69,340,645...70,237,538

G

phosphoenolpyruvate carboxykinase 1

decreases expression

Cephaloridine results in decreased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

PCNA clamp associated factor

increases expression

Cephaloridine results in increased expression of PCLAF mRNA

NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994
Ensembl chr 8:66,420,587...66,432,994

G

proliferating cell nuclear antigen

increases expression

Cephaloridine results in increased expression of PCNA mRNA

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

protein disulfide isomerase family A, member 4

increases expression

Cephaloridine results in increased expression of PDIA4 mRNA

NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107

G

profilin 3

decreases expression

Cephaloridine results in decreased expression of PFN3 mRNA

NCBI chr17:9,217,595...9,218,122

G

pipecolic acid and sarcosine oxidase

increases expression

Cephaloridine results in increased expression of PIPOX mRNA

NCBI chr10:62,769,874...62,783,484
Ensembl chr10:62,769,900...62,782,370

G

pirin

increases expression

Cephaloridine results in increased expression of PIR mRNA

NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218

G

PKHD1 ciliary IPT domain containing fibrocystin/polyductin

decreases expression

Cephaloridine results in decreased expression of PKHD1 mRNA

NCBI chr 9:22,547,396...23,037,443
Ensembl chr 9:22,549,513...23,037,381

G

protein kinase, membrane associated tyrosine/threonine 1

increases expression

Cephaloridine results in increased expression of PKMYT1 mRNA

NCBI chr10:12,748,221...12,758,995
Ensembl chr10:12,748,237...12,758,995

G

phospholipase A1 member A

increases expression

Cephaloridine results in increased expression of PLA1A mRNA

NCBI chr11:62,320,112...62,357,779
Ensembl chr11:62,320,493...62,357,779

G

pleckstrin 2

increases expression

Cephaloridine results in increased expression of PLEK2 mRNA

NCBI chr 6:97,700,123...97,719,417
Ensembl chr 6:97,701,106...97,719,326

G

pleckstrin homology domain containing A5

decreases expression

Cephaloridine results in decreased expression of PLEKHA5 mRNA

NCBI chr 4:173,333,891...173,503,546
Ensembl chr 4:173,334,055...173,503,546

G

polo-like kinase 1

decreases expression

Cephaloridine results in decreased expression of PLK1 mRNA

NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400

G

DNA polymerase alpha 2, accessory subunit

increases expression

Cephaloridine results in increased expression of POLA2 mRNA

NCBI chr 1:203,227,183...203,251,350
Ensembl chr 1:203,203,388...203,251,348

G

DNA polymerase delta 1, catalytic subunit

increases expression

Cephaloridine results in increased expression of POLD1 mRNA

NCBI chr 1:95,025,462...95,041,559
Ensembl chr 1:95,025,499...95,036,465

G

DNA polymerase epsilon, catalytic subunit

increases expression

Cephaloridine results in increased expression of POLE mRNA

NCBI chr12:46,345,420...46,393,984
Ensembl chr12:46,345,420...46,393,939

G

inorganic pyrophosphatase 1

increases expression

Cephaloridine results in increased expression of PPA1 mRNA

NCBI chr20:29,590,733...29,617,711
Ensembl chr20:29,590,707...29,619,215

G

protein phosphatase, Mg2+/Mn2+ dependent, 1J

increases expression

Cephaloridine results in increased expression of PPM1J mRNA

NCBI chr 2:192,278,597...192,283,883
Ensembl chr 2:192,278,517...192,283,882

G

protein phosphatase 1, regulatory subunit 15A

decreases expression

Cephaloridine results in decreased expression of PPP1R15A mRNA

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171

G

protein regulator of cytokinesis 1

decreases expression

Cephaloridine results in decreased expression of PRC1 mRNA

NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765

G

DNA primase subunit 1

increases expression

Cephaloridine results in increased expression of PRIM1 mRNA

NCBI chr 7:446,342...462,526
Ensembl chr 7:431,805...462,526

G

protein kinase cAMP-dependent type I regulatory subunit beta

increases expression

Cephaloridine results in increased expression of PRKAR1B mRNA

NCBI chr12:15,492,233...15,624,942
Ensembl chr12:15,511,801...15,624,942

G

proline dehydrogenase 2

decreases expression

Cephaloridine results in decreased expression of PRODH2 mRNA

NCBI chr 1:85,753,558...85,767,165
Ensembl chr 1:85,753,644...85,767,162

G

paired related homeobox 1

decreases expression

Cephaloridine results in decreased expression of PRRX1 mRNA

NCBI chr13:75,600,777...75,671,896
Ensembl chr13:75,601,706...75,670,866

G

serine protease 35

decreases expression

Cephaloridine results in decreased expression of PRSS35 mRNA

NCBI chr 8:87,714,449...87,731,009
Ensembl chr 8:87,714,966...87,731,009

G

proteasome 20S subunit beta 4

increases expression

Cephaloridine results in increased expression of PSMB4 mRNA

NCBI chr 2:182,442,757...182,445,532
Ensembl chr 2:182,442,756...182,445,746

G

polypyrimidine tract binding protein 1

increases expression

Cephaloridine results in increased expression of PTBP1 mRNA

NCBI chr 7:9,842,574...9,852,332
Ensembl chr 7:9,842,574...9,852,397

G

prostaglandin reductase 1

increases expression

Cephaloridine results in increased expression of PTGR1 mRNA

NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666

G

protein tyrosine phosphatase, non-receptor type 11

decreases expression

Cephaloridine results in decreased expression of PTPN11 mRNA

NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925

G

protein tyrosine phosphatase, receptor type, B

decreases expression

Cephaloridine results in decreased expression of PTPRB mRNA

NCBI chr 7:51,953,375...52,034,751
Ensembl chr 7:51,930,015...52,034,748

G

protein tyrosine phosphatase, receptor type N2

increases expression

Cephaloridine results in increased expression of PTPRN2 mRNA

NCBI chr 6:137,439,572...138,191,575
Ensembl chr 6:137,439,540...138,191,575

G

peptidyl-tRNA hydrolase 1 homolog

increases expression

Cephaloridine results in increased expression of PTRH1 mRNA

NCBI chr 3:16,064,867...16,071,098
Ensembl chr 3:16,064,880...16,070,648

G

PVR cell adhesion molecule

increases expression

Cephaloridine results in increased expression of PVR mRNA

NCBI chr 1:79,561,294...79,576,700
Ensembl chr 1:79,546,879...79,576,715

G

RAB11 family interacting protein 3

decreases expression

Cephaloridine results in decreased expression of RAB11FIP3 mRNA

NCBI chr10:15,002,650...15,086,382
Ensembl chr10:15,002,926...15,118,479

G

RAB31, member RAS oncogene family

decreases expression

Cephaloridine results in decreased expression of RAB31 mRNA

NCBI chr 9:105,246,712...105,382,973
Ensembl chr 9:105,246,709...105,381,253

G

RAD18 E3 ubiquitin protein ligase

increases expression

Cephaloridine results in increased expression of RAD18 mRNA

NCBI chr 4:145,735,654...145,821,102
Ensembl chr 4:145,735,654...145,821,069

G

RB transcriptional corepressor 1

affects activity

Cephaloridine affects the activity of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

retinol binding protein 2

increases expression

Cephaloridine results in increased expression of RBP2 mRNA

NCBI chr 8:99,079,293...99,104,489
Ensembl chr 8:99,079,104...99,104,473

G

rabenosyn, RAB effector

decreases expression

Cephaloridine results in decreased expression of RBSN mRNA

NCBI chr 4:124,682,228...124,712,578
Ensembl chr 4:124,683,969...124,712,578

G

retinol dehydrogenase 16

decreases expression

Cephaloridine results in decreased expression of RDH2 mRNA

NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124

G

RecQ like helicase 4

increases expression

Cephaloridine results in increased expression of RECQL4 mRNA

NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619

G

RELA proto-oncogene, NF-kB subunit

affects activity

Cephaloridine affects the activity of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

replication factor C subunit 3

increases expression

Cephaloridine results in increased expression of RFC3 mRNA

NCBI chr12:1,000,987...1,011,778
Ensembl chr12:1,000,994...1,011,778

G

replication factor C subunit 4

increases expression

Cephaloridine results in increased expression of RFC4 mRNA

NCBI chr11:77,749,642...77,764,123
Ensembl chr11:77,749,638...77,764,122

G

regucalcin

decreases expression

Cephaloridine results in decreased expression of RGN mRNA

PMID:8584014 PMID:18500788

NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450

G

regulator of G-protein signaling 11

increases expression

Cephaloridine results in increased expression of RGS11 mRNA

NCBI chr10:15,222,804...15,231,062
Ensembl chr10:15,222,803...15,231,060

G

Rh family, C glycoprotein

increases expression

Cephaloridine results in increased expression of RHCG mRNA

NCBI chr 1:133,531,704...133,555,902
Ensembl chr 1:133,531,716...133,555,876

G

Rho-related BTB domain containing 1

decreases expression

Cephaloridine results in decreased expression of RHOBTB1 mRNA

NCBI chr20:19,327,142...19,456,121
Ensembl chr20:19,327,155...19,403,012

G

rhophilin, Rho GTPase binding protein 2

increases expression

Cephaloridine results in increased expression of RHPN2 mRNA

NCBI chr 1:87,991,143...88,051,895
Ensembl chr 1:87,991,144...88,051,902

G

reactive intermediate imine deaminase A homolog

decreases expression

Cephaloridine results in decreased expression of RIDA mRNA

NCBI chr 7:65,691,429...65,705,257
Ensembl chr 7:65,691,435...65,705,716

G

Rho family GTPase 1

increases expression

Cephaloridine results in increased expression of RND1 mRNA

NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399

G

ring finger protein 227

increases expression

Cephaloridine results in increased expression of RNF227 mRNA

NCBI chr10:54,061,054...54,063,015
Ensembl chr10:54,059,947...54,063,010

G

ribosomal protein L23A

increases expression

Cephaloridine results in increased expression of RPL23A mRNA

NCBI chr10:63,076,660...63,079,346
Ensembl chr10:63,076,066...63,079,346

G

ribosomal protein L23A like 1

increases expression

Cephaloridine results in increased expression of RPL23AL1 mRNA

NCBI chr 2:38,452,814...38,453,384
Ensembl chr 2:38,451,401...38,453,417

G

ribosomal protein L32 like 4

decreases expression

Cephaloridine results in decreased expression of RPL32L4 mRNA

NCBI chr 8:84,691,128...84,692,042

G

ribonucleotide reductase regulatory subunit M2

decreases expression

Cephaloridine results in decreased expression of RRM2 mRNA

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

RUNX1 partner transcriptional co-repressor 1

decreases expression

Cephaloridine results in decreased expression of RUNX1T1 mRNA

NCBI chr 5:27,187,674...27,338,070
Ensembl chr 5:27,187,551...27,335,592

G

retinoid X receptor gamma

increases expression

Cephaloridine results in increased expression of RXRG mRNA

NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167

G

secretoglobin, family 3A, member 1

increases expression

Cephaloridine results in increased expression of SCGB3A1 mRNA

NCBI chr10:33,968,059...33,969,366
Ensembl chr10:33,968,059...33,969,476

G

secretoglobin, family 3A, member 2

increases expression

Cephaloridine results in increased expression of SCGB3A2 mRNA

NCBI chr18:35,932,840...35,935,762
Ensembl chr18:35,932,840...35,935,762

G

secretin

increases expression

Cephaloridine results in increased expression of SCT mRNA

NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658

G

secreted and transmembrane 1B

increases expression

Cephaloridine results in increased expression of SECTM1A mRNA

NCBI chr10:106,324,070...106,333,779
Ensembl chr10:106,325,203...106,333,769

G

selenoprotein P

decreases expression

Cephaloridine results in decreased expression of SELENOP mRNA

NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852

G

semaphorin 4C

decreases expression

Cephaloridine results in decreased expression of SEMA4C mRNA

NCBI chr 9:38,791,668...38,802,171
Ensembl chr 9:38,791,670...38,802,128

G

septin 10

decreases expression

Cephaloridine results in decreased expression of SEPTIN10 mRNA

NCBI chr20:27,101,764...27,194,997
Ensembl chr20:27,101,752...27,194,780

G

SH2B adaptor protein 2

increases expression

Cephaloridine results in increased expression of SH2B2 mRNA

NCBI chr12:20,427,057...20,456,845
Ensembl chr12:20,429,043...20,456,844

G

SH3-domain binding protein 2

increases expression

Cephaloridine results in increased expression of SH3BP2 mRNA

NCBI chr14:76,176,097...76,213,300
Ensembl chr14:76,176,101...76,213,251

G

shroom family member 4

decreases expression

Cephaloridine results in decreased expression of SHROOM4 mRNA

NCBI chr X:15,869,065...16,076,850
Ensembl chr X:15,869,065...16,076,869

G

sialic acid binding Ig-like lectin 5

increases expression

Cephaloridine results in increased expression of SIGLEC5 mRNA

NCBI chr 1:93,768,190...93,776,696
Ensembl chr 1:93,768,319...93,776,694

G

spindle and kinetochore associated complex subunit 1

decreases expression

Cephaloridine results in decreased expression of SKA1 mRNA

NCBI chr18:67,794,722...67,805,037
Ensembl chr18:67,794,725...67,805,037

G

solute carrier family 15 member 3

increases expression

Cephaloridine results in increased expression of SLC15A3 mRNA

NCBI chr 1:207,492,365...207,507,158
Ensembl chr 1:207,492,365...207,507,157

G

solute carrier family 16, member 12

decreases expression

Cephaloridine results in decreased expression of SLC16A12 mRNA

NCBI chr 1:232,184,004...232,262,170
Ensembl chr 1:232,185,907...232,262,141

G

solute carrier family 16, member 14

decreases expression

Cephaloridine results in decreased expression of SLC16A14 mRNA

NCBI chr 9:86,110,066...86,137,546
Ensembl chr 9:86,112,894...86,137,318

G

solute carrier family 1 member 5

increases expression

Cephaloridine results in increased expression of SLC1A5 mRNA

NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952

G

solute carrier family 22, member 23

decreases expression

Cephaloridine results in decreased expression of SLC22A23 mRNA

NCBI chr17:30,544,106...30,709,790
Ensembl chr17:30,544,106...30,709,790

G

solute carrier family 22 member 5

decreases expression

Cephaloridine results in decreased expression of SLC22A5 mRNA

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 22 member 6

increases import
multiple interactions
increases uptake

SLC22A6 protein results in increased import of Cephaloridine
Cephaloridine inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]
SLC22A6 protein results in increased uptake of Cephaloridine

PMID:10594788 PMID:16098483

NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173

G

solute carrier family 22 member 8

increases uptake
multiple interactions

SLC22A8 protein results in increased uptake of Cephaloridine
Cephaloridine inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

solute carrier family 35 member D2

increases expression

Cephaloridine results in increased expression of SLC35D2 mRNA

NCBI chr17:987,899...1,019,747
Ensembl chr17:988,157...1,019,743

G

solute carrier family 39 member 4

increases expression

Cephaloridine results in increased expression of SLC39A4 mRNA

NCBI chr 7:108,333,368...108,337,553
Ensembl chr 7:108,333,381...108,337,553

G

solute carrier family 41 member 2

increases expression

Cephaloridine results in increased expression of SLC41A2 mRNA

NCBI chr 7:20,383,714...20,491,178
Ensembl chr 7:20,383,757...20,491,166

G

solute carrier family 46, member 3

increases expression

Cephaloridine results in increased expression of SLC46A3 mRNA

NCBI chr12:7,140,610...7,157,093
Ensembl chr12:7,140,668...7,157,092

G

solute carrier family 4 member 4

decreases expression

Cephaloridine results in decreased expression of SLC4A4 mRNA

NCBI chr14:18,841,289...19,293,297
Ensembl chr14:18,845,159...19,272,883

G

solute carrier family 5 member 3

increases expression

Cephaloridine results in increased expression of SLC5A3 mRNA

NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883

G

solute carrier family 7 member 10

increases expression

Cephaloridine results in increased expression of SLC7A10 mRNA

NCBI chr 1:87,829,084...87,845,073
Ensembl chr 1:87,829,175...87,845,071

G

solute carrier family 7 member 5

increases expression

Cephaloridine results in increased expression of SLC7A5 mRNA

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

solute carrier family 7 member 7

decreases expression

Cephaloridine results in decreased expression of SLC7A7 mRNA

NCBI chr15:27,822,088...27,873,121
Ensembl chr15:27,822,091...27,865,648

G

solute carrier family 8 member A1

decreases expression

Cephaloridine results in decreased expression of SLC8A1 mRNA

NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628

G

secretory leukocyte peptidase inhibitor

increases expression

Cephaloridine results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

SET and MYND domain containing 1

increases expression

Cephaloridine results in increased expression of SMYD1 mRNA

NCBI chr 4:103,195,330...103,252,989
Ensembl chr 4:103,200,322...103,311,766

G

small nuclear RNA activating complex, polypeptide 2

increases expression

Cephaloridine results in increased expression of SNAPC2 mRNA

NCBI chr12:2,605,794...2,608,997
Ensembl chr12:2,605,810...2,608,999

G

suppressor of cytokine signaling 3

decreases expression

Cephaloridine results in decreased expression of SOCS3 mRNA

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

Spetex-2B protein

increases expression

Cephaloridine results in increased expression of SPETEX2B mRNA

G

Spetex-2D protein

increases expression

Cephaloridine results in increased expression of SPETEX2D mRNA

G

sphingosine kinase 1

increases expression

Cephaloridine results in increased expression of SPHK1 mRNA

NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240

G

serine peptidase inhibitor, Kazal type 1

decreases expression

Cephaloridine results in decreased expression of SPINK1 mRNA

NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642

G

SRP receptor subunit alpha

decreases expression

Cephaloridine results in decreased expression of SRPRA mRNA

NCBI chr 8:33,560,365...33,566,458
Ensembl chr 8:33,560,348...33,566,470

G

signal transducer and activator of transcription 3

increases expression

Cephaloridine results in increased expression of STAT3 mRNA

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

serine/threonine kinase 35

increases expression

Cephaloridine results in increased expression of STK35 mRNA

NCBI chr 3:117,016,819...117,049,131
Ensembl chr 3:117,016,950...117,048,066

G

signaling receptor and transporter of retinol STRA6

decreases expression

Cephaloridine results in decreased expression of STRA6 mRNA

NCBI chr 8:58,548,899...58,568,861
Ensembl chr 8:58,549,736...58,568,860

G

sulfotransferase family 1C member 2A

decreases expression

Cephaloridine results in decreased expression of SULT1C2 mRNA; Cephaloridine results in decreased expression of SULT1C2A mRNA

NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734

G

sulfotransferase family 4A, member 1

increases expression

Cephaloridine results in increased expression of SULT4A1 mRNA

NCBI chr 7:115,216,066...115,240,156
Ensembl chr 7:115,216,066...115,240,085

G

surfeit 6

decreases expression

Cephaloridine results in decreased expression of SURF6 mRNA

NCBI chr 3:10,221,450...10,232,306
Ensembl chr 3:10,221,452...10,232,251

G

sushi domain containing 2

decreases expression

Cephaloridine results in decreased expression of SUSD2 mRNA

NCBI chr20:13,017,516...13,024,820
Ensembl chr20:13,017,477...13,024,903

G

spectrin repeat containing nuclear envelope protein 1

decreases expression

Cephaloridine results in decreased expression of SYNE1 mRNA

NCBI chr 1:41,512,146...41,983,382
Ensembl chr 1:41,512,030...41,983,322

G

spectrin repeat containing nuclear envelope protein 2

decreases expression

Cephaloridine results in decreased expression of SYNE2 mRNA

NCBI chr 6:94,537,088...94,848,085
Ensembl chr 6:94,537,088...94,848,064

G

synaptotagmin-like 5

increases expression

Cephaloridine results in increased expression of SYTL5 mRNA

NCBI chr X:12,775,529...13,030,134
Ensembl chr X:12,788,698...13,030,175

G

tachykinin precursor 3

increases expression

Cephaloridine results in increased expression of TAC2 mRNA

NCBI chr 7:63,562,552...63,569,170
Ensembl chr 7:63,562,552...63,569,170

G

T-box transcription factor 3

decreases expression

Cephaloridine results in decreased expression of TBX3 mRNA

NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708

G

transcription factor 12

decreases expression

Cephaloridine results in decreased expression of TCF12 mRNA

NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201

G

transcription factor 19

increases expression

Cephaloridine results in increased expression of TCF19 mRNA

NCBI chr20:3,218,756...3,222,861
Ensembl chr20:3,218,693...3,223,271

G

transferrin receptor

increases expression

Cephaloridine results in increased expression of TFRC mRNA

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

TOPBP1-interacting checkpoint and replication regulator

increases expression

Cephaloridine results in increased expression of TICRR mRNA

NCBI chr 1:133,597,618...133,639,513
Ensembl chr 1:133,597,716...133,639,523

G

timeless circadian regulator

increases expression

Cephaloridine results in increased expression of TIMELESS mRNA

NCBI chr 7:654,804...678,769
Ensembl chr 7:654,822...678,738

G

TIMP metallopeptidase inhibitor 1

increases expression

Cephaloridine results in increased expression of TIMP1 mRNA

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

toll-like receptor 2

increases expression

Cephaloridine results in increased expression of TLR2 mRNA

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

transmembrane protein 163

increases expression

Cephaloridine results in increased expression of TMEM163 mRNA

NCBI chr13:38,967,913...39,141,664
Ensembl chr13:38,968,101...39,141,452

G

transmembrane protein 252

decreases expression

Cephaloridine results in decreased expression of TMEM252 mRNA

NCBI chr 1:222,316,982...222,321,946
Ensembl chr 1:222,316,795...222,321,943

G

transmembrane protein 270

increases expression

Cephaloridine results in increased expression of TMEM270 mRNA

NCBI chr12:21,793,631...21,798,723
Ensembl chr12:21,794,130...21,798,731

G

transmembrane protein 63c

increases expression

Cephaloridine results in increased expression of TMEM63C mRNA

NCBI chr 6:106,667,389...106,738,778
Ensembl chr 6:106,672,934...106,736,990

G

transmembrane protein 86A

decreases expression

Cephaloridine results in decreased expression of TMEM86A mRNA

NCBI chr 1:97,595,910...97,600,260
Ensembl chr 1:97,595,842...97,600,260

G

TNF receptor superfamily member 12A

increases expression

Cephaloridine results in increased expression of TNFRSF12A mRNA

NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045

G

TNF receptor superfamily member 1A

increases expression

Cephaloridine results in increased expression of TNFRSF1A mRNA

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

tensin 1

decreases expression

Cephaloridine results in decreased expression of TNS1 mRNA

NCBI chr 9:75,491,886...75,702,853
Ensembl chr 9:75,495,814...75,703,225

G

tensin 4

increases expression

Cephaloridine results in increased expression of TNS4 mRNA

NCBI chr10:84,021,965...84,041,346
Ensembl chr10:84,021,966...84,041,346

G

tonsoku-like, DNA repair protein

increases expression

Cephaloridine results in increased expression of TONSL mRNA

NCBI chr 7:108,345,704...108,360,792
Ensembl chr 7:108,346,047...108,360,750

G

DNA topoisomerase II alpha

decreases expression

Cephaloridine results in decreased expression of TOP2A mRNA

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

G

tryptophan hydroxylase 1

increases expression

Cephaloridine results in increased expression of TPH1 mRNA

NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344

G

tribbles pseudokinase 3

increases expression

Cephaloridine results in increased expression of TRIB3 mRNA

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

TLR4 interactor with leucine-rich repeats

decreases expression

Cephaloridine results in decreased expression of TRIL mRNA

NCBI chr 4:82,922,327...82,927,172
Ensembl chr 4:82,922,328...82,927,172

G

transient receptor potential cation channel, subfamily C, member 6

increases expression

Cephaloridine results in increased expression of TRPC6 mRNA

NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092

G

tetratricopeptide repeat domain 39A

increases expression

Cephaloridine results in increased expression of TTC39A mRNA

NCBI chr 5:124,165,102...124,204,740
Ensembl chr 5:124,151,760...124,204,973

G

Ttk protein kinase

decreases expression

Cephaloridine results in decreased expression of TTK mRNA

NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651

G

tubulin tyrosine ligase like 2

increases expression

Cephaloridine results in increased expression of TTLL2 mRNA

NCBI chr 1:52,967,183...52,976,690
Ensembl chr 1:52,968,408...52,976,697

G

tubulin, beta 3 class III

increases expression

Cephaloridine results in increased expression of TUBB3 mRNA

NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243

G

tubulin, beta 6 class V

increases expression

Cephaloridine results in increased expression of TUBB6 mRNA

NCBI chr18:60,943,394...60,953,031
Ensembl chr18:60,943,375...60,954,418

G

thymidylate synthetase

increases expression

Cephaloridine results in increased expression of TYMS mRNA

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

ubiquitin D

increases expression

Cephaloridine results in increased expression of UBD mRNA

NCBI chr20:1,385,487...1,387,438
Ensembl chr20:1,385,864...1,408,639
Ensembl chr20:1,385,864...1,408,639

G

ubiquitin-conjugating enzyme E2C

decreases expression

Cephaloridine results in decreased expression of UBE2C mRNA

NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339

G

ubiquitin-conjugating enzyme E2L 6

increases expression

Cephaloridine results in increased expression of UBE2L6 mRNA

NCBI chr 3:69,873,025...69,888,042
Ensembl chr 3:69,873,424...69,888,048

G

ubiquitin-like 7

increases expression

Cephaloridine results in increased expression of UBL7 mRNA

NCBI chr 8:58,321,279...58,340,353
Ensembl chr 8:58,320,866...58,340,344

G

ubiquitin C-terminal hydrolase L1

increases expression

Cephaloridine results in increased expression of UCHL1 mRNA

NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases expression

Cephaloridine results in increased expression of UGT1A2 mRNA

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A6

increases expression

Cephaloridine results in increased expression of UGT1A6 mRNA

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 2 member B7

increases expression

Cephaloridine results in increased expression of UGT2B7 mRNA

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

G

U2AF homology motif kinase 1

increases expression

Cephaloridine results in increased expression of UHMK1 mRNA

NCBI chr13:82,396,646...82,416,292
Ensembl chr13:82,401,187...82,416,292

G

U2AF homology motif kinase 1l1

increases expression

Cephaloridine results in increased expression of UHMK1L1 mRNA

NCBI chr17:42,241,640...42,243,666

G

uridine phosphorylase 1

increases expression

Cephaloridine results in increased expression of UPP1 mRNA

NCBI chr14:83,809,495...83,829,299
Ensembl chr14:83,809,960...83,829,462

G

ubiquitin specific peptidase 24

decreases expression

Cephaloridine results in decreased expression of USP24 mRNA

NCBI chr 5:121,080,687...121,210,321
Ensembl chr 5:121,080,470...121,210,311

G

vascular cell adhesion molecule 1

increases expression

Cephaloridine results in increased expression of VCAM1 mRNA

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

V-set pre-B cell surrogate light chain 3

increases expression

Cephaloridine results in increased expression of VPREB3 mRNA

NCBI chr20:12,717,421...12,718,785
Ensembl chr20:12,716,779...12,719,520

G

WD repeat and HMG-box DNA binding protein 1

increases expression

Cephaloridine results in increased expression of WDHD1 mRNA

NCBI chr15:20,478,310...20,523,106
Ensembl chr15:20,489,291...20,523,096

G

zinc finger CCCH type containing 13

decreases expression

Cephaloridine results in decreased expression of ZC3H13 mRNA

NCBI chr15:50,607,335...50,671,802
Ensembl chr15:50,607,380...50,671,802

G

zinc finger DHHC-type palmitoyltransferase 18

decreases expression

Cephaloridine results in decreased expression of ZDHHC18 mRNA

NCBI chr 5:145,821,534...145,859,989
Ensembl chr 5:145,831,446...145,859,993

G

zinc finger AN1-type containing 2A

decreases expression

Cephaloridine results in decreased expression of ZFAND2A mRNA

NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677

G

zinc finger protein 367

increases expression

Cephaloridine results in increased expression of ZFP367 mRNA

NCBI chr17:965,161...984,290
Ensembl chr17:965,161...984,287

cefalotin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 2

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

BCL2 associated X, apoptosis regulator

increases expression

Cephalothin results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

caspase 3

multiple interactions

Cephalothin results in increased cleavage of and results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

[Cephalothin co-treated with Neomycin] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

fibroblast growth factor 19

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of FGF15 mRNA

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

NPC1 like intracellular cholesterol transporter 1

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of NPC1L1 mRNA

NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of NR5A2 mRNA

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

solute carrier family 10 member 1

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 25 member 20

multiple interactions

Cephalothin binds to and results in decreased activity of SLC25A20 protein; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

SLC51 subunit beta

multiple interactions

[Cephalothin co-treated with Neomycin] results in decreased expression of SLC51B mRNA

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

solute carrier organic anion transporter family member 1B2

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of SLCO1B2 mRNA

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

tumor protein p53

increases expression

Cephalothin results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

vitamin D receptor

multiple interactions

[Cephalothin co-treated with Neomycin] results in increased expression of VDR mRNA

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

cefotiam

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 6

multiple interactions

Cefotiam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]

NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173

G

solute carrier family 22 member 8

increases uptake
multiple interactions

SLC22A8 protein results in increased uptake of Cefotiam
Cefotiam inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

cefoxitin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interferon gamma

multiple interactions

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA]

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 10

multiple interactions

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IL10 mRNA]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IL1B mRNA]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

MYD88, innate immune signal transduction adaptor

multiple interactions

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA]

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of RELA mRNA]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RT1 class I, locus CE16

affects expression

Cefoxitin affects the expression of HLA-A mRNA

NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563

G

RT1 class II, locus Ha

affects expression

Cefoxitin affects the expression of HLA-DPA1 mRNA

NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244

G

transforming growth factor, beta 1

multiple interactions

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

toll-like receptor 2

multiple interactions

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA]

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

tumor necrosis factor

multiple interactions

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor associated factor 6

multiple interactions

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TRAF6 mRNA]

NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507

cephalexin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RT1 class II, locus Ha

affects expression

Cephalexin affects the expression of HLA-DPA1 mRNA

NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244

G

solute carrier family 15 member 1

increases transport

SLC15A1 protein results in increased transport of Cephalexin

NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545

clindamycin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases expression

Clindamycin results in increased expression of and results in increased activity of CYP3A4 protein
Clindamycin results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

matrix metallopeptidase 13

increases expression

Clindamycin results in increased expression of MMP13 mRNA

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

RT1 class Ia, locus A2

affects expression

Clindamycin affects the expression of HLA-E mRNA

NCBI chr20:4,870,939...4,910,183

G

RT1 class II, locus Db1

affects expression

Clindamycin affects the expression of HLA-DRB1 mRNA

NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258

clindamycin phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

paraoxonase 1

decreases activity

clindamycin phosphate results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

cloxacillin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

Cloxacillin results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

caspase 3

increases activity
multiple interactions

Cloxacillin results in increased activity of CASP3 protein
[Cloxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Cloxacillin co-treated with IL1B protein] results in increased activity of CASP3 protein; [Cloxacillin co-treated with IL6 protein] results in increased activity of CASP3 protein; [Cloxacillin co-treated with TNF protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Cloxacillin results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

interleukin 1 beta

multiple interactions

[Cloxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Cloxacillin co-treated with IL1B protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Cloxacillin results in increased activity of CASP3 protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

[Cloxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Cloxacillin co-treated with IL6 protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Cloxacillin results in increased activity of CASP3 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

tumor necrosis factor

multiple interactions

[Cloxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Cloxacillin co-treated with TNF protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Cloxacillin results in increased activity of CASP3 protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

dihydroergotamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

Dihydroergotamine results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 4

decreases activity

Dihydroergotamine results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases activity
increases activity

Dihydroergotamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
Dihydroergotamine results in decreased activity of CYP1A1 protein
Dihydroergotamine results in increased activity of CYP1A1 protein

PMID:18420780 PMID:18493746 PMID:33814510

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Dihydroergotamine results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily a, polypeptide 3

decreases activity

Dihydroergotamine results in decreased activity of CYP2A4 protein

NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases activity

Dihydroergotamine results in decreased activity of CYP2B10 protein

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases activity

Dihydroergotamine results in decreased activity of CYP2C29 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

decreases activity

Dihydroergotamine results in decreased activity of CYP2D6 protein
Dihydroergotamine results in decreased activity of CYP2D22 protein

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity

Dihydroergotamine results in decreased activity of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

5-hydroxytryptamine (serotonin) receptor 5B

multiple interactions

dihydroergotamine binds to protein 5-Htr5b; inhibits the reaction[5-carboxamidotryptamine binds to 5-Htr5b]

RGD

NCBI chr13:32,686,911...32,699,835
Ensembl chr13:32,687,042...32,699,835

G

interleukin 24

increases expression

Dihydroergotamine results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

nuclear receptor subfamily 1, group I, member 2

increases activity

Dihydroergotamine results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

eprinomectin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity

eprinomectin results in decreased activity of ABCB1A protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

anoctamin 1

decreases activity

eprinomectin results in decreased activity of ANO1 protein

NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069

G

nuclear receptor coactivator 2

multiple interactions

eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]

NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

KT 5720

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions

KT 5720 inhibits the reaction [Capsaicin results in increased expression of ABCA1 protein]

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 1A

decreases activity

KT 5720 results in decreased activity of ABCB1 protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 2

multiple interactions

KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]
KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]

PMID:26049102 PMID:29052767 PMID:31300867

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

adrenoceptor alpha 1A

multiple interactions

KT 5720 inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in decreased transport of Potassium]

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

AKT serine/threonine kinase 1

multiple interactions

KT 5720 inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

multiple interactions

KT 5720 inhibits the reaction [cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

activating transcription factor 2

multiple interactions

KT 5720 inhibits the reaction [Bucladesine results in increased expression of ATF2 protein modified form]

NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236

G

calcitonin-related polypeptide alpha

multiple interactions

KT 5720 inhibits the reaction [NPPA protein results in increased secretion of CALCA protein]

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

CART prepropeptide

multiple interactions

KT 5720 inhibits the reaction [CARTPT protein results in increased phosphorylation of GRIN1 protein]

NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713

G

caspase 3

multiple interactions

KT 5720 inhibits the reaction [cilostazol results in increased activity of CASP3 protein]; KT 5720 inhibits the reaction [Colforsin results in increased activity of CASP3 protein]
KT 5720 inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP3 protein]
KT 5720 inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased cleavage of CASP3 protein]

PMID:20131233 PMID:21873648 PMID:32115946

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cholinergic receptor, muscarinic 1

multiple interactions

KT 5720 affects the reaction [muscarinic toxin 7 binds to CHRM1 protein]; KT 5720 promotes the reaction [Acetylcholine binds to CHRM1 protein]; KT 5720 promotes the reaction [N-Methylscopolamine binds to CHRM1 protein]; Staurosporine affects the reaction [KT 5720 promotes the reaction [N-Methylscopolamine binds to CHRM1 protein]]

PMID:10860942 PMID:16439611

NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356

G

cholinergic receptor, muscarinic 2

multiple interactions

KT 5720 promotes the reaction [N-Methylscopolamine binds to CHRM2 protein]

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

cholinergic receptor, muscarinic 3

affects binding

KT 5720 binds to CHRM3 protein

NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278

G

cell death-inducing DFFA-like effector c

multiple interactions

KT 5720 inhibits the reaction [Isoproterenol results in increased expression of CIDEC protein]

NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173

G

casein kinase 2 alpha 1

multiple interactions

KT 5720 inhibits the reaction [cilostazol results in increased phosphorylation of CSNK2A1 protein]

NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696

G

E1A binding protein p300

multiple interactions

KT 5720 inhibits the reaction [cilostazol affects the expression of EP300 protein]

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

fibroblast growth factor 1

multiple interactions

KT 5720 inhibits the reaction [Norepinephrine inhibits the reaction [Carbachol results in increased expression of FGF1 protein]]

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

G protein-coupled estrogen receptor 1

multiple interactions

KT 5720 inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]

NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889

G

glutamate ionotropic receptor NMDA type subunit 1

multiple interactions

KT 5720 inhibits the reaction [CARTPT protein results in increased phosphorylation of GRIN1 protein]

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutathione S-transferase alpha 1

multiple interactions

KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA1 mRNA]

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase alpha 2

multiple interactions

KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA2 mRNA]

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase alpha 4

multiple interactions

KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA4 mRNA]

NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182

G

heme oxygenase 1

multiple interactions

KT 5720 inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]
Dinoprostone inhibits the reaction [KT 5720 promotes the reaction [Lipopolysaccharides results in increased activity of HMOX1 protein]]; KT 5720 inhibits the reaction [Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; KT 5720 promotes the reaction [Lipopolysaccharides results in increased activity of HMOX1 protein]; KT 5720 promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]

PMID:16439612 PMID:24003391

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

interleukin 1 beta

multiple interactions

KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

integrin subunit alpha M

multiple interactions

KT 5720 inhibits the reaction [2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein modified form]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

LDL receptor related protein 1

multiple interactions

KT 5720 inhibits the reaction [Capsaicin results in decreased expression of LRP1 protein]

NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910

G

mitogen activated protein kinase 1

multiple interactions

KT 5720 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK1 protein]]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

KT 5720 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK3 protein]]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

nitric oxide synthase 1

multiple interactions

KT 5720 inhibits the reaction [Mevinphos results in increased expression of NOS1 protein]

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

natriuretic peptide A

multiple interactions

KT 5720 inhibits the reaction [NPPA protein results in increased secretion of CALCA protein]

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

nucleobindin 2

multiple interactions

KT 5720 inhibits the reaction [NUCB2 protein results in increased import of Calcium]

NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353

G

phospholipase A2 group VI

multiple interactions

KT 5720 inhibits the reaction [UCN protein results in decreased expression of PLA2G6 protein]

NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114

G

protein kinase cAMP-activated catalytic subunit alpha

multiple interactions

KT 5720 inhibits the reaction [Bucladesine results in increased activity of PRKACA protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[KT 5720 co-treated with Dinoprostone] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; KT 5720 affects the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

sirtuin 1

multiple interactions

KT 5720 inhibits the reaction [cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]]; KT 5720 inhibits the reaction [cilostazol results in increased phosphorylation of SIRT1 protein]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 1 member 2

multiple interactions

KT 5720 inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]

NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498

G

suppressor of cytokine signaling 3

multiple interactions

KT 5720 inhibits the reaction [isoeugenol results in increased expression of SOCS3 mRNA]

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

tyrosine hydroxylase

decreases expression
multiple interactions

KT 5720 results in decreased expression of TH mRNA
KT 5720 inhibits the reaction [Colforsin results in increased expression of TH mRNA]; KT 5720 inhibits the reaction [HU 211 results in decreased expression of TH mRNA]

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

tumor necrosis factor

multiple interactions

KT 5720 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of TNF mRNA]]; KT 5720 inhibits the reaction [Terbutaline results in decreased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 11

multiple interactions

KT 5720 inhibits the reaction [modafinil results in increased expression of TNFSF11 mRNA]

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

urocortin

multiple interactions

KT 5720 inhibits the reaction [UCN protein results in decreased expression of PLA2G6 protein]

NCBI chr 6:25,238,120...25,238,950
Ensembl chr 6:25,238,120...25,238,950

G

zinc finger protein 36

multiple interactions

KT 5720 inhibits the reaction [isoeugenol results in increased expression of ZFP36 protein]

NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564

O-(chloroacetylcarbamoyl)fumagillol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cyclin D1

increases expression

O-(chloroacetylcarbamoyl)fumagillol results in increased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin-dependent kinase inhibitor 1A

increases expression

O-(chloroacetylcarbamoyl)fumagillol results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

fibroblast growth factor 2

multiple interactions
decreases expression

[O-(chloroacetylcarbamoyl)fumagillol co-treated with docetaxel] results in decreased expression of FGF2 protein
O-(chloroacetylcarbamoyl)fumagillol results in decreased expression of FGF2 protein

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

matrix metallopeptidase 9

multiple interactions

[O-(chloroacetylcarbamoyl)fumagillol co-treated with docetaxel] results in decreased expression of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

nuclear factor kappa B subunit 1

multiple interactions

O-(chloroacetylcarbamoyl)fumagillol inhibits the reaction [Diethylnitrosamine results in increased activity of [NFKB1 protein binds to RELA protein]]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 2

multiple interactions

O-(chloroacetylcarbamoyl)fumagillol inhibits the reaction [Diethylnitrosamine results in increased activity of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

RB transcriptional corepressor 1

decreases phosphorylation

O-(chloroacetylcarbamoyl)fumagillol results in decreased phosphorylation of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

O-(chloroacetylcarbamoyl)fumagillol inhibits the reaction [Diethylnitrosamine results in increased activity of [NFKB1 protein binds to RELA protein]]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

superoxide dismutase 2

multiple interactions

O-(chloroacetylcarbamoyl)fumagillol inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of and results in increased activity of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

tumor protein p53

increases expression

O-(chloroacetylcarbamoyl)fumagillol results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

oxycodone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 8

increases expression

Oxycodone results in increased expression of ABCA8 mRNA

NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988

G

ATP binding cassette subfamily B member 1A

increases expression

Oxycodone results in increased expression of ABCB1A mRNA; Oxycodone results in increased expression of ABCB1A protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

increases expression

Oxycodone results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily G member 1

decreases expression

Oxycodone results in decreased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 5

increases expression

Oxycodone results in increased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

abhydrolase domain containing 6, acylglycerol lipase

increases expression

Oxycodone results in increased expression of ABHD6 mRNA

NCBI chr15:16,859,740...16,907,094
Ensembl chr15:16,859,738...16,906,985

G

acyl-CoA synthetase medium-chain family member 2

increases expression

Oxycodone results in increased expression of ACSM2A mRNA

NCBI chr 1:173,916,368...173,955,116
Ensembl chr 1:173,916,368...173,955,116

G

actinin, alpha 1

decreases expression

Oxycodone results in decreased expression of ACTN1 mRNA

NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251

G

ADAM metallopeptidase domain 17

decreases expression

Oxycodone results in decreased expression of ADAM17 mRNA

NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

increases expression

Oxycodone results in increased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

adhesion G protein-coupled receptor E1

decreases expression

Oxycodone results in decreased expression of ADGRE1 mRNA

NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000

G

aryl hydrocarbon receptor

increases expression

Oxycodone results in increased expression of AHR mRNA

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aldo-keto reductase family 1, member C3

decreases expression

Oxycodone results in decreased expression of AKR1C3 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

AKT serine/threonine kinase 1

increases expression

Oxycodone increases expression of Akt1 mRNA in the hippocampal formation
Oxycodone increases expression of Akt1 mRNA in the hippocampus

RGD

PMID:31071414 PMID:25446355

RGD:405866388, RGD:407445976

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

annexin A3

decreases expression

Oxycodone results in decreased expression of ANXA3 mRNA

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

Rho GDP dissociation inhibitor beta

decreases expression

Oxycodone results in decreased expression of ARHGDIB mRNA

NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658

G

argininosuccinate lyase

increases expression

Oxycodone results in increased expression of ASL mRNA

NCBI chr12:26,659,664...26,677,136
Ensembl chr12:26,659,565...26,679,662

G

activating transcription factor 4

increases expression

Oxycodone results in increased expression of ATF4 protein

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

ATPase Na+/K+ transporting subunit beta 1

increases expression

Oxycodone results in increased expression of ATP1B1 mRNA

NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459

G

beta-1,4-N-acetyl-galactosaminyl transferase 1

increases expression

Oxycodone results in increased expression of B4GALNT1 mRNA

NCBI chr 7:62,988,429...62,996,190
Ensembl chr 7:62,988,930...62,996,190

G

BCL2-related protein A1

decreases expression

Oxycodone results in decreased expression of BCL2A1 mRNA

NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998

G

biliverdin reductase A

decreases expression

Oxycodone results in decreased expression of BLVRA mRNA

NCBI chr 3:114,340,778...114,366,048
Ensembl chr 3:114,340,838...114,366,033

G

carbonic anhydrase 3

decreases expression

Oxycodone results in decreased expression of CA3 mRNA

NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280

G

caveolin 2

decreases expression

Oxycodone results in decreased expression of CAV2 mRNA

NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244

G

C-C motif chemokine ligand 9

decreases expression

Oxycodone results in decreased expression of CCL6 mRNA

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

Cd5 molecule-like

decreases expression

Oxycodone results in decreased expression of CD5L mRNA

NCBI chr 2:172,791,007...172,802,018
Ensembl chr 2:172,790,934...172,829,753

G

cyclin-dependent kinase inhibitor 1A

increases expression

Oxycodone results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

carboxylesterase 2H

affects expression
increases expression

Oxycodone affects the expression of CES2 mRNA
Oxycodone results in increased expression of CES2 mRNA

PMID:20487198 PMID:23439660

NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830

G

chromodomain helicase DNA binding protein 1-like

increases expression

Oxycodone results in increased expression of CHD1L mRNA

NCBI chr 2:185,138,526...185,217,498
Ensembl chr 2:185,139,308...185,217,595

G

CKLF-like MARVEL transmembrane domain containing 6

decreases expression

Oxycodone results in decreased expression of CMTM6 mRNA

NCBI chr 8:114,422,934...114,441,034
Ensembl chr 8:114,422,921...114,441,033

G

2',3'-cyclic nucleotide 3' phosphodiesterase

decreases expression

Oxycodone results in decreased expression of CNP1 mRNA

NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720

G

coactosin-like F-actin binding protein 1

decreases expression

Oxycodone results in decreased expression of COTL1 mRNA

NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689

G

cysteine and glycine-rich protein 1

decreases expression

Oxycodone results in decreased expression of CSRP1 mRNA

NCBI chr13:47,158,171...47,179,388
Ensembl chr13:47,167,789...47,179,384

G

cathepsin C

decreases expression

Oxycodone results in decreased expression of CTSC mRNA

NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387

G

cathepsin L

increases expression

Oxycodone results in increased expression of CTSL mRNA

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cytochrome b-245 alpha chain

decreases expression

Oxycodone results in decreased expression of CYBA mRNA

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome P450, family 17, subfamily a, polypeptide 1

affects expression
increases expression

Oxycodone affects the expression of CYP17A1 mRNA
Oxycodone results in increased expression of CYP17A1 mRNA

PMID:20487198 PMID:23439660

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 27, subfamily a, polypeptide 1

increases expression

Oxycodone results in increased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily a, polypeptide 1

increases expression

Oxycodone results in increased expression of CYP2A1 mRNA

NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887

G

cytochrome P450, family 2, subfamily b, polypeptide 2

affects expression
increases expression

Oxycodone affects the expression of CYP2B2 mRNA
Oxycodone results in increased expression of CYP2B2 mRNA; Oxycodone results in increased expression of CYP2B2 protein

PMID:20487198 PMID:23439660

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, subfamily 2, polypeptide 11

decreases expression

Oxycodone results in decreased expression of CYP2C11 mRNA

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily c, polypeptide 13

affects expression
decreases expression

Oxycodone affects the expression of CYP2C13 mRNA
Oxycodone results in decreased expression of CYP2C13 mRNA

PMID:20487198 PMID:23439660

NCBI chr 1:238,786,764...238,867,195
Ensembl chr 1:238,786,765...238,867,191

G

cytochrome P450, family 2, subfamily c, polypeptide 7

decreases expression

Oxycodone results in decreased expression of CYP2C9 mRNA

NCBI chr 1:237,332,641...237,388,714
Ensembl chr 1:237,332,659...237,388,709

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects response to substance
multiple interactions

CYP2D6 gene polymorphism affects the susceptibility to Oxycodone
[Quinidine results in decreased activity of CYP2D6 protein] which affects the susceptibility to Oxycodone

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

Oxycodone results in increased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily j, polypeptide 4

increases expression

Oxycodone results in increased expression of CYP2J4 mRNA

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
affects metabolic processing
decreases expression

Oxycodone inhibits the reaction [CYP3A2 protein results in increased hydroxylation of Testosterone]
CYP3A4 protein alternative form affects the metabolism of Oxycodone
telithromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Oxycodone]
Oxycodone results in decreased expression of CYP3A2 mRNA; Oxycodone results in decreased expression of CYP3A2 protein

PMID:19755414 PMID:20487198 PMID:33393779

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression

Oxycodone results in increased expression of CYP3A23-3A1 mRNA; Oxycodone results in increased expression of CYP3A23-3A1 protein

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 4, subfamily b, polypeptide 1

increases expression

Oxycodone results in increased expression of CYP4B1 mRNA

NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348

G

dihydrolipoamide branched chain transacylase E2

increases expression

Oxycodone results in increased expression of DBT mRNA

NCBI chr 2:204,481,744...204,510,612
Ensembl chr 2:204,481,737...204,510,609

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

increases expression

Oxycodone results in increased expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions
increases phosphorylation

Naloxone inhibits the reaction [Oxycodone results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

elongation factor for RNA polymerase II 2

increases expression

Oxycodone results in increased expression of ELL2 mRNA

NCBI chr 2:5,189,375...5,258,781
Ensembl chr 2:5,189,971...5,258,781

G

epoxide hydrolase 2

affects expression

Oxycodone affects the expression of EPHX2 mRNA

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

G

exosome component 5

increases expression

Oxycodone results in increased expression of EXOSC5 mRNA

NCBI chr 1:81,168,128...81,177,266
Ensembl chr 1:81,166,023...81,177,265

G

Fc gamma receptor 2A

decreases expression

Oxycodone results in decreased expression of FCGR2A mRNA

NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967

G

FKBP prolyl isomerase 5

increases expression

Oxycodone results in increased expression of FKBP5 mRNA

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

flavin containing dimethylaniline monoxygenase 1

affects expression
increases expression

Oxycodone affects the expression of FMO1 mRNA
Oxycodone results in increased expression of FMO1 mRNA

PMID:20487198 PMID:23439660

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Oxycodone results in increased expression of FOS protein

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glycerol-3-phosphate acyltransferase, mitochondrial

increases expression

Oxycodone results in increased expression of GPAM mRNA

NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639

G

glutamic--pyruvic transaminase

increases expression

Oxycodone results in increased expression of GPT mRNA

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutamic--pyruvic transaminase 2

increases expression

Oxycodone results in increased expression of GPT2 mRNA

NCBI chr19:21,526,800...21,561,314
Ensembl chr19:21,517,621...21,560,610

G

glutathione S-transferase alpha 3

increases expression

Oxycodone results in increased expression of GSTA3 mRNA

NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240

G

glutathione S-transferase alpha 5

increases expression

Oxycodone results in increased expression of GSTA5 mRNA; Oxycodone results in increased expression of GSTA5 protein

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

2-hydroxyacyl-CoA lyase 1

increases expression

Oxycodone results in increased expression of HACL1 mRNA

NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027

G

hydroxyacid oxidase 2

decreases expression

Oxycodone results in decreased expression of HAO2 mRNA

NCBI chr 2:186,200,137...186,232,997
Ensembl chr 2:186,200,504...186,224,425

G

HCK proto-oncogene, Src family tyrosine kinase

decreases expression

Oxycodone results in decreased expression of HCK mRNA

NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693

G

hexosaminidase subunit beta

increases expression

Oxycodone results in increased expression of HEXB mRNA

NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223

G

heterogeneous nuclear ribonucleoprotein A/B

increases expression

Oxycodone results in increased expression of HNRNPAB mRNA

NCBI chr10:35,857,040...35,862,935
Ensembl chr10:35,857,041...35,863,344

G

homer scaffold protein 1

increases expression

Oxycodone results in increased expression of HOMER1 mRNA

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

hydroxysteroid 11-beta dehydrogenase 1

decreases expression

Oxycodone results in decreased expression of HSD11B1 mRNA

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

heat shock protein family A (Hsp70) member 5

increases expression

Oxycodone results in increased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

insulin-like growth factor binding protein, acid labile subunit

decreases expression

Oxycodone results in decreased expression of IGFALS mRNA

NCBI chr10:13,897,468...13,903,920
Ensembl chr10:13,898,395...13,902,677

G

insulin-like growth factor binding protein 1

increases expression

Oxycodone results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

interleukin 18 binding protein

decreases expression

Oxycodone results in decreased expression of IL18BP mRNA

NCBI chr 1:156,372,923...156,374,963
Ensembl chr 1:156,372,883...156,374,963

G

inhibin subunit beta E

decreases expression

Oxycodone results in decreased expression of INHBE mRNA

NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172

G

inositol hexakisphosphate kinase 2

increases expression

Oxycodone results in increased expression of IP6K2 mRNA

NCBI chr 8:109,483,843...109,510,172
Ensembl chr 8:109,484,310...109,510,166

G

integrin subunit beta 2

decreases expression

Oxycodone results in decreased expression of ITGB2 mRNA

NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600

G

inositol 1,4,5-trisphosphate receptor, type 1

increases expression

Oxycodone results in increased expression of ITPR1 mRNA

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

joining chain of multimeric IgA and IgM

decreases expression

Oxycodone results in decreased expression of JCHAIN mRNA

NCBI chr14:19,538,927...19,547,023
Ensembl chr14:19,538,952...19,546,298

G

kinesin light chain 4

increases expression

Oxycodone results in increased expression of KLC4 mRNA

NCBI chr 9:14,337,164...14,351,075
Ensembl chr 9:14,337,534...14,351,066

G

lymphocyte cytosolic protein 1

decreases expression

Oxycodone results in decreased expression of LCP1 mRNA

NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680

G

galectin 3

decreases expression

Oxycodone results in decreased expression of LGALS3 mRNA

NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025

G

phospholysine phosphohistidine inorganic pyrophosphate phosphatase

increases expression

Oxycodone results in increased expression of LHPP mRNA

NCBI chr 1:187,403,390...187,494,577
Ensembl chr 1:187,403,433...187,494,578

G

lin-7 homolog A, crumbs cell polarity complex component

decreases expression

Oxycodone results in decreased expression of LIN7A mRNA

NCBI chr 7:42,586,704...42,742,609
Ensembl chr 7:42,586,719...42,730,550

G

lymphocyte antigen 86

decreases expression

Oxycodone results in decreased expression of LY86 mRNA

NCBI chr17:27,415,807...27,499,695
Ensembl chr17:27,415,830...27,487,260

G

mitogen activated protein kinase 1

increases phosphorylation

Oxycodone results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation

Oxycodone results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MBL associated serine protease 1

decreases expression

Oxycodone results in decreased expression of MASP1 mRNA

NCBI chr11:77,334,794...77,405,271
Ensembl chr11:77,334,859...77,402,974

G

myotubularin related protein 7

increases expression

Oxycodone results in increased expression of MTMR7 mRNA

NCBI chr16:51,641,267...51,732,212
Ensembl chr16:51,641,190...51,732,182

G

myosin Ib

increases expression

Oxycodone results in increased expression of MYO1B mRNA

NCBI chr 9:49,690,043...49,852,373
Ensembl chr 9:49,690,086...49,850,798

G

notch receptor 2

decreases expression

Oxycodone results in decreased expression of NOTCH2 mRNA

NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088

G

nuclear receptor subfamily 1, group I, member 2

increases expression

Oxycodone results in increased expression of NR1I2 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

increases expression

Oxycodone results in increased expression of NR1I3 mRNA

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

neuronal regeneration related protein

decreases expression

Oxycodone results in decreased expression of NREP mRNA

NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591

G

opioid receptor, delta 1

affects binding

Oxycodone binds to OPRD1 protein

NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960

G

opioid receptor, kappa 1

affects binding

Oxycodone binds to OPRK1 protein

NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823

G

opioid receptor, mu 1

affects binding

Oxycodone binds to OPRM1 protein

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

orosomucoid 1

decreases expression

Oxycodone results in decreased expression of ORM1 mRNA

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

oxidative stress induced growth inhibitor 1

decreases expression

Oxycodone results in decreased expression of OSGIN1 mRNA

NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516

G

phosphodiesterase 4B

decreases expression

Oxycodone results in decreased expression of PDE4B mRNA

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

platelet derived growth factor receptor alpha

increases expression

Oxycodone results in increased expression of PDGFRA protein

NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1

increases expression

Oxycodone results in increased expression of PFKFB1 mRNA

NCBI chr X:19,508,522...19,562,165
Ensembl chr X:19,508,546...19,562,182

G

phosphatidylinositol 3-kinase, catalytic subunit type 3

decreases expression

Oxycodone results in decreased expression of PIK3C3 mRNA

NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048

G

phospholipase A2 group 4A

decreases expression

Oxycodone results in decreased expression of PLA2G4A mRNA

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

phospholipase D1

decreases expression

Oxycodone results in decreased expression of PLD1 mRNA

NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692

G

phospholipid scramblase 1

decreases expression

Oxycodone results in decreased expression of PLSCR1 mRNA

NCBI chr 8:92,784,279...92,804,698
Ensembl chr 8:92,784,356...92,804,692

G

patatin-like phospholipase domain containing 7

increases expression

Oxycodone results in increased expression of PNPLA7 mRNA

NCBI chr 3:7,782,572...7,861,504
Ensembl chr 3:7,782,572...7,861,497

G

cytochrome p450 oxidoreductase

increases expression

Oxycodone results in increased expression of POR mRNA

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

protein kinase AMP-activated non-catalytic subunit beta 1

decreases expression

Oxycodone results in decreased expression of PRKAB1 mRNA

NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661

G

protein kinase cAMP-activated catalytic subunit alpha

increases phosphorylation

Oxycodone results in increased phosphorylation of PRKACA protein

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

prolactin receptor

increases expression

Oxycodone results in increased expression of PRLR mRNA

NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718

G

phosphatidylserine synthase 2

increases expression

Oxycodone results in increased expression of PTDSS2 mRNA

NCBI chr 1:196,241,439...196,267,632
Ensembl chr 1:196,241,494...196,267,685

G

protein tyrosine phosphatase 4A1

increases expression

Oxycodone results in increased expression of PTP4A1 mRNA

NCBI chr 9:33,214,201...33,245,046
Ensembl chr 9:33,214,208...33,221,964

G

peroxisomal membrane protein 4

increases expression

Oxycodone results in increased expression of PXMP4 mRNA

NCBI chr 3:143,093,371...143,110,620
Ensembl chr 3:143,093,018...143,110,651

G

PYD and CARD domain containing

decreases expression

Oxycodone results in decreased expression of PYCARD mRNA

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

RAB30, member RAS oncogene family

increases expression

Oxycodone results in increased expression of RAB30 mRNA

NCBI chr 1:146,803,719...146,898,369
Ensembl chr 1:146,803,714...146,892,181

G

RAB38, member RAS oncogene family

decreases expression

Oxycodone results in decreased expression of RAB38 mRNA

NCBI chr 1:142,182,566...142,262,923
Ensembl chr 1:142,182,556...142,262,924

G

Rac family small GTPase 2

decreases expression

Oxycodone results in decreased expression of RAC2 mRNA

NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720

G

regulator of calcineurin 1

decreases expression

Oxycodone results in decreased expression of RCAN1 mRNA

NCBI chr11:31,622,208...31,702,150
Ensembl chr11:31,622,210...31,702,045

G

serpin family A member 7

decreases expression

Oxycodone results in decreased expression of SERPINA7 mRNA

NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040

G

src kinase associated phosphoprotein 2

decreases expression

Oxycodone results in decreased expression of SKAP2 mRNA

NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891

G

solute carrier family 10 member 2

decreases expression

Oxycodone results in decreased expression of SLC10A2 mRNA

NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475

G

solute carrier family 15 member 3

decreases expression

Oxycodone results in decreased expression of SLC15A3 mRNA

NCBI chr 1:207,492,365...207,507,158
Ensembl chr 1:207,492,365...207,507,157

G

solute carrier family 16 member 1

decreases expression

Oxycodone results in decreased expression of SLC16A1 mRNA

NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611

G

solute carrier family 16 member 10

increases expression

Oxycodone results in increased expression of SLC16A10 mRNA

NCBI chr20:43,454,819...43,567,839
Ensembl chr20:43,459,709...43,567,839

G

solute carrier family 17 member 5

increases expression

Oxycodone results in increased expression of SLC17A5 mRNA

NCBI chr 8:79,394,416...79,429,387

G

solute carrier family 1 member 2

increases expression

Oxycodone results in increased expression of SLC1A2 mRNA

NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498

G

solute carrier family 22 member 5

increases expression

Oxycodone results in increased expression of SLC22A5 mRNA

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 22 member 8

decreases expression

Oxycodone results in decreased expression of SLC22A8 mRNA

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

solute carrier family 25 member 15

increases expression

Oxycodone results in increased expression of SLC25A15 mRNA

NCBI chr16:69,631,581...69,654,869
Ensembl chr16:69,634,414...69,653,010

G

solute carrier family 25 member 29

increases expression

Oxycodone results in increased expression of SLC25A29 mRNA

NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940

G

solute carrier family 25, member 30

decreases expression

Oxycodone results in decreased expression of SLC25A30 mRNA

NCBI chr15:51,076,998...51,099,613
Ensembl chr15:51,077,002...51,099,613

G

solute carrier family 27 member 5

increases expression

Oxycodone results in increased expression of SLC27A5 mRNA

NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172

G

solute carrier family 2 member 2

increases expression

Oxycodone results in increased expression of SLC2A2 mRNA

NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933

G

solute carrier family 34 member 2

decreases expression

Oxycodone results in decreased expression of SLC34A2 mRNA

NCBI chr14:57,910,931...57,930,236
Ensembl chr14:57,910,480...57,930,436

G

solute carrier family 35 member B2

decreases expression

Oxycodone results in decreased expression of SLC35B2 mRNA

NCBI chr 9:15,438,594...15,442,227
Ensembl chr 9:15,438,594...15,442,234

G

solute carrier family 37 member 4

increases expression

Oxycodone results in increased expression of SLC37A4 mRNA

NCBI chr 8:44,723,216...44,729,301
Ensembl chr 8:44,723,339...44,729,301

G

solute carrier family 38, member 4

increases expression

Oxycodone results in increased expression of SLC38A4 mRNA

NCBI chr 7:128,142,866...128,203,000
Ensembl chr 7:128,144,807...128,202,995

G

solute carrier family 39 member 4

increases expression

Oxycodone results in increased expression of SLC39A4 mRNA

NCBI chr 7:108,333,368...108,337,553
Ensembl chr 7:108,333,381...108,337,553

G

solute carrier family 41 member 2

decreases expression

Oxycodone results in decreased expression of SLC41A2 mRNA

NCBI chr 7:20,383,714...20,491,178
Ensembl chr 7:20,383,757...20,491,166

G

solute carrier family 49 member 4

increases expression

Oxycodone results in increased expression of SLC49A4 mRNA

NCBI chr11:64,995,629...65,068,929
Ensembl chr11:64,995,679...65,068,926

G

solute carrier family 6 member 9

decreases expression

Oxycodone results in decreased expression of SLC6A9 mRNA

NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728

G

solute carrier family 7 member 7

decreases expression

Oxycodone results in decreased expression of SLC7A7 mRNA

NCBI chr15:27,822,088...27,873,121
Ensembl chr15:27,822,091...27,865,648

G

solute carrier organic anion transporter family member 1B2

increases expression

Oxycodone results in increased expression of SLCO1B2 mRNA

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

secretory leukocyte peptidase inhibitor

decreases expression

Oxycodone results in decreased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

SWI/SNF related BAF chromatin remodeling complex subunit D2

increases expression

Oxycodone results in increased expression of SMARCD2 mRNA

NCBI chr10:91,193,752...91,202,817
Ensembl chr10:91,193,752...91,204,341

G

SH3 and cysteine rich domain 3

decreases expression

Oxycodone results in decreased expression of STAC3 mRNA

NCBI chr 7:63,343,078...63,350,590
Ensembl chr 7:63,343,186...63,350,589

G

sulfatase 2

increases expression

Oxycodone results in increased expression of SULF2 mRNA

NCBI chr 3:154,822,079...154,904,566
Ensembl chr 3:154,822,085...154,904,415

G

sulfotransferase family 1A member 1

decreases expression

Oxycodone results in decreased expression of SULT1A2 mRNA

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

G

synaptonemal complex protein 3

increases expression

Oxycodone results in increased expression of SYCP3 mRNA

NCBI chr 7:22,874,055...22,888,512
Ensembl chr 7:22,874,055...22,888,511

G

threonyl-tRNA synthetase 1

decreases expression

Oxycodone results in decreased expression of TARS1 mRNA

NCBI chr 2:60,368,893...60,387,715
Ensembl chr 2:60,367,796...60,387,717

G

THUMP domain containing 1

decreases expression

Oxycodone results in decreased expression of THUMPD1 mRNA

NCBI chr 1:174,078,875...174,084,915
Ensembl chr 1:174,078,878...174,084,937

G

translocase of inner mitochondrial membrane 8A1

increases expression

Oxycodone results in increased expression of TIMM8A mRNA

NCBI chr X:97,717,932...97,722,170
Ensembl chr X:97,717,920...97,721,960

G

TLE family member 1, transcriptional corepressor

increases expression

Oxycodone results in increased expression of TLE1 mRNA

NCBI chr 5:85,851,827...85,934,806
Ensembl chr 5:85,851,827...85,934,774

G

transmembrane protein 19

decreases expression

Oxycodone results in decreased expression of TMEM19 mRNA

NCBI chr 7:50,958,884...50,985,601
Ensembl chr 7:50,958,888...50,986,809

G

TSC22 domain family, member 3

increases expression

Oxycodone results in increased expression of TSC22D3 mRNA

NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861

G

tsukushi, small leucine rich proteoglycan

increases expression

Oxycodone results in increased expression of TSKU mRNA

NCBI chr 1:152,660,259...152,671,682
Ensembl chr 1:152,656,693...152,672,588

G

tubulin, beta 5 class I

decreases expression

Oxycodone results in decreased expression of TUBB5 mRNA

NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940

G

UDP glucuronosyltransferase family 1 member A1

increases expression

Oxycodone results in increased expression of UGT1A1 mRNA

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

ubiquitin specific peptidase 12

decreases expression

Oxycodone results in decreased expression of USP12 mRNA

NCBI chr12:8,309,845...8,363,686
Ensembl chr12:8,309,750...8,363,656

G

integral membrane transport protein UST5r

decreases expression

Oxycodone results in decreased expression of UST5R mRNA

NCBI chr 1:205,210,558...205,286,868
Ensembl chr 1:205,211,034...205,286,718

G

vasodilator-stimulated phosphoprotein

decreases expression

Oxycodone results in decreased expression of VASP mRNA

NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061

G

vimentin

decreases expression

Oxycodone results in decreased expression of VIM mRNA

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

zinc finger protein 354A

increases expression

Oxycodone results in increased expression of ZNF354A mRNA

NCBI chr10:35,396,242...35,408,069
Ensembl chr10:35,396,231...35,408,068

pravastatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression
decreases expression

[[colestimide co-treated with Pravastatin] results in increased expression of ABCA1 protein] which results in decreased abundance of Cholesterol; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 mRNA; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 protein
cotreatment with pravastatin and colestimide increases expression of abca1 mRNA and protein in rat liver; and decreases expression of abca1 mRNA and protein in rat small intestine
Pravastatin results in decreased expression of ABCA1

CTD
RGD

PMID:17526932 PMID:19461118 PMID:17526932

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions
affects import

Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]
ABCB11 protein affects the import of Pravastatin

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases transport

ABCB1 protein results in increased transport of Pravastatin; ABCB1 protein results in increased transport of Pravastatin analog

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

increases expression

Pravastatin results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

affects export
increases expression
multiple interactions
affects transport

ABCC2 protein affects the export of Pravastatin
Pravastatin results in increased expression of ABCC2 protein
ABCC2 protein binds to and results in increased uptake of Pravastatin analog; Pravastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Pravastatin promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein]
ABCC2 protein affects the transport of Pravastatin

PMID:15901800 PMID:15955871 PMID:23562342 PMID:24909372

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression

Pravastatin results in increased expression of ABCC3 protein

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

increases transport

ABCC4 protein results in increased transport of Pravastatin

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily D member 3

decreases expression

Pravastatin results in decreased expression of ABCD3 mRNA

NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020

G

ATP binding cassette subfamily G member 2

affects export
increases activity

ABCG2 protein affects the export of Pravastatin
Pravastatin results in increased activity of ABCG2 protein

PMID:15901800 PMID:27475308

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 5

increases expression

Pravastatin results in increased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

increases expression

Pravastatin results in increased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-Coenzyme A acyltransferase 1B

decreases expression

Pravastatin results in decreased expression of ACAA1B mRNA

NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825

G

acetyl-CoA acyltransferase 2

decreases expression

Pravastatin results in decreased expression of ACAA2 mRNA

NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA acetyltransferase 1

decreases expression

Pravastatin results in decreased expression of ACAT1 mRNA

NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855

G

angiotensin I converting enzyme

multiple interactions

[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in increased expression of ACE protein]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

multiple interactions

[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein]

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acyl-CoA thioesterase 1

increases expression
decreases expression

Pravastatin results in increased expression of ACOT1 mRNA
Pravastatin results in decreased expression of ACOT1 mRNA

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

acyl-CoA thioesterase 12

decreases expression

Pravastatin results in decreased expression of ACOT12 mRNA

NCBI chr 2:22,986,867...23,027,538
Ensembl chr 2:22,986,626...23,027,536

G

acyl-CoA thioesterase 2

affects expression

Pravastatin affects the expression of ACOT2 mRNA

NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245

G

acyl-CoA thioesterase 3

decreases expression

Pravastatin results in decreased expression of ACOT3 mRNA

NCBI chr 6:103,682,518...103,688,735
Ensembl chr 6:103,682,596...103,688,427
Ensembl chr 6:103,682,596...103,688,427

G

acyl-CoA thioesterase 4

decreases expression

Pravastatin results in decreased expression of ACOT4 mRNA

NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917

G

acyl-CoA oxidase 1

decreases expression

Pravastatin results in decreased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA synthetase family member 2

increases expression
decreases expression

Pravastatin results in increased expression of ACSF2 mRNA
Pravastatin results in decreased expression of ACSF2 mRNA

NCBI chr10:79,504,510...79,546,714
Ensembl chr10:79,504,511...79,546,673

G

acyl-CoA synthetase long-chain family member 1

decreases expression

Pravastatin results in decreased expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

actin, alpha 1, skeletal muscle

decreases expression

Pravastatin results in decreased expression of ACTA1 mRNA

NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742

G

ADAM-like, decysin 1

increases expression

Pravastatin results in increased expression of ADAMDEC1 mRNA

NCBI chr15:42,900,629...42,921,684
Ensembl chr15:42,900,636...42,921,712

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

decreases expression

Pravastatin results in decreased expression of ADH1 mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide

decreases expression

Pravastatin results in decreased expression of ADH7 mRNA

NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182

G

angiotensinogen

decreases expression

Pravastatin results in decreased expression of AGT mRNA

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

allograft inflammatory factor 1

decreases expression

Pravastatin results in decreased expression of AIF1 mRNA

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

aldo-keto reductase family 1, member C3

decreases expression

Pravastatin results in decreased expression of AKR1C18 mRNA
Pravastatin results in decreased expression of AKR1C3 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

Pravastatin inhibits the reaction [Carboplatin results in increased activity of and results in increased phosphorylation of AKT1 protein]
[Pravastatin co-treated with olmesartan] results in increased phosphorylation of AKT1 protein; [resveratrol co-treated with Pravastatin] results in increased phosphorylation of AKT1 protein
Pravastatin results in increased phosphorylation of AKT1 protein

PMID:17170375 PMID:17188708 PMID:18483861

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 1 family, member A1

decreases expression

Pravastatin results in decreased expression of ALDH1A1 mRNA

PMID:16763553 PMID:27225895

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 1 family, member A2

multiple interactions
decreases expression

Cholesterol, Dietary inhibits the reaction [Pravastatin results in decreased expression of ALDH1A2 mRNA]

NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107

G

aldehyde dehydrogenase 1 family, member A3

affects expression

Pravastatin affects the expression of ALDH1A3 mRNA

NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436

G

aldolase 1 A retrogene 2

increases expression
decreases expression

Pravastatin results in increased expression of ALDOART2 mRNA
Pravastatin results in decreased expression of ALDOART2 mRNA

NCBI chr 6:72,939,821...72,941,511
Ensembl chr 6:72,939,788...72,941,709

G

adenosine monophosphate deaminase 3

increases expression

Pravastatin results in increased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887

G

angiopoietin-like 3

decreases expression

Pravastatin results in decreased expression of ANGPTL3 mRNA

NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957

G

ankyrin 2

increases expression
decreases expression

Pravastatin results in increased expression of ANK2 mRNA
Pravastatin results in decreased expression of ANK2 mRNA

NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923

G

ankyrin repeat and sterile alpha motif domain containing 6

increases expression
decreases expression

Pravastatin results in increased expression of ANKS6 mRNA
Pravastatin results in decreased expression of ANKS6 mRNA

NCBI chr 5:61,309,183...61,350,596
Ensembl chr 5:61,309,183...61,350,596

G

apolipoprotein A1

increases expression
decreases expression

Pravastatin results in increased expression of APOA1 mRNA
Pravastatin results in decreased expression of APOA1 mRNA

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

amyloid beta precursor protein

increases expression

Pravastatin results in increased expression of APP

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

arginase 2

increases expression

Pravastatin results in increased expression of ARG2 mRNA

NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378

G

Rho GTPase activating protein 11A

decreases expression
affects expression

Pravastatin results in decreased expression of ARHGAP11A mRNA
Pravastatin affects the expression of ARHGAP11A mRNA

NCBI chr 3:100,590,865...100,607,146
Ensembl chr 3:100,590,865...100,607,559

G

arrestin domain containing 3

decreases expression

Pravastatin results in decreased expression of ARRDC3 mRNA

NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978

G

ATPase H+/K+ transporting subunit alpha

decreases expression

Pravastatin results in decreased expression of ATP4A mRNA

NCBI chr 1:85,961,607...85,974,972
Ensembl chr 1:85,961,708...85,974,844

G

ATPase H+ transporting V0 subunit D2

increases expression
decreases expression

Pravastatin results in increased expression of ATP6V0D2 mRNA
Pravastatin results in decreased expression of ATP6V0D2 mRNA

NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354

G

axin 2

decreases expression

Pravastatin results in decreased expression of AXIN2 mRNA

NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231

G

BRCA1 associated RING domain 1

decreases expression
affects expression

Pravastatin results in decreased expression of BARD1 mRNA
Pravastatin affects the expression of BARD1 mRNA

NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265

G

BCL2 associated X, apoptosis regulator

multiple interactions

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

basic helix-loop-helix family, member a15

decreases expression

Pravastatin results in decreased expression of BHLHA15 mRNA

NCBI chr12:10,420,465...10,424,641
Ensembl chr12:10,420,467...10,424,713

G

basic helix-loop-helix ARNT like 2

affects expression
increases expression

Pravastatin affects the expression of BMAL2 mRNA
Pravastatin results in increased expression of BMAL2 mRNA

NCBI chr 4:179,699,432...179,747,710
Ensembl chr 4:179,699,502...179,746,949

G

BMP-binding endothelial regulator

affects expression
increases expression

Pravastatin affects the expression of BMPER mRNA
Pravastatin results in increased expression of BMPER mRNA

NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256

G

BUB1 mitotic checkpoint serine/threonine kinase B

affects expression
decreases expression

Pravastatin affects the expression of BUB1B mRNA
Pravastatin results in decreased expression of BUB1B mRNA

NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547

G

complement C1q B chain

decreases expression

Pravastatin results in decreased expression of C1QB mRNA

NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407

G

complement C1q C chain

decreases expression

Pravastatin results in decreased expression of C1QC mRNA

NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017

G

complement C5a receptor 1

decreases expression

Pravastatin results in decreased expression of C5AR1 mRNA

NCBI chr 1:76,948,622...76,959,826

G

caspase 3

multiple interactions
increases cleavage

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]
Pravastatin results in increased cleavage of CASP3 protein
Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]; Pravastatin inhibits the reaction [Cisplatin results in increased expression of CASP3 protein]

PMID:18483861 PMID:20368269 PMID:26875785

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

increases activity

Pravastatin results in increased activity of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 12

decreases expression

Pravastatin results in decreased expression of CCL12 mRNA

NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780

G

C-C motif chemokine ligand 2

multiple interactions

Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]
Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of CCL2 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of CCL2 protein]

PMID:18323514 PMID:20884875

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 9

decreases expression

Pravastatin results in decreased expression of CCL6 mRNA

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

CD209d molecule

decreases expression

Pravastatin results in decreased expression of CD209 mRNA

NCBI chr12:1,891,109...1,897,559
Ensembl chr12:1,891,113...1,901,171

G

Cd28 molecule

decreases expression
affects expression

Pravastatin results in decreased expression of CD28 mRNA
Pravastatin affects the expression of CD28 mRNA

NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685

G

CD40 molecule

affects expression

Pravastatin affects the expression of CD40 mRNA

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

Cd7 molecule

decreases expression

Pravastatin results in decreased expression of CD7 mRNA

NCBI chr10:106,304,046...106,306,963
Ensembl chr10:106,304,056...106,306,967

G

cell division cycle 27

affects expression
increases expression

Pravastatin affects the expression of CDC27 mRNA
Pravastatin results in increased expression of CDC27 mRNA

NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736

G

cell division cycle 6

decreases expression
affects expression

Pravastatin results in decreased expression of CDC6 mRNA
Pravastatin affects the expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cell division cycle associated 7 like

affects expression
decreases expression

Pravastatin affects the expression of CDCA7L mRNA
Pravastatin results in decreased expression of CDCA7L mRNA

NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888

G

cadherin-related family member 5

decreases expression
increases expression

Pravastatin results in decreased expression of CDHR5 mRNA
Pravastatin results in increased expression of CDHR5 mRNA

NCBI chr 1:196,373,110...196,381,609
Ensembl chr 1:196,373,112...196,381,543

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

Pravastatin inhibits the reaction [Benzo(a)pyrene results in decreased degradation of CDKN1A protein]; Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CDP-diacylglycerol synthase 1

increases expression

Pravastatin results in increased expression of CDS1 mRNA

NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681

G

CCAAT/enhancer binding protein delta

increases expression

Pravastatin results in increased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

ceramide synthase 6

decreases expression

Pravastatin results in decreased expression of CERS6 mRNA

NCBI chr 3:53,630,637...53,879,692
Ensembl chr 3:53,630,959...53,876,848

G

carboxylesterase-like 1

decreases expression

Pravastatin results in decreased expression of CESL1 mRNA

NCBI chr19:22,670,709...23,006,329
Ensembl chr19:22,670,712...22,712,608

G

cilia and flagella associated protein 96

increases expression

Pravastatin results in increased expression of CFAP96 mRNA

NCBI chr16:46,291,075...46,315,616
Ensembl chr16:46,291,311...46,315,625

G

cellular inhibitor of PP2A

decreases expression

Pravastatin results in decreased expression of CIP2A mRNA

NCBI chr11:51,792,143...51,823,016
Ensembl chr11:51,795,024...51,822,938

G

Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1

decreases expression
increases expression

Pravastatin results in decreased expression of CITED1 mRNA
Pravastatin results in increased expression of CITED1 mRNA

NCBI chr X:67,350,376...67,355,072
Ensembl chr X:67,350,373...67,355,162

G

chloride voltage-gated channel 6

increases expression

Pravastatin results in increased expression of CLCN6 mRNA

NCBI chr 5:158,434,299...158,465,174
Ensembl chr 5:158,434,299...158,465,059

G

C-type lectin domain family 4, member F

decreases expression

Pravastatin results in decreased expression of CLEC4F mRNA

NCBI chr 4:116,129,023...116,138,744
Ensembl chr 4:116,129,023...116,138,775

G

calsyntenin 3

decreases expression
affects expression

Pravastatin results in decreased expression of CLSTN3 mRNA
Pravastatin affects the expression of CLSTN3 mRNA

NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769

G

calponin 1

decreases expression

Pravastatin results in decreased expression of CNN1 mRNA

NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098

G

carnitine palmitoyltransferase 1B

decreases expression
affects expression

Pravastatin results in decreased expression of CPT1B mRNA
Pravastatin affects the expression of CPT1B mRNA

NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404

G

carnitine palmitoyltransferase 2

decreases expression

Pravastatin results in decreased expression of CPT2 mRNA

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

carnitine O-acetyltransferase

increases expression
affects expression

Pravastatin results in increased expression of CRAT mRNA
Pravastatin affects the expression of CRAT mRNA

NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255

G

cAMP responsive element binding protein 3-like 3

decreases expression
affects expression

Pravastatin results in decreased expression of CREB3L3 mRNA
Pravastatin affects the expression of CREB3L3 mRNA

NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048

G

C-reactive protein

decreases expression
increases expression

Pravastatin results in decreased expression of CRP mRNA
Pravastatin results in increased expression of CRP mRNA

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

cysteine sulfinic acid decarboxylase

decreases expression

Pravastatin results in decreased expression of CSAD mRNA

NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615

G

colony stimulating factor 1 receptor

decreases expression

Pravastatin results in decreased expression of CSF1R mRNA

NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415

G

CUB and Sushi multiple domains 1

decreases expression

Pravastatin results in decreased expression of CSMD1 mRNA

NCBI chr16:72,218,189...73,818,380
Ensembl chr16:72,218,503...73,817,614

G

catenin beta 1

affects localization
multiple interactions

Pravastatin affects the localization of CTNNB1 protein
[resveratrol co-treated with Pravastatin] affects the localization of CTNNB1 protein

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

C-X-C motif chemokine ligand 2

affects expression
increases expression

Pravastatin affects the expression of CXCL2 mRNA
Pravastatin results in increased expression of CXCL2 mRNA

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

cytochrome b-245 alpha chain

decreases expression

Pravastatin results in decreased expression of CYBA protein

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome c, somatic

multiple interactions

Pravastatin inhibits the reaction [Carboplatin results in increased expression of CYCS protein]

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases expression

Pravastatin results in decreased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

affects expression
increases expression

Pravastatin affects the expression of CYP1B1 mRNA
Pravastatin results in increased expression of CYP1B1 mRNA

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily b, polypeptide 21

decreases expression

Pravastatin results in decreased expression of CYP2B21 mRNA

NCBI chr 1:81,886,097...81,915,066
Ensembl chr 1:81,886,098...81,915,066

G

cytochrome P450, family 2, subfamily b, polypeptide 3

affects expression

Pravastatin affects the expression of CYP2B10 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily d, polypeptide 3

decreases expression

Pravastatin results in decreased expression of CYP2D3 mRNA

NCBI chr 7:113,917,711...113,922,068
Ensembl chr 7:113,908,947...113,922,084

G

cytochrome P450, family 2, subfamily j, polypeptide 4

decreases expression

Pravastatin results in decreased expression of CYP2J4 mRNA

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

decreases expression

Pravastatin results in decreased expression of CYP3A23-3A1 mRNA

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 4, subfamily a, polypeptide 1

decreases expression

Pravastatin results in decreased expression of CYP4A1 mRNA

NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464

G

cytochrome P450, family 4, subfamily a, polypeptide 2

affects expression

Pravastatin affects the expression of CYP4A2 mRNA

NCBI chr 5:128,922,355...128,934,188
Ensembl chr 5:128,923,615...128,934,165

G

cytochrome P450, family 4, subfamily a, polypeptide 3

decreases expression

Pravastatin results in decreased expression of CYP4A3 mRNA

NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463

G

cytochrome P450, family 51

increases expression

Pravastatin results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

2,4-dienoyl-CoA reductase 1

decreases expression

Pravastatin results in decreased expression of DECR1 mRNA

NCBI chr 5:29,411,172...29,439,054
Ensembl chr 5:29,411,172...29,439,018

G

DEP domain containing 1B

decreases expression
affects expression

Pravastatin results in decreased expression of DEPDC1B mRNA
Pravastatin affects the expression of DEPDC1B mRNA

NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779

G

derlin 3

decreases expression

Pravastatin results in decreased expression of DERL3 mRNA

NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027

G

iodothyronine deiodinase 3

decreases expression

Pravastatin results in decreased expression of DIO3 mRNA

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

DLG associated protein 1

increases expression

Pravastatin results in increased expression of DLGAP1 mRNA

NCBI chr 9:109,857,500...110,726,817
Ensembl chr 9:110,167,448...110,726,817

G

DnaJ heat shock protein family (Hsp40) member A1

affects farnesylation

Pravastatin affects the farnesylation of DNAJA1 protein

NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967

G

deoxyribonuclease 2 beta

increases expression
decreases expression

Pravastatin results in increased expression of DNASE2B mRNA
Pravastatin results in decreased expression of DNASE2B mRNA

NCBI chr 2:235,470,915...235,515,211
Ensembl chr 2:235,470,919...235,486,295

G

dihydropyrimidinase-like 2

increases expression

Pravastatin results in increased expression of DPYSL2 mRNA

NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829

G

denticleless E3 ubiquitin protein ligase homolog

decreases expression
affects expression

Pravastatin results in decreased expression of DTL mRNA
Pravastatin affects the expression of DTL mRNA

NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890

G

enoyl-CoA hydratase 1

decreases expression

Pravastatin results in decreased expression of ECH1 mRNA

NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795

G

endothelin 1

decreases expression

Pravastatin results in decreased expression of EDN1 protein
Pravastatin results in decreased expression of EDN1 mRNA; Pravastatin results in decreased expression of EDN1 protein

PMID:12105140 PMID:19812503

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

EF hand domain family, member B

increases expression

Pravastatin results in increased expression of EFHB mRNA

NCBI chr 9:6,372,191...6,441,678
Ensembl chr 9:6,372,194...6,441,919

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

decreases expression

Pravastatin results in decreased expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

ectonucleotide pyrophosphatase/phosphodiesterase family member 5

affects expression
decreases expression

Pravastatin affects the expression of ENPP5 mRNA
Pravastatin results in decreased expression of ENPP5 mRNA

NCBI chr 9:16,910,187...16,917,633
Ensembl chr 9:16,910,831...16,917,480

G

ectonucleoside triphosphate diphosphohydrolase 2

decreases expression
increases expression

Pravastatin results in decreased expression of ENTPD2 mRNA
Pravastatin results in increased expression of ENTPD2 mRNA

NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866

G

epoxide hydrolase 2

decreases expression

Pravastatin results in decreased expression of EPHX2 mRNA

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

G

epoxide hydrolase 4

increases expression
affects expression

Pravastatin results in increased expression of EPHX4 mRNA
Pravastatin affects the expression of EPHX4 mRNA

NCBI chr14:2,343,376...2,372,680
Ensembl chr14:2,340,248...2,373,022

G

ecotropic viral integration site 2A

decreases expression

Pravastatin results in decreased expression of EVI2A mRNA

NCBI chr10:64,485,760...64,489,660
Ensembl chr10:64,485,200...64,489,843

G

coagulation factor XIII A1 chain

decreases expression

Pravastatin results in decreased expression of F13A1 mRNA

NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700

G

fatty acid binding protein 1

decreases expression

Pravastatin results in decreased expression of FABP1 mRNA

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid binding protein 2

increases expression
decreases expression

Pravastatin results in increased expression of FABP2 mRNA
Pravastatin results in decreased expression of FABP2 mRNA

NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089

G

fatty acid binding protein 5

increases expression

Pravastatin results in increased expression of FABP5 mRNA

NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773

G

fatty acyl CoA reductase 1

increases expression

Pravastatin results in increased expression of FAR1 mRNA

NCBI chr 1:167,644,622...167,705,868
Ensembl chr 1:167,644,677...167,705,730

G

fibrillin 1

increases expression

Pravastatin results in increased expression of FBN1 mRNA

NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889

G

fructose-bisphosphatase 2

affects expression

Pravastatin affects the expression of FBP2 mRNA

NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698

G

farnesyl diphosphate farnesyl transferase 1

affects activity

Pravastatin affects the activity of FDFT1 protein

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

FYVE, RhoGEF and PH domain containing 2

decreases expression

Pravastatin results in decreased expression of FGD2 mRNA

NCBI chr20:7,424,795...7,441,603
Ensembl chr20:7,424,790...7,441,603

G

fibroblast growth factor 13

affects expression
increases expression

Pravastatin affects the expression of FGF13 mRNA
Pravastatin results in increased expression of FGF13 mRNA

NCBI chr X:137,276,498...137,800,056
Ensembl chr X:137,276,511...137,800,391

G

flagellum associated containing coiled-coil domains 1

increases expression

Pravastatin results in increased expression of FLACC1 mRNA

NCBI chr 9:60,315,581...60,343,692
Ensembl chr 9:60,315,582...60,343,648

G

flotillin 1

decreases expression

Pravastatin results in decreased expression of FLOT1 protein

NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978

G

folate receptor beta

decreases expression

Pravastatin results in decreased expression of FOLR2 mRNA

NCBI chr 1:156,200,044...156,218,380
Ensembl chr 1:156,200,060...156,205,724

G

forkhead box O1

decreases phosphorylation

Pravastatin results in decreased phosphorylation of FOXO1 protein

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

glucokinase

decreases expression

Pravastatin results in decreased expression of GCK mRNA

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

glutamate-cysteine ligase, catalytic subunit

increases expression
decreases expression

Pravastatin results in increased expression of GCLC mRNA
Pravastatin results in decreased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glucosaminyl (N-acetyl) transferase 2

increases expression
decreases expression

Pravastatin results in increased expression of GCNT2 mRNA
Pravastatin results in decreased expression of GCNT2 mRNA

NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611

G

galactosidase, beta 1

multiple interactions

Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased activity of GLB1 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

glycine decarboxylase

decreases expression

Pravastatin results in decreased expression of GLDC mRNA

NCBI chr 1:227,883,249...227,962,119
Ensembl chr 1:227,883,249...227,962,097

G

glutaminase 2

decreases expression

Pravastatin results in decreased expression of GLS2 mRNA

NCBI chr 7:617,252...633,424
Ensembl chr 7:617,288...633,426

G

G protein-coupled receptor 85

increases expression

Pravastatin results in increased expression of GPR85 mRNA

NCBI chr 4:42,100,138...42,109,584
Ensembl chr 4:42,102,941...42,109,566

G

glutathione S-transferase kappa 1

decreases expression

Pravastatin results in decreased expression of GSTK1 mRNA

NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292

G

hydroxyacyl-CoA dehydrogenase

decreases expression

Pravastatin results in decreased expression of HADH mRNA

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

decreases expression

Pravastatin results in decreased expression of HADHA mRNA

NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

decreases expression

Pravastatin results in decreased expression of HADHB mRNA

NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869

G

hepcidin antimicrobial peptide

increases expression

Pravastatin results in increased expression of HAMP mRNA

NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891

G

HCLS1 associated protein X-1

multiple interactions

Pravastatin inhibits the reaction [Carboplatin results in decreased expression of HAX1 protein]

NCBI chr 2:175,434,242...175,437,926
Ensembl chr 2:175,434,238...175,437,714

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases response to substance
increases expression
decreases activity
affects expression

HMGCR gene SNP results in decreased susceptibility to Pravastatin
Pravastatin results in increased expression of HMGCR mRNA
Pravastatin results in decreased activity of HMGCR protein
Pravastatin affects the expression of HMGCR mRNA

PMID:8517861 PMID:8593127 PMID:15199031 PMID:27225895 PMID:29969672

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

increases expression

Pravastatin results in increased expression of HMGCS1 mRNA

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

heme oxygenase 1

multiple interactions
increases expression

[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with pirinixic acid] results in increased expression of HMOX1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin results in increased expression of HMOX1 protein]; Pravastatin promotes the reaction [PPARA protein binds to HMOX1 promoter]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

HOP homeobox

decreases expression

Pravastatin results in decreased expression of HOPX mRNA

NCBI chr14:31,055,912...31,082,909
Ensembl chr14:31,075,148...31,082,909

G

histidine-rich glycoprotein

decreases expression

Pravastatin results in decreased expression of HRG mRNA

NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389

G

hydroxysteroid (17-beta) dehydrogenase 7

increases expression

Pravastatin results in increased expression of HSD17B7 mRNA

NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017

G

hydroxysteroid dehydrogenase like 2

decreases expression
increases expression

Pravastatin results in decreased expression of HSDL2 mRNA
Pravastatin results in increased expression of HSDL2 mRNA

NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839

G

isopentenyl-diphosphate delta isomerase 1

increases expression

Pravastatin results in increased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

interferon beta 1

multiple interactions

Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]

NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523

G

interleukin 1 beta

decreases expression
increases expression

Pravastatin results in decreased expression of IL1B mRNA
Pravastatin results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
decreases expression

Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]
Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of IL6 protein]
Pravastatin results in decreased expression of IL6 protein

PMID:17729120 PMID:18323514 PMID:19330073 PMID:20884875

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions
increases response to substance

[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein]; [INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in increased expression of ACE protein]
[LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of INS1 protein
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased susceptibility to INS1 protein

PMID:26875785 PMID:29682576

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

interferon regulatory factor 3

multiple interactions

Pravastatin inhibits the reaction [Palmitic Acid results in increased phosphorylation of IRF3 protein]

NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935

G

integrin subunit alpha 2

multiple interactions

geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit beta 1

multiple interactions

geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

integrin subunit beta 6

affects expression

Pravastatin affects the expression of ITGB6 mRNA

NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671

G

potassium voltage-gated channel, modifier subfamily S, member 3

increases expression

Pravastatin results in increased expression of KCNS3 mRNA

NCBI chr 6:33,808,314...33,865,018
Ensembl chr 6:33,808,216...33,865,125

G

potassium channel tetramerization domain containing 12

decreases expression

Pravastatin results in decreased expression of KCTD12 mRNA

NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282

G

kinesin family member 20A

affects expression
decreases expression

Pravastatin affects the expression of KIF20A mRNA
Pravastatin results in decreased expression of KIF20A mRNA

NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780

G

kinesin family member 20B

affects expression
decreases expression

Pravastatin affects the expression of KIF20B mRNA
Pravastatin results in decreased expression of KIF20B mRNA

NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787

G

kinesin family member 23

affects expression
decreases expression

Pravastatin affects the expression of KIF23 mRNA
Pravastatin results in decreased expression of KIF23 mRNA

NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072

G

KIT ligand

increases expression
affects expression

Pravastatin results in increased expression of KITLG mRNA
Pravastatin affects the expression of KITL mRNA

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

klotho beta

decreases expression

Pravastatin results in decreased expression of KLB mRNA

NCBI chr14:42,899,050...42,950,788
Ensembl chr14:42,899,510...42,950,799

G

keratin 23

decreases expression

Pravastatin results in decreased expression of KRT23 mRNA

NCBI chr10:84,434,445...84,450,773
Ensembl chr10:84,434,380...84,450,983

G

low density lipoprotein receptor

increases activity
increases response to substance
multiple interactions

Pravastatin results in increased activity of LDLR protein
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased susceptibility to INS1 protein; LDLR gene mutant form results in increased susceptibility to Pravastatin
[LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of INS1 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of SNAP25 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of STX1A protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein

PMID:8593127 PMID:26875785

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

leptin

multiple interactions

Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

galectin 4

increases expression
decreases expression

Pravastatin results in increased expression of LGALS4 mRNA
Pravastatin results in decreased expression of LGALS4 mRNA

NCBI chr 1:84,124,766...84,132,481
Ensembl chr 1:84,124,764...84,132,481

G

leucine-rich repeat LGI family, member 2

increases expression

Pravastatin results in increased expression of LGI2 mRNA

NCBI chr14:58,415,965...58,443,450
Ensembl chr14:58,415,965...58,443,407

G

lamin A/C

increases expression

Pravastatin results in increased expression of LMNA protein

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

lipoprotein lipase

decreases expression

Pravastatin results in decreased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

leucine rich melanocyte differentiation associated

decreases expression

Pravastatin results in decreased expression of LRMDA mRNA

NCBI chr15:1,223,098...2,284,764
Ensembl chr15:1,225,710...2,284,749

G

lanosterol synthase

increases expression

Pravastatin results in increased expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

latent transforming growth factor beta binding protein 2

increases expression

Pravastatin results in increased expression of LTBP2 mRNA

NCBI chr 6:104,429,947...104,530,498
Ensembl chr 6:104,429,947...104,526,208

G

lymphocyte antigen 86

decreases expression

Pravastatin results in decreased expression of LY86 mRNA

NCBI chr17:27,415,807...27,499,695
Ensembl chr17:27,415,830...27,487,260

G

microtubule-associated protein tau

affects expression
decreases expression

Pravastatin affects the expression of MAPT
Pravastatin results in decreased expression of MAPT mRNA

PMID:19461118 PMID:27225895

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

microtubule associated serine/threonine kinase-like

affects expression
decreases expression

Pravastatin affects the expression of MASTL mRNA
Pravastatin results in decreased expression of MASTL mRNA

NCBI chr17:85,250,512...85,287,479
Ensembl chr17:85,251,997...85,287,353

G

MDM2 proto-oncogene

increases phosphorylation
increases expression
multiple interactions

Pravastatin results in increased phosphorylation of MDM2 protein
Pravastatin results in increased expression of MDM2 protein
[Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein; Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]; U 0126 inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

meiosis specific with OB-fold

decreases expression
increases expression

Pravastatin results in decreased expression of MEIOB mRNA
Pravastatin results in increased expression of MEIOB mRNA

NCBI chr10:13,833,170...13,865,684
Ensembl chr10:13,833,750...13,865,046

G

monoglyceride lipase

decreases expression
affects expression

Pravastatin results in decreased expression of MGLL mRNA
Pravastatin affects the expression of MGLL mRNA

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

G

myo-inositol oxygenase

decreases expression

Pravastatin results in decreased expression of MIOX mRNA

NCBI chr 7:120,405,031...120,407,529
Ensembl chr 7:120,405,031...120,407,537

G

MIS18 kinetochore protein A

increases expression
decreases expression

Pravastatin results in increased expression of MIS18A mRNA
Pravastatin results in decreased expression of MIS18A mRNA

NCBI chr11:29,968,030...29,981,058
Ensembl chr11:29,967,701...29,981,062

G

malonyl-CoA decarboxylase

decreases expression
affects expression

Pravastatin results in decreased expression of MLYCD mRNA
Pravastatin affects the expression of MLYCD mRNA

NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793

G

membrane metallo-endopeptidase

affects expression
decreases expression

Pravastatin affects the expression of MME mRNA
Pravastatin results in decreased expression of MME mRNA

NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792

G

matrix metallopeptidase 14

decreases expression

Pravastatin results in decreased expression of MMP14 mRNA

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

matrix metallopeptidase 2

decreases activity
decreases expression

Pravastatin results in decreased activity of MMP2 protein
Pravastatin results in decreased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

affects response to substance

MMP3 promoter polymorphism affects the susceptibility to Pravastatin

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

decreases activity
decreases expression

Pravastatin results in decreased activity of MMP9 protein
Pravastatin results in decreased expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

MSS51 mitochondrial translational activator

decreases expression
increases expression

Pravastatin results in decreased expression of MSS51 mRNA
Pravastatin results in increased expression of MSS51 mRNA

NCBI chr15:3,805,240...3,819,385
Ensembl chr15:3,807,516...3,819,385

G

myostatin

increases expression

Pravastatin results in increased expression of MSTN protein

NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933

G

mechanistic target of rapamycin kinase

increases phosphorylation

Pravastatin results in increased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mevalonate diphosphate decarboxylase

increases expression

Pravastatin results in increased expression of MVD mRNA

NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971

G

nuclear factor, erythroid 2

increases expression

Pravastatin results in increased expression of NFE2 mRNA

NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108

G

nicotinamide N-methyltransferase

increases expression
decreases expression

Pravastatin results in increased expression of NNMT mRNA
Pravastatin results in increased expression of NNMT protein
Pravastatin results in decreased expression of NNMT mRNA

PMID:27225895 PMID:33073877

NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655

G

nitric oxide synthase 2

multiple interactions

Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions
increases phosphorylation

[Resveratrol co-treated with Pravastatin] results in increased phosphorylation of NOS3 protein; Pravastatin promotes the reaction [NOS3 protein binds to NOS3 protein]; Pravastatin promotes the reaction [olmesartan results in increased activity of and results in increased phosphorylation of NOS3 protein]; Pravastatin results in increased activity of and results in increased phosphorylation of NOS3 protein
Pravastatin results in increased phosphorylation of NOS3 protein

PMID:17170375 PMID:17188708

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

nuclear receptor subfamily 0, group B, member 2

decreases expression

Pravastatin results in decreased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

NAD(P) dependent steroid dehydrogenase-like

increases expression

Pravastatin results in increased expression of NSDHL mRNA

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

oxidized low density lipoprotein receptor 1

increases expression

Pravastatin results in increased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

origin recognition complex, subunit 1

affects expression
decreases expression

Pravastatin affects the expression of ORC1 mRNA
Pravastatin results in decreased expression of ORC1 mRNA

NCBI chr 5:123,324,273...123,348,375
Ensembl chr 5:123,324,315...123,348,375

G

P2Y receptor family member 10B

affects expression

Pravastatin affects the expression of P2RY10B mRNA

NCBI chr X:72,255,526...72,281,013
Ensembl chr X:72,238,713...72,281,012

G

protocadherin beta 5

increases expression

Pravastatin results in increased expression of PCDHB4 mRNA

NCBI chr18:29,024,315...29,032,183
Ensembl chr18:29,028,382...29,053,259

G

proprotein convertase subtilisin/kexin type 9

increases expression

Pravastatin results in increased expression of PCSK9 mRNA

NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688

G

phosphatidylcholine transfer protein

decreases expression

Pravastatin results in decreased expression of PCTP mRNA

NCBI chr10:74,808,887...74,856,260
Ensembl chr10:74,808,887...74,849,867

G

phosphodiesterase 4A

decreases expression
increases expression

Pravastatin results in decreased expression of PDE4A mRNA
Pravastatin results in increased expression of PDE4A mRNA

NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961

G

pyruvate dehydrogenase kinase 4

affects expression
increases expression

Pravastatin affects the expression of PDK4 mRNA
Pravastatin results in increased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

phosphatidylethanolamine N-methyltransferase

decreases expression

Pravastatin results in decreased expression of PEMT mRNA

NCBI chr10:44,775,910...44,849,990
Ensembl chr10:44,775,911...44,850,013

G

peroxisomal biogenesis factor 11 alpha

decreases expression

Pravastatin results in decreased expression of PEX11A mRNA

NCBI chr 1:133,680,091...133,687,172
Ensembl chr 1:133,680,091...133,687,172

G

platelet factor 4

decreases expression

Pravastatin results in decreased expression of PF4 mRNA

NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365

G

phospholipase A2 receptor 1

increases expression

Pravastatin results in increased expression of PLA2R1 mRNA

NCBI chr 3:44,883,943...45,013,793
Ensembl chr 3:44,883,943...45,013,660

G

phospholipid phosphatase related 1

decreases expression

Pravastatin results in decreased expression of PLPPR1 mRNA

NCBI chr 5:63,437,457...63,725,286
Ensembl chr 5:63,437,816...63,763,835

G

phosphomevalonate kinase

increases expression

Pravastatin results in increased expression of PMVK mRNA

NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364

G

patatin-like phospholipase domain containing 7

decreases expression

Pravastatin results in decreased expression of PNPLA7 mRNA

NCBI chr 3:7,782,572...7,861,504
Ensembl chr 3:7,782,572...7,861,497

G

DNA polymerase epsilon 2, accessory subunit

affects expression
decreases expression

Pravastatin affects the expression of POLE2 mRNA
Pravastatin results in decreased expression of POLE2 mRNA

NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305

G

peroxisome proliferator activated receptor alpha

increases expression
multiple interactions
affects localization

Pravastatin results in increased expression of PPARA protein
Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
Pravastatin affects the localization of PPARA protein
[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin affects the localization of PPARA protein]; Pravastatin promotes the reaction [PPARA protein binds to HMOX1 promoter]

PMID:18812576 PMID:20368269

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

multiple interactions

Pravastatin inhibits the reaction [[troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase, Mg2+/Mn2+ dependent, 1J

decreases expression
increases expression

Pravastatin results in decreased expression of PPM1J mRNA
Pravastatin results in increased expression of PPM1J mRNA

NCBI chr 2:192,278,597...192,283,883
Ensembl chr 2:192,278,517...192,283,882

G

protein kinase AMP-activated catalytic subunit alpha 1

increases activity

Pravastatin results in increased activity of PRKAA1 protein

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

prion like protein doppel

decreases expression

Pravastatin results in decreased expression of PRND mRNA

NCBI chr 3:119,213,462...119,218,742
Ensembl chr 3:119,213,429...119,218,745

G

prostaglandin-endoperoxide synthase 2

increases expression

Pravastatin results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine phosphatase, receptor type, N

increases expression
affects expression

Pravastatin results in increased expression of PTPRN mRNA
Pravastatin affects the expression of PTPRN mRNA

NCBI chr 9:76,741,010...76,756,704
Ensembl chr 9:76,741,016...76,756,190

G

retinol dehydrogenase 11

increases expression

Pravastatin results in increased expression of RDH11 mRNA

NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252

G

receptor accessory protein 1

affects expression
increases expression

Pravastatin affects the expression of REEP1 mRNA
Pravastatin results in increased expression of REEP1 mRNA

NCBI chr 4:103,746,004...103,862,347
Ensembl chr 4:103,745,633...103,862,338

G

retinol saturase

decreases expression

Pravastatin results in decreased expression of RETSAT mRNA

NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310

G

regulator of G-protein signaling 16

decreases expression

Pravastatin results in decreased expression of RGS16 mRNA

NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857

G

ring finger protein 186

decreases expression
affects expression

Pravastatin results in decreased expression of RNF186 mRNA
Pravastatin affects the expression of RNF186 mRNA

NCBI chr 5:151,210,492...151,211,716
Ensembl chr 5:151,210,492...151,211,716

G

Ras-related GTP binding D

decreases expression

Pravastatin results in decreased expression of RRAGD mRNA

NCBI chr 5:47,373,902...47,409,369
Ensembl chr 5:47,373,463...47,409,356

G

retinoid X receptor alpha

multiple interactions

[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

S100 calcium-binding protein A4

affects expression
increases expression

Pravastatin affects the expression of S100A4 mRNA
Pravastatin results in increased expression of S100A4 mRNA

NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254

G

S100 calcium binding protein G

decreases expression

Pravastatin results in decreased expression of S100G mRNA

NCBI chr X:31,705,853...31,708,422
Ensembl chr X:31,705,866...31,708,433

G

spermidine/spermine N1-acetyltransferase family member 2

decreases expression

Pravastatin results in decreased expression of SAT2 mRNA

NCBI chr10:54,340,756...54,343,507
Ensembl chr10:54,340,372...54,343,224

G

stearoyl-CoA desaturase

increases expression

Pravastatin results in increased expression of SCD mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

stearoyl-Coenzyme A desaturase 2

increases expression

Pravastatin results in increased expression of SCD2 mRNA

NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232

G

selectin P

decreases expression

Pravastatin results in decreased expression of SELP protein

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

serpin family B member 1A

decreases expression

Pravastatin results in decreased expression of SERPINB1A mRNA

NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102

G

secreted frizzled-related protein 1

increases expression

Pravastatin results in increased expression of SFRP1 mRNA

NCBI chr16:68,575,763...68,614,180
Ensembl chr16:68,575,763...68,614,286

G

shisa family member 4

increases expression

Pravastatin results in increased expression of SHISA4 mRNA

NCBI chr13:46,799,735...46,803,816
Ensembl chr13:46,799,772...46,803,998

G

sirtuin 1

increases phosphorylation

Pravastatin results in increased phosphorylation of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 10 member 1

decreases expression

Pravastatin results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 13 member 3

decreases expression

Pravastatin results in decreased expression of SLC13A3 mRNA

NCBI chr 3:154,141,878...154,204,604
Ensembl chr 3:154,141,872...154,204,606

G

solute carrier family 15 member 3

decreases expression

Pravastatin results in decreased expression of SLC15A3 mRNA

NCBI chr 1:207,492,365...207,507,158
Ensembl chr 1:207,492,365...207,507,157

G

solute carrier family 16 member 5

decreases expression
affects expression

Pravastatin results in decreased expression of SLC16A5 mRNA
Pravastatin affects the expression of SLC16A5 mRNA

NCBI chr10:100,707,434...100,721,338
Ensembl chr10:100,707,434...100,721,338

G

solute carrier family 17 member 1

decreases expression

Pravastatin results in decreased expression of SLC17A1 mRNA

NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304

G

solute carrier family 17 member 3

decreases expression

Pravastatin results in decreased expression of SLC17A3 mRNA

NCBI chr17:41,270,804...41,300,132
Ensembl chr17:41,270,812...41,295,256

G

solute carrier family 22 member 5

affects expression
decreases expression

Pravastatin affects the expression of SLC22A5 mRNA
Pravastatin results in decreased expression of SLC22A5 mRNA

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 23 member 1

decreases expression

Pravastatin results in decreased expression of SLC23A1 mRNA

NCBI chr18:27,214,940...27,230,564
Ensembl chr18:27,216,281...27,230,697

G

solute carrier family 25 member 20

decreases expression

Pravastatin results in decreased expression of SLC25A20 mRNA

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

solute carrier family 25, member 34

affects expression

Pravastatin affects the expression of SLC25A34 mRNA

NCBI chr 5:153,932,081...153,936,854

G

solute carrier family 25, member 42

decreases expression

Pravastatin results in decreased expression of SLC25A42 mRNA

NCBI chr16:19,213,914...19,251,990
Ensembl chr16:19,213,950...19,237,025

G

solute carrier family 27 member 2

decreases expression

Pravastatin results in decreased expression of SLC27A2 mRNA

NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208

G

solute carrier family 2 member 4

decreases expression

Pravastatin results in decreased expression of SLC2A4 mRNA

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 34 member 2

decreases expression

Pravastatin results in decreased expression of SLC34A2 mRNA

NCBI chr14:57,910,931...57,930,236
Ensembl chr14:57,910,480...57,930,436

G

solute carrier family 9 member B2

affects expression
increases expression

Pravastatin affects the expression of SLC9B2 mRNA
Pravastatin results in increased expression of SLC9B2 mRNA

NCBI chr 2:223,726,982...223,761,234
Ensembl chr 2:223,736,354...223,761,225

G

solute carrier organic anion transporter family, member 1a4

affects transport
decreases expression

SLCO1A4 protein affects the transport of Pravastatin
Pravastatin results in decreased expression of SLCO1A4 protein

PMID:19833843 PMID:24909372

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family, member 1A5

increases expression
decreases expression

Pravastatin results in increased expression of SLCO1A5 mRNA
Pravastatin results in decreased expression of SLCO1A5 mRNA

NCBI chr 4:175,172,390...175,254,598
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family member 1B2

multiple interactions

Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

solute carrier organic anion transporter family, member 2b1

multiple interactions

Pravastatin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein]

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

solute carrier organic anion transporter family, member 4a1

increases expression

Pravastatin results in increased expression of SLCO4A1 mRNA

NCBI chr 3:167,559,177...167,578,307
Ensembl chr 3:167,559,316...167,578,305

G

small integral membrane protein 3

increases expression

Pravastatin results in increased expression of SMIM3 mRNA

NCBI chr18:53,930,019...53,982,339
Ensembl chr18:53,930,020...53,957,416

G

synaptosome associated protein 25

multiple interactions

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of SNAP25 protein

NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760

G

suppressor of cytokine signaling 3

increases expression

Pravastatin results in increased expression of SOCS3 protein

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

sperm associated antigen 5

affects expression
decreases expression

Pravastatin affects the expression of SPAG5 mRNA
Pravastatin results in decreased expression of SPAG5 mRNA

NCBI chr10:63,198,717...63,216,746
Ensembl chr10:63,198,768...63,216,745

G

Spi-C transcription factor

decreases expression
increases expression

Pravastatin results in decreased expression of SPIC mRNA
Pravastatin results in increased expression of SPIC mRNA

NCBI chr 7:23,069,815...23,077,517
Ensembl chr 7:23,069,821...23,077,548

G

steroid 5 alpha-reductase 2

decreases expression

Pravastatin results in decreased expression of SRD5A2 mRNA

NCBI chr 6:21,426,225...21,465,727
Ensembl chr 6:21,426,215...21,462,112

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3

decreases expression

Pravastatin results in decreased expression of ST8SIA3 mRNA

NCBI chr18:57,754,349...57,760,839
Ensembl chr18:57,754,347...57,760,839

G

StAR-related lipid transfer domain containing 4

increases expression

Pravastatin results in increased expression of STARD4 mRNA

NCBI chr18:24,814,683...24,830,024
Ensembl chr18:24,817,107...24,830,024

G

signal transducer and activator of transcription 1

multiple interactions

Pravastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein]

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 3

decreases phosphorylation

Pravastatin results in decreased phosphorylation of STAT3 protein

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

syntaxin 1A

multiple interactions

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of STX1A protein

NCBI chr12:21,641,971...21,670,022
Ensembl chr12:21,641,969...21,669,930

G

sulfotransferase family 1C member 2A

affects expression
decreases expression

Pravastatin affects the expression of SULT1C2 mRNA
Pravastatin results in decreased expression of SULT1C2 mRNA

NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734

G

sulfotransferase family 1E member 1

decreases expression

Pravastatin results in decreased expression of SULT1E1 mRNA

NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275

G

sulfotransferase family 2A member 1

decreases expression

Pravastatin results in decreased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

testis expressed 12

decreases expression

Pravastatin results in decreased expression of TEX12 mRNA

NCBI chr 8:50,908,161...50,913,202
Ensembl chr 8:50,909,052...50,913,217

G

thrombomodulin

affects expression
increases expression

Pravastatin affects the expression of THBD mRNA
Pravastatin results in increased expression of THBD mRNA

NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193

G

TIMP metallopeptidase inhibitor 1

decreases expression

Pravastatin results in decreased expression of TIMP1 mRNA

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

TIMP metallopeptidase inhibitor 2

decreases expression

Pravastatin results in decreased expression of TIMP2 mRNA

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

G

TLC domain containing 4

decreases expression

Pravastatin results in decreased expression of TLCD4 mRNA

NCBI chr 2:209,284,873...209,360,156
Ensembl chr 2:209,289,732...209,341,353

G

transmembrane 7 superfamily member 2

increases expression

Pravastatin results in increased expression of TM7SF2 mRNA

NCBI chr 1:203,355,930...203,360,287
Ensembl chr 1:203,355,931...203,360,270

G

transmembrane protein 139

increases expression
decreases expression

Pravastatin results in increased expression of TMEM139 mRNA
Pravastatin results in decreased expression of TMEM139 mRNA

NCBI chr 4:71,147,072...71,149,151
Ensembl chr 4:71,146,724...71,167,399

G

transmembrane protein 164

decreases expression
increases expression

Pravastatin results in decreased expression of TMEM164 mRNA
Pravastatin results in increased expression of TMEM164 mRNA

NCBI chr X:106,288,019...106,448,642
Ensembl chr X:106,289,371...106,448,640

G

transmembrane protein 205

decreases expression

Pravastatin results in decreased expression of TMEM205 mRNA

NCBI chr 8:20,452,092...20,458,011
Ensembl chr 8:20,452,092...20,457,828

G

tumor necrosis factor

multiple interactions
increases expression

Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]
Pravastatin results in increased expression of TNF mRNA

PMID:17729120 PMID:18323514 PMID:27225895

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 18

affects expression

Pravastatin affects the expression of TNFSF18 mRNA

NCBI chr13:73,833,478...73,907,249
Ensembl chr13:73,831,252...73,843,169

G

troponin T2, cardiac type

increases expression

Pravastatin results in increased expression of TNNT2 mRNA

NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388

G

tumor protein p53

multiple interactions

[Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein; Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of TP53 protein]; Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein]; Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased expression of TP53 protein]
Pravastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein]

PMID:15625077 PMID:20650967 PMID:20884875

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tetraspanin 13

increases expression

Pravastatin results in increased expression of TSPAN13 mRNA

NCBI chr 6:52,738,748...52,765,503
Ensembl chr 6:52,738,758...52,765,547

G

tubulin, alpha 1A

increases expression

Pravastatin results in increased expression of TUBA1A mRNA

NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186

G

UDP glucuronosyltransferase 2 family, polypeptide B1

decreases expression

Pravastatin results in decreased expression of UGT2B1 mRNA

NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986

G

urocanate hydratase 1

decreases expression

Pravastatin results in decreased expression of UROC1 mRNA

NCBI chr 4:122,844,933...122,876,584
Ensembl chr 4:122,844,926...122,876,591

G

vesicle-associated membrane protein 2

multiple interactions

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein

NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809

G

vanin 1

decreases expression

Pravastatin results in decreased expression of VNN1 mRNA

NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395

G

zinc finger CCCH type containing 12A

increases expression
decreases expression

Pravastatin results in increased expression of ZC3H12A mRNA
Pravastatin results in decreased expression of ZC3H12A mRNA

NCBI chr 5:137,376,562...137,385,351
Ensembl chr 5:137,376,564...137,385,351

ridaforolimus

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions

ridaforolimus inhibits the reaction [Radon results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

cadherin 1

multiple interactions

ridaforolimus inhibits the reaction [Radon results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

multiple interactions

ridaforolimus inhibits the reaction [Radon results in increased expression of CDH2 protein]

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

fibronectin 1

multiple interactions

ridaforolimus inhibits the reaction [Radon results in increased expression of FN1 protein]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

mechanistic target of rapamycin kinase

multiple interactions
decreases activity

ridaforolimus inhibits the reaction [Radon results in increased expression of MTOR protein modified form]
ridaforolimus results in decreased activity of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

snail family transcriptional repressor 1

multiple interactions

ridaforolimus inhibits the reaction [Radon results in increased expression of SNAI1 protein]

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

vimentin

multiple interactions

ridaforolimus inhibits the reaction [Radon results in increased expression of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

rifampicin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylacetamide deacetylase

multiple interactions
increases hydrolysis
decreases acetylation

AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]
AADAC protein results in increased hydrolysis of Rifampin

PMID:21856291 PMID:22207054

NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734

G

ATP binding cassette subfamily A member 1

decreases expression
increases expression

Rifampin results in decreased expression of ABCA1 mRNA; Rifampin results in decreased expression of ABCA1 protein
Rifampin results in increased expression of ABCA1 mRNA; Rifampin results in increased expression of ABCA1 protein

PMID:15883047 PMID:17088262

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily A member 2

increases expression

Rifampin results in increased expression of ABCA2 mRNA

NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537

G

ATP binding cassette subfamily A member 8

decreases expression

Rifampin results in decreased expression of ABCA8 mRNA

NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988

G

ATP binding cassette subfamily B member 11

decreases expression
multiple interactions
decreases activity

Rifampin results in decreased expression of ABCB11 mRNA
[Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein
Rifampin results in decreased expression of ABCB11 protein
tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 protein]
Rifampin results in decreased activity of ABCB11 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Rifampin results in decreased expression of ABCB11 mRNA; Rifampin results in decreased expression of ABCB11 protein

PMID:12135489 PMID:16837569 PMID:20829430 PMID:24014644 PMID:25886055 More...

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression
decreases activity
affects activity

[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter]
Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein
[Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate
Rifampin affects the activity of ABCB1 protein

PMID:8632764 PMID:11744607 PMID:14722322 PMID:15276086 PMID:15290871 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

increases expression

Rifampin results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily B member 6

increases expression

Rifampin results in increased expression of ABCB6 mRNA

NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924

G

ATP binding cassette subfamily C member 1

increases expression

Rifampin results in increased expression of ABCC1 mRNA

PMID:17191263 PMID:35972551

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 10

increases expression

Rifampin results in increased expression of ABCC10 mRNA

NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178

G

ATP binding cassette subfamily C member 2

affects export
multiple interactions
increases expression

ABCC2 protein affects the export of Rifampin
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein
Rifampin results in increased expression of ABCC2; Rifampin results in increased expression of ABCC2 mRNA; Rifampin results in increased expression of ABCC2 protein
[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein

PMID:11836020 PMID:12206135 PMID:15652233 PMID:16837569 PMID:16952291 More...

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions
increases expression
increases activity

[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; Rifampin inhibits the reaction [Decitabine results in increased expression of ABCC3 mRNA]
Rifampin results in increased expression of ABCC3 mRNA
Rifampin results in increased activity of ABCC3 protein

PMID:14570758 PMID:16837569 PMID:16952291 PMID:19041851 PMID:20832446 More...

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 5

increases expression

Rifampin results in increased expression of ABCC5 mRNA

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily C member 6

increases expression

Rifampin results in increased expression of ABCC6 mRNA

NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464

G

ATP binding cassette subfamily F member 1

increases expression

Rifampin results in increased expression of ABCF1 mRNA

NCBI chr20:2,802,519...2,815,433
Ensembl chr20:2,802,488...2,815,433

G

ATP binding cassette subfamily G member 1

increases expression

Rifampin results in increased expression of ABCG1 mRNA; Rifampin results in increased expression of ABCG1 protein

PMID:12040753 PMID:17088262

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 2

increases expression
multiple interactions

Rifampin results in increased expression of ABCG2 mRNA; Rifampin results in increased expression of ABCG2 protein
Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]; Rifampin promotes the reaction [Lipopolysaccharides results in decreased expression of ABCG2 mRNA]

PMID:16837569 PMID:27199754 PMID:35972551 PMID:38423481

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 8

increases expression

Rifampin results in increased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

ABI family, member 3

decreases expression

Rifampin results in decreased expression of ABI3 mRNA

NCBI chr10:80,769,819...80,780,816
Ensembl chr10:80,769,822...80,780,816

G

acetyl-CoA carboxylase alpha

increases expression

Rifampin results in increased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

angiotensin converting enzyme 2

decreases expression

Rifampin results in decreased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

actin related protein 10

increases expression

Rifampin results in increased expression of ACTR10 mRNA

NCBI chr 6:89,446,141...89,472,350
Ensembl chr 6:89,446,093...89,473,047

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

increases expression

Rifampin results in increased expression of ADH1C mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

adiponectin, C1Q and collagen domain containing

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of ADIPOQ mRNA

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adenosine A2a receptor

decreases expression

Rifampin results in decreased expression of ADORA2A mRNA

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 2

decreases expression

Rifampin results in decreased expression of AGAP2 mRNA

NCBI chr 7:62,897,282...62,914,295
Ensembl chr 7:62,897,282...62,914,295

G

aryl hydrocarbon receptor

multiple interactions
increases expression

[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in decreased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of AHR protein; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]
Rifampin results in increased expression of AHR mRNA; Rifampin results in increased expression of AHR protein

PMID:22733800 PMID:28428138

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aldo-keto reductase family 1 member B10

increases expression
multiple interactions

Rifampin results in increased expression of AKR1B10 mRNA
pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

5'-aminolevulinate synthase 1

increases expression

Rifampin results in increased expression of ALAS1 mRNA

PMID:24259679 PMID:24552687

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

alkaline phosphatase, biomineralization associated

increases activity
multiple interactions

Rifampin results in increased activity of ALPL protein
[Rifampin co-treated with Isoniazid] results in increased activity of ALPL protein

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

angiopoietin-like 3

decreases expression

Rifampin results in decreased expression of ANGPTL3 mRNA

NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957

G

angiopoietin-like 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin repeat domain 40

increases expression

Rifampin results in increased expression of TMPRSS2 mRNA

NCBI chr10:79,282,075...79,295,322
Ensembl chr10:79,282,075...79,295,320

G

ankyrin repeat domain 65

decreases expression

Rifampin results in decreased expression of ANKRD65 mRNA

NCBI chr 5:166,398,359...166,400,616
Ensembl chr 5:166,397,748...166,400,953

G

ankyrin repeat and sterile alpha motif domain containing 1B

decreases expression

Rifampin results in decreased expression of ANKS1B mRNA

NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693

G

annexin A5

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA

NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369

G

apolipoprotein B

decreases expression
multiple interactions
affects secretion

Rifampin results in decreased expression of APOB mRNA
ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA]
Rifampin affects the secretion of APOB protein

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C3

decreases expression
decreases secretion

Rifampin results in decreased expression of APOC3 mRNA
Rifampin results in decreased secretion of APOC3 protein

NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583

G

aquaporin 3 (Gill blood group)

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

aquaporin 4

decreases expression

Rifampin results in decreased expression of AQP4 mRNA

NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856

G

arylsulfatase family, member J

decreases expression

Rifampin results in decreased expression of ARSJ mRNA

NCBI chr 2:214,774,631...214,854,614
Ensembl chr 2:214,774,654...214,854,612

G

activating transcription factor 3

multiple interactions

[Rifampin co-treated with Cobicistat] results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

multiple interactions
increases expression

ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]
Rifampin results in increased expression of ATF4 mRNA; Rifampin results in increased expression of ATF4 protein
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 protein]

PMID:24638036 PMID:27470132

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

increases expression

Rifampin results in increased expression of ATF6 mRNA

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

ATM serine/threonine kinase

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein
Rifampin results in decreased expression of ATM mRNA

PMID:21224054 PMID:24552687

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase H+ transporting V0 subunit a1

increases expression
multiple interactions

Rifampin results in increased expression of ATP6V0A1 protein
[Rotenone co-treated with Rifampin] results in increased expression of ATP6V0A1 protein; Rifampin inhibits the reaction [Rotenone results in decreased expression of ATP6V0A1 mRNA]; Rotenone inhibits the reaction [Rifampin results in increased expression of ATP6V0A1 protein]

NCBI chr10:85,935,802...85,989,901
Ensembl chr10:85,935,854...85,989,895

G

ATPase H+ transporting V0 subunit D1

multiple interactions

ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]

NCBI chr19:33,403,352...33,447,357
Ensembl chr19:33,403,355...33,447,450

G

ATRX, chromatin remodeler

increases expression

Rifampin results in increased expression of ATRX mRNA

NCBI chr X:70,850,981...70,997,330
Ensembl chr X:70,850,981...70,997,330

G

BCL2 associated X, apoptosis regulator

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein]
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein
Rifampin results in decreased expression of BAX protein

PMID:11958592 PMID:12645856 PMID:21224054 PMID:21419764 PMID:31629065 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

increases expression
multiple interactions

Rifampin results in increased expression of BCL2 protein
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein
[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]

PMID:11958592 PMID:21419764 PMID:31629065

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

increases expression
multiple interactions

Rifampin results in increased expression of BCL2L1 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA

PMID:11958592 PMID:12645856 PMID:21224054

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

basic helix-loop-helix family, member e40

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

bone morphogenetic protein 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

similar to human chromosome 9 open reading frame 153

decreases expression

Rifampin results in decreased expression of C9ORF153 mRNA

NCBI chr17:4,975,415...4,982,400
Ensembl chr17:4,964,834...4,982,766

G

similar to human chromosome 4 open reading frame 51

decreases expression

Rifampin results in decreased expression of C4ORF51 mRNA

NCBI chr19:28,669,044...28,704,512
Ensembl chr19:28,669,059...28,704,508

G

carbonic anhydrase 1

decreases expression

Rifampin results in decreased expression of CA1 mRNA

NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208

G

caspase 1

multiple interactions

Rifampin inhibits the reaction [Rotenone results in increased cleavage of CASP1 protein]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3
[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]

PMID:11958592 PMID:12645856 PMID:17936189 PMID:21419764 PMID:23764483 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]

PMID:11958592 PMID:12645856

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

catalase

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

carbonyl reductase 3

multiple interactions

[Rifampin co-treated with Cobicistat] results in increased expression of CBR3 mRNA

NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875

G

C-C motif chemokine ligand 2

decreases expression

Rifampin results in decreased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

decreases expression

Rifampin results in decreased expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cyclin D1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin G1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

C-C motif chemokine receptor 6

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA

NCBI chr 1:52,474,477...52,508,301
Ensembl chr 1:52,474,168...52,498,603

G

C-C motif chemokine receptor 7

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA

NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309

G

CD36 molecule

increases expression

Rifampin results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2B

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

CCAAT/enhancer binding protein alpha

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPA mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CCAAT/enhancer binding protein beta

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPB mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CCAAT/enhancer binding protein delta

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPD mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

carboxylesterase 1D

increases expression

Rifampin results in increased expression of CES1 protein

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

carboxylesterase 2H

increases expression
multiple interactions

Rifampin results in increased expression of CES2 mRNA; Rifampin results in increased expression of CES2 protein
Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]

PMID:10640517 PMID:17003103

NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830

G

CASP8 and FADD-like apoptosis regulator

multiple interactions
increases expression

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]
Rifampin results in increased expression of CFLAR protein

PMID:11958592 PMID:12645856

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

checkpoint kinase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

CDKN1A interacting zinc finger protein 1

decreases expression

Rifampin results in decreased expression of CIZ1 mRNA

NCBI chr 3:15,658,479...15,673,762
Ensembl chr 3:15,658,539...15,673,762

G

CDC-like kinase 2

decreases expression

Rifampin results in decreased expression of CLK2 mRNA

NCBI chr 2:174,570,614...174,582,645
Ensembl chr 2:174,570,653...174,588,985

G

centlein

increases expression

Rifampin results in increased expression of CNTLN mRNA

NCBI chr 5:99,295,865...99,576,402
Ensembl chr 5:99,296,000...99,576,396

G

carnitine palmitoyltransferase 1A

increases expression

Rifampin results in increased expression of CPT1A mRNA

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

corticotropin releasing hormone receptor 1

decreases expression

Rifampin results in decreased expression of CRHR1 mRNA

NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481

G

C-reactive protein

multiple interactions

[Floxacillin co-treated with Gentamicins co-treated with Rifampin] results in increased expression of CRP protein

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

casein kinase 1, gamma 1

decreases expression

Rifampin results in decreased expression of CSNK1G1 mRNA

NCBI chr 8:66,439,760...66,577,247
Ensembl chr 8:66,439,864...66,572,826

G

C-X-C motif chemokine ligand 1

increases expression

Rifampin results in increased expression of CXCL1 protein

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 10

multiple interactions
affects expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA
Rifampin affects the expression of CXCL10 protein

PMID:21224054 PMID:25051504

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

cytochrome b5 reductase-like

increases expression

Rifampin results in increased expression of CYB5RL mRNA

NCBI chr 5:121,846,223...121,868,287
Ensembl chr 5:121,847,952...121,868,745

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases activity
increases expression

Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
Rifampin results in increased activity of CYP1A1 protein
Rifampin results in increased expression of CYP1A1 mRNA; Rifampin results in increased expression of CYP1A1 protein
[Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP1A1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 protein; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A1 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

PMID:12040753 PMID:18493746 PMID:19118567 PMID:19409404 PMID:22733800 More...

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression

[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A2 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]
Rifampin results in increased expression of CYP1A2 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein]
Rifampin results in increased expression of CYP1A2 mRNA; Rifampin results in increased expression of CYP1A2 protein

PMID:15977188 PMID:17590308 PMID:18493746 PMID:25835148 PMID:29162470 More...

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1B1 mRNA

PMID:21224054 PMID:29162470

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 24, subfamily a, polypeptide 1

multiple interactions
increases expression
increases activity

NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]
Rifampin results in increased activity of CYP24A1 protein

PMID:15630458 PMID:21127053

NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383

G

cytochrome P450, family 26, subfamily a, polypeptide 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA

NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions
increases expression

Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]
Rifampin results in increased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily a, polypeptide 1

increases expression
decreases expression

Rifampin results in increased expression of CYP2A1 mRNA
Rifampin results in increased expression of CYP2A13 mRNA
Rifampin results in decreased expression of CYP2A13 mRNA

PMID:19118567 PMID:22258563

NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887

G

cytochrome P450, family 2, subfamily a, polypeptide 3

increases expression

Rifampin results in increased expression of CYP2A4 mRNA

NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases activity
multiple interactions
increases expression

Rifampin results in increased activity of CYP2B6 protein
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA
Rifampin results in increased expression of CYP2B10 mRNA
Rifampin results in increased expression of CYP2B6 mRNA; Rifampin results in increased expression of CYP2B6 protein
[Rifampin co-treated with Monocrotophos] results in increased activity of CYP2B6 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP2B6 protein

PMID:12040753 PMID:12571232 PMID:12695351 PMID:14709624 PMID:14977870 More...

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

decreases expression

Rifampin results in decreased expression of CYP2C18 mRNA; Rifampin results in decreased expression of CYP2C18 protein

PMID:22258563 PMID:31629065

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases activity
increases expression
multiple interactions

Rifampin results in increased activity of CYP2C19 protein
Rifampin results in increased expression of CYP2C29 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein
Rifampin results in increased expression of CYP2C19 mRNA; Rifampin results in increased expression of CYP2C19 protein
Rifampin results in increased expression of and results in increased activity of CYP2C19 protein

PMID:12584154 PMID:14709624 PMID:15629111 PMID:17954527 PMID:19118567 More...

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 79

affects binding
multiple interactions
increases expression
increases activity

[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]
Rifampin results in increased expression of CYP2C8 mRNA; Rifampin results in increased expression of CYP2C8 protein
Rifampin results in increased activity of CYP2C8 protein

PMID:12040753 PMID:15771232 PMID:15933212 PMID:17954527 PMID:19118567 More...

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases expression
increases activity
decreases expression

Rifampin results in increased expression of CYP2D6 mRNA
Rifampin results in increased activity of CYP2D6 protein
Rifampin results in decreased expression of CYP2D22 mRNA

PMID:19041851 PMID:30503582 PMID:33844597

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases activity
decreases expression
multiple interactions
increases expression

Rifampin results in increased activity of CYP2E1 protein
Rifampin results in decreased expression of CYP2E1 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA
Rifampin results in increased expression of CYP2E1 mRNA; Rifampin results in increased expression of CYP2E1 protein
[Rifampin co-treated with Monocrotophos] results in increased activity of CYP2E1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 protein
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]

PMID:15132840 PMID:18071298 PMID:22258563 PMID:22733800 PMID:25835148 More...

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily f, polypeptide 4

decreases expression

Rifampin results in decreased expression of CYP2F1 mRNA

NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896

G

cytochrome P450, family 2, subfamily j, polypeptide 4

decreases expression

Rifampin results in decreased expression of CYP2J2 mRNA

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 2, subfamily s, polypeptide 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA

NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
affects activity
increases expression
decreases response to substance
increases activity

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A2 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A2 protein
Rifampin affects the activity of CYP3A4 protein
Rifampin results in increased expression of CYP3A4; Rifampin results in increased expression of CYP3A4 mRNA; Rifampin results in increased expression of CYP3A4 mRNA alternative form; Rifampin results in increased expression of CYP3A4 protein
[[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA; [HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP3A4 mRNA; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP3A4 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [Rifampin results in increased expression of CYP3A4 protein] which results in increased hydroxylation of Testosterone; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Arsenic Trioxide inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased hydroxylation of Midazolam]; Dexamethasone promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Econazole promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; lorlatinib inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin binds to and results in increased activity of CYP3A4 protein; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased metabolism of Lidocaine]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A4 protein; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; sulforaphane inhibits the reaction [Rifampin results in increased expression of CYP3A4]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; trichostatin A affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; trichostatin A promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
CYP3A4 protein results in decreased susceptibility to Rifampin
[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of CYP3A4 protein
Rifampin results in increased expression of CYP3A2 mRNA; Rifampin results in increased expression of CYP3A4 mRNA

PMID:8632764 PMID:9298257 PMID:9512926 PMID:10219967 PMID:10640517 More...

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions
increases expression

[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A23-3A1 mRNA]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA]

PMID:12370413 PMID:19041297 PMID:22159698 PMID:22310326

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

Rifampin results in increased expression of CYP3A5 mRNA

PMID:12040753 PMID:12673034 PMID:15629111 PMID:15681896 PMID:19118567 More...

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein
Rifampin results in decreased expression of CYP7A1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]

PMID:15629111 PMID:21127053 PMID:21224054 PMID:22258563 PMID:24259679 More...

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

DDB1 and CUL4 associated factor 5

decreases expression

Rifampin results in decreased expression of DCAF5 mRNA

NCBI chr 6:99,171,506...99,260,183
Ensembl chr 6:99,171,506...99,260,110

G

DNA cross-link repair 1B

decreases expression

Rifampin results in decreased expression of DCLRE1B mRNA

NCBI chr 2:191,309,909...191,318,399
Ensembl chr 2:191,309,913...191,318,423

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of DDIT3 mRNA]
Rifampin results in increased expression of DDIT3 mRNA; Rifampin results in increased expression of DDIT3 protein

PMID:21224054 PMID:27470132 PMID:32535746 PMID:33629115

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

24-dehydrocholesterol reductase

multiple interactions

[Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

iodothyronine deiodinase 1

increases expression

Rifampin results in increased expression of DIO1 mRNA

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

distal-less homeobox 4

decreases expression

Rifampin results in decreased expression of DLX4 mRNA

NCBI chr10:80,085,037...80,090,434
Ensembl chr10:80,085,465...80,090,456

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA

NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967

G

E2F transcription factor 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

endothelin 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

early growth response 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA

PMID:21127053 PMID:21224054

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 2

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

early growth response 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA

NCBI chr 4:118,047,869...118,050,328
Ensembl chr 4:118,047,869...118,050,328

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases phosphorylation
increases expression
multiple interactions

Rifampin results in increased phosphorylation of EIF2AK3 protein
Rifampin results in increased expression of EIF2AK3 mRNA; Rifampin results in increased expression of EIF2AK3 protein
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 protein]

PMID:24638036 PMID:27470132

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation

Rifampin results in increased phosphorylation of EIF2S1 protein

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

ETS transcription factor ELK1

decreases expression

Rifampin results in decreased expression of ELK1 mRNA

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

endothelial PAS domain protein 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

epoxide hydrolase 1

increases expression
multiple interactions

Rifampin results in increased expression of EPHX1 mRNA
pimecrolimus inhibits the reaction [Rifampin results in increased expression of EPHX1 mRNA]

PMID:22258563 PMID:25313206 PMID:29356861

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions
increases expression

Rifampin results in increased expression of and results in increased phosphorylation of ERN1 protein
Rifampin results in increased expression of ERN1 mRNA

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

ethanolamine-phosphate phospho-lyase

increases expression

Rifampin results in increased expression of ETNPPL mRNA

NCBI chr 2:219,173,048...219,194,646
Ensembl chr 2:219,172,978...219,192,212

G

coagulation factor XIII B chain

increases expression

Rifampin results in increased expression of F13B mRNA

NCBI chr13:51,130,908...51,156,383
Ensembl chr13:51,130,920...51,156,381

G

Fas cell surface death receptor

multiple interactions

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]

PMID:11958592 PMID:12645856

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA
Rifampin results in decreased expression of FASLG mRNA; Rifampin results in decreased expression of FASLG protein
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]

PMID:11958592 PMID:12645856 PMID:21224054 PMID:24552687

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fatty acid synthase

increases expression
affects expression
multiple interactions

Rifampin results in increased expression of FASN mRNA
Rifampin affects the expression of FASN mRNA
pimecrolimus inhibits the reaction [Rifampin results in increased expression of FASN mRNA]

PMID:27806127 PMID:29356861 PMID:34689256

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibroblast growth factor 19

multiple interactions
increases expression

[Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA
Rifampin results in increased expression of FGF19 mRNA

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

flavin containing dimethylaniline monoxygenase 4

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA

NCBI chr13:75,154,683...75,172,874
Ensembl chr13:75,154,684...75,172,874

G

forkhead box A1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA

NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188

G

forkhead box P1

increases expression

Rifampin results in increased expression of FOXP1 mRNA

NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258

G

fucosyltransferase 1

decreases expression

Rifampin results in decreased expression of FUT1 mRNA

NCBI chr 1:96,086,934...96,090,352
Ensembl chr 1:96,086,635...96,090,616

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions
decreases expression
affects expression

[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]
Rifampin results in decreased expression of G6PC1 mRNA

PMID:24204015 PMID:34689256

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

GATA binding protein 5

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA

NCBI chr 3:167,418,563...167,426,751
Ensembl chr 3:167,418,565...167,426,751

G

glucokinase

decreases expression
multiple interactions

Rifampin results in decreased expression of GCK protein
NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

GLIS family zinc finger 2

increases expression

Rifampin results in increased expression of GLIS2 mRNA

NCBI chr10:10,951,157...10,978,524
Ensembl chr10:10,951,371...10,971,578

G

G protein subunit alpha L

decreases expression

Rifampin results in decreased expression of GNAL mRNA

NCBI chr18:60,622,311...60,762,599
Ensembl chr18:60,622,311...60,762,599

G

glutamic-oxaloacetic transaminase 1

multiple interactions
increases activity

[Rifampin co-treated with Isoniazid] results in increased activity of GOT1 protein
Rifampin results in increased activity of GOT1 protein

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

multiple interactions
increases activity
increases expression

4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of GPT protein]; [Rifampin co-treated with Acetaminophen] results in decreased activity of GPT protein
Rifampin results in increased activity of GPT protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]
[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein]; Rifampin inhibits the reaction [Acetaminophen results in increased expression of GPT protein]

PMID:24685772 PMID:25886055 PMID:27470132 PMID:31678598 PMID:32633153 More...

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of GPX2 mRNA

PMID:21224054 PMID:33629115

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione peroxidase 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glutamate ionotropic receptor AMPA type subunit 1

decreases expression

Rifampin results in decreased expression of GRIA1 mRNA

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutathione-disulfide reductase

increases activity

Rifampin results in increased activity of GSR protein

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 1

multiple interactions
increases expression

[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of GSTA1 mRNA; Ketoconazole inhibits the reaction [Rifampin results in increased expression of GSTA1 mRNA]

PMID:16608920 PMID:19118567 PMID:29162470

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase mu 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase, mu 5

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

glutathione S-transferase pi 1

multiple interactions
increases expression

[Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 protein
Rifampin results in increased expression of GSTP1 mRNA; Rifampin results in increased expression of GSTP1 protein

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

multiple interactions

GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]

PMID:18397238 PMID:20485159

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

GTF2I repeat domain containing 2

increases expression

Rifampin results in increased expression of GTF2IRD2 mRNA

NCBI chr12:22,497,767...22,536,455
Ensembl chr12:22,498,091...22,536,263

G

granzyme B

increases secretion

Rifampin results in increased secretion of GZMB protein

NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814

G

heparin-binding EGF-like growth factor

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

histone deacetylase 3

multiple interactions

Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]

NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856

G

histone deacetylase 5

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA

NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235

G

hes-related family bHLH transcription factor with YRPW motif 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA

NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312

G

hepatocyte growth factor

multiple interactions

HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

PMID:21127053 PMID:36878459

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

high mobility group nucleosome binding domain 5

increases expression

Rifampin results in increased expression of HMGN5 mRNA

NCBI chr X:74,085,871...74,094,488
Ensembl chr X:74,085,875...74,094,441

G

heme oxygenase 1

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA
dorsomorphin inhibits the reaction [Rifampin results in increased expression of HMOX1 protein]
Rifampin results in increased expression of HMOX1 mRNA; Rifampin results in increased expression of HMOX1 protein
[arsenite co-treated with Rifampin] results in increased expression of HMOX1 mRNA

PMID:21224054 PMID:22159698 PMID:22258563 PMID:31678598

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hepatocyte nuclear factor 4, alpha

multiple interactions

[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]

PMID:21127053 PMID:21292004 PMID:21764778 PMID:25069801

NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320

G

histamine receptor H 1

increases expression

Rifampin results in increased expression of HRH1 mRNA

NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455

G

heat shock protein family A (Hsp70) member 1 like

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA

NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression

ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]
[Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]
Rifampin results in increased expression of HSPA5 mRNA; Rifampin results in increased expression of HSPA5 protein

PMID:24638036 PMID:27470132 PMID:32535746 PMID:33629115

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family B (small) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

heat shock protein family D (Hsp60) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA

NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662

G

heat shock protein family E (Hsp10) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA

NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089

G

interferon gamma

increases secretion

Rifampin results in increased secretion of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor binding protein 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

insulin-like growth factor binding protein 3

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA

NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083

G

insulin-like growth factor binding protein 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA

NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225

G

interleukin 10

affects expression

Rifampin affects the expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12 receptor subunit beta 2

decreases expression

Rifampin results in decreased expression of IL12RB2 mRNA

NCBI chr 4:96,426,396...96,515,251
Ensembl chr 4:96,426,842...96,515,289

G

interleukin 13

increases secretion

Rifampin results in increased secretion of IL13 protein

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 18

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; Rifampin inhibits the reaction [Rotenone results in increased expression of and results in increased secretion of IL1B protein]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]
Rifampin results in decreased expression of IL1B mRNA; Rifampin results in decreased expression of IL1B protein

PMID:21224054 PMID:25051504 PMID:26086368 PMID:31648047

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

decreases expression
multiple interactions
increases expression

Rifampin results in decreased expression of IL6 protein
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]
Rifampin results in increased expression of IL6 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA

PMID:21224054 PMID:21357946 PMID:25051504 PMID:31648047

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

INO80 complex subunit D

decreases expression

Rifampin results in decreased expression of INO80D mRNA

NCBI chr 9:64,447,075...64,514,013
Ensembl chr 9:64,457,165...64,515,242

G

insulin 2

multiple interactions

INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]
Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]

PMID:24204015 PMID:33412187

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

integrator complex subunit 6

decreases expression

Rifampin results in decreased expression of INTS6 mRNA

NCBI chr15:36,908,966...37,048,043
Ensembl chr15:36,933,724...37,021,527

G

IQ motif containing with AAA domain 1

decreases expression

Rifampin results in decreased expression of IQCA1 mRNA

NCBI chr 9:90,626,735...90,742,563
Ensembl chr 9:90,626,744...90,742,618

G

integrin subunit beta like 1

decreases expression

Rifampin results in decreased expression of ITGBL1 mRNA

NCBI chr15:100,780,184...101,041,734
Ensembl chr15:100,780,184...101,041,733

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

kirre like nephrin family adhesion molecule 3

decreases expression

Rifampin results in decreased expression of KIRREL3 mRNA

NCBI chr 8:32,865,779...33,407,555
Ensembl chr 8:32,862,776...33,405,676

G

KLF transcription factor 2

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA

NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944

G

KLF transcription factor 5

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

KLF transcription factor 6

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

low density lipoprotein receptor

increases expression

Rifampin results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

left right determination factor 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA

NCBI chr13:92,649,226...92,659,722
Ensembl chr13:92,656,323...92,659,720

G

leptin

increases expression

Rifampin results in increased expression of LEP protein

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

leukocyte receptor tyrosine kinase

increases expression

Rifampin results in increased expression of LTK mRNA

NCBI chr 3:106,734,675...106,741,552
Ensembl chr 3:106,734,676...106,743,369

G

MAF bZIP transcription factor F

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

microtubule-associated protein 1 light chain 3 beta

decreases metabolic processing
multiple interactions
increases lipidation

Rifampin results in decreased metabolism of MAP1LC3B protein
ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Rifampin results in increased lipidation of MAP1LC3B protein]; Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]

PMID:29908302 PMID:31648047

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen-activated protein kinase 8

multiple interactions

Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]]; Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

MAPK activated protein kinase 2

increases phosphorylation

Rifampin results in increased phosphorylation of MAPKAPK2 protein

NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457

G

microtubule-associated protein, RP/EB family, member 3

increases expression

Rifampin results in increased expression of MAPRE3 mRNA

NCBI chr 6:25,513,800...25,558,876
Ensembl chr 6:25,513,800...25,558,881

G

matrilin 2

increases expression

Rifampin results in increased expression of MATN2 mRNA

NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113

G

myelin basic protein

affects expression

Rifampin affects the expression of MBP mRNA

NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions

[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

MDM2 proto-oncogene

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

mediator complex subunit 1

multiple interactions
decreases expression

Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]
Rifampin results in decreased expression of MED1 mRNA

PMID:21292004 PMID:22214767 PMID:24552687

NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299

G

multiple inositol-polyphosphate phosphatase 1

increases expression

Rifampin results in increased expression of MINPP1 mRNA

NCBI chr 1:230,354,483...230,379,730
Ensembl chr 1:230,354,438...230,379,730

G

microRNA 143

increases expression

Rifampin results in increased expression of MIR143 mRNA

NCBI chr18:55,101,006...55,101,110
Ensembl chr18:55,101,006...55,101,110

G

microRNA 145

increases expression

Rifampin results in increased expression of MIR145 mRNA

NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727

G

microRNA 148b

decreases expression

Rifampin results in decreased expression of MIR148B mRNA

NCBI chr 7:134,421,398...134,421,494
Ensembl chr 7:134,421,398...134,421,494

G

microRNA 15b

increases expression

Rifampin results in increased expression of MIR15B mRNA

NCBI chr 2:153,245,200...153,245,297
Ensembl chr 2:153,245,200...153,245,297

G

microRNA 186

multiple interactions

[Isoniazid co-treated with Rifampin] results in increased expression of MIR186 mRNA

NCBI chr 2:246,582,806...246,582,891
Ensembl chr 2:246,582,806...246,582,891

G

microRNA 192

decreases expression

Rifampin results in decreased expression of MIR192 mRNA

NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055

G

microRNA 200a

increases expression

Rifampin results in increased expression of MIR200A mRNA

NCBI chr 5:166,648,494...166,648,582

G

microRNA 202

increases expression

Rifampin results in increased expression of MIR202 mRNA

NCBI chr 1:194,754,730...194,754,801
Ensembl chr 1:194,754,730...194,754,801

G

microRNA 204

increases expression

Rifampin results in increased expression of MIR204 mRNA

NCBI chr 1:220,316,931...220,317,040
Ensembl chr 1:220,316,931...220,317,040

G

microRNA 20b

increases expression

Rifampin results in increased expression of MIR20B mRNA

NCBI chr X:132,422,211...132,422,282
Ensembl chr X:132,422,211...132,422,282

G

microRNA 21

increases expression

Rifampin results in increased expression of MIR21 mRNA

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

microRNA 212

decreases expression

Rifampin results in decreased expression of MIR212 mRNA

NCBI chr10:60,023,403...60,023,513
Ensembl chr10:60,023,403...60,023,513

G

microRNA 22

increases expression

Rifampin results in increased expression of MIR22 mRNA

NCBI chr10:60,307,039...60,307,133
Ensembl chr10:60,307,039...60,307,133

G

microRNA 26b

increases expression

Rifampin results in increased expression of MIR26B mRNA

NCBI chr 9:75,976,596...75,976,680
Ensembl chr 9:75,976,596...75,976,680

G

microRNA 296

decreases expression

Rifampin results in decreased expression of MIR296 mRNA

NCBI chr 3:163,051,838...163,051,915
Ensembl chr 3:163,051,838...163,051,915

G

microRNA 29a

decreases expression

Rifampin results in decreased expression of MIR29A mRNA

NCBI chr 4:59,650,608...59,650,695

G

microRNA 31

increases expression

Rifampin results in increased expression of MIR31 mRNA

NCBI chr 5:103,599,038...103,599,143

G

microRNA 328

increases expression

Rifampin results in increased expression of MIR328 mRNA

NCBI chr19:33,184,766...33,184,849
Ensembl chr19:33,184,766...33,184,849

G

microRNA 340-1

increases expression

Rifampin results in increased expression of MIR340 mRNA

NCBI chr10:34,393,568...34,393,665
Ensembl chr10:34,393,568...34,393,665

G

microRNA 34a

decreases expression

Rifampin results in decreased expression of MIR34A mRNA

NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103

G

microRNA 374b

increases expression

Rifampin results in increased expression of MIR374B mRNA

NCBI chr X:68,591,732...68,591,799
Ensembl chr X:68,591,732...68,591,799

G

microRNA 532

decreases expression

Rifampin results in decreased expression of MIR532 mRNA

NCBI chr X:15,247,315...15,247,393
Ensembl chr X:15,247,315...15,247,393

G

microRNA 628

decreases expression

Rifampin results in decreased expression of MIR628 mRNA

NCBI chr 8:73,739,846...73,739,929
Ensembl chr 8:73,739,846...73,739,929

G

microRNA 652

decreases expression

Rifampin results in decreased expression of MIR652 mRNA

NCBI chr X:106,343,293...106,343,373
Ensembl chr X:106,343,293...106,343,373

G

microRNA 874

decreases expression

Rifampin results in decreased expression of MIR874 mRNA

NCBI chr17:6,620,649...6,620,724
Ensembl chr17:6,620,649...6,620,724

G

marker of proliferation Ki-67

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 3

decreases secretion

Rifampin results in decreased secretion of MMP3 protein

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

myeloperoxidase

multiple interactions

Rifampin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

major histocompatibility complex, class I-related

affects expression

Rifampin affects the expression of MR1 mRNA

NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970

G

microsomal triglyceride transfer protein

decreases expression

Rifampin results in decreased expression of MTTP mRNA

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

myosin heavy chain 6

increases expression

Rifampin results in increased expression of MYH6 mRNA

NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720

G

nuclear assembly factor 1 ribonucleoprotein

decreases expression

Rifampin results in decreased expression of NAF1 mRNA

NCBI chr16:22,837,583...22,868,320
Ensembl chr16:22,837,588...22,868,293

G

nucleosome assembly protein 1-like 5

increases expression

Rifampin results in increased expression of NAP1L5 mRNA

NCBI chr 4:88,022,670...88,024,988
Ensembl chr 4:88,022,569...88,024,654

G

nuclear receptor coactivator 1

multiple interactions

Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Miconazole promotes the reaction [Rifampin results in increased expression of NCOA1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]

PMID:11581012 PMID:12072427 PMID:16819505 PMID:17088262 PMID:17438109 More...

NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664

G

nuclear receptor coactivator 2

multiple interactions

Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]

NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451

G

nuclear receptor coactivator 6

multiple interactions

NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]

NCBI chr 3:143,890,896...143,961,916
Ensembl chr 3:143,890,896...143,952,268

G

nuclear receptor co-repressor 1

multiple interactions

Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]

NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032

G

nuclear receptor co-repressor 2

multiple interactions

[NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]

PMID:12072427 PMID:22214767 PMID:25313206 PMID:26883953 PMID:28289823 More...

NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions
decreases expression
decreases activity

Rifampin results in increased expression of NFE2L2 protein
[tanshinone co-treated with Rifampin] results in increased expression of NFE2L2 mRNA; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 protein]
Rifampin results in decreased expression of NFE2L2 mRNA; Rifampin results in decreased expression of NFE2L2 protein
Rifampin inhibits the reaction [arsenite results in increased activity of NFE2L2 protein]
Rifampin results in decreased activity of NFE2L2 protein

PMID:31678598 PMID:33307820 PMID:33412187

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear transcription factor Y subunit alpha

decreases expression

Rifampin results in decreased expression of NFYA mRNA

NCBI chr 9:12,587,437...12,613,911
Ensembl chr 9:12,586,259...12,613,898

G

NLR family, pyrin domain containing 3

multiple interactions

Rifampin inhibits the reaction [Rotenone results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA
Rifampin results in increased expression of NOS2 mRNA

PMID:21224054 PMID:24552687

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neuronal PAS domain protein 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA

NCBI chr 1:77,167,375...77,187,887
Ensembl chr 1:77,167,381...77,186,762

G

natriuretic peptide B

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

nuclear receptor subfamily 0, group B, member 2

increases expression
decreases expression

Rifampin results in increased expression of NR0B2 mRNA
Rifampin results in decreased expression of NR0B2 mRNA

PMID:15670600 PMID:34689256

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

affects response to substance
affects localization
decreases acetylation
increases response to substance
increases activity
decreases response to substance
multiple interactions
increases expression
increases localization
affects binding

NR1I2 protein affects the susceptibility to Rifampin
Rifampin affects the localization of NR1I2 protein
Rifampin results in decreased acetylation of NR1I2 protein
NR1I2 protein results in increased susceptibility to Rifampin
[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of NR1I2 protein
NR1I2 protein mutant form results in decreased susceptibility to Rifampin
1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [fexofenadine co-treated with Rifampin] results in increased activity of NR1I2 protein; [Ketoconazole co-treated with Rifampin] results in increased activity of NR1I2 protein; [Loperamide co-treated with Rifampin] results in increased activity of NR1I2 protein; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I2 protein; [Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Camptothecin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; caraway oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Clove Oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; coriander oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Doxorubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Epirubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Fluconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; hydroxyitraconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Itraconazole promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; jasmine oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin binds to and results in increased activity of NR1I2 protein]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; lemongrass oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Miconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of amprenavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Midazolam]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Nelfinavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Saquinavir]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased abundance of Lipids]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Oils, Volatile inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Oils, Volatile promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; oxiconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pazopanib inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin binds to and results in increased activity of NR1I2 protein; Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin inhibits the reaction [oxiconazole results in increased expression of NR1I2 mRNA]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin inhibits the reaction [trichostatin A results in increased acetylation of NR1I2 protein]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; sulforaphane inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; trichostatin A affects the reaction [Rifampin affects the localization of NR1I2 protein]; triptolide inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]
Rifampin results in increased expression of NR1I2 mRNA; Rifampin results in increased expression of NR1I2 protein
Rifampin results in increased localization of NR1I2 protein
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased localization of NR1I2 protein]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA]
Rifampin binds to NR1I2 gene mutant form
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CES2A mRNA; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CYP3A11 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; NR1I2 affects the reaction [Rifampin results in increased activity of CYP3A4 protein]; Rifampin affects the localization of and results in increased activity of NR1I2 protein; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]
[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter; Rifampin binds to NR1I2 protein

PMID:11581012 PMID:12065438 PMID:12072427 PMID:12370413 PMID:12417264 More...

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

increases expression
multiple interactions

Rifampin results in increased expression of NR1I3 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein
Rifampin results in increased expression of NR1I3 mRNA; Rifampin results in increased expression of NR1I3 protein
[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 protein

PMID:19118567 PMID:22733800 PMID:25835148

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
increases expression

Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
Rifampin results in increased expression of NR3C1 mRNA

PMID:10219967 PMID:12673034 PMID:12695351

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

neural retina leucine zipper

increases expression

Rifampin results in increased expression of NRL mRNA

NCBI chr15:29,007,059...29,011,480
Ensembl chr15:29,008,104...29,009,832

G

obscurin like cytoskeletal adaptor 1

decreases expression

Rifampin results in decreased expression of OBSL1 mRNA

NCBI chr 9:76,967,802...76,993,771
Ensembl chr 9:76,974,253...76,993,560

G

occludin

affects localization

Rifampin affects the localization of OCLN protein

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

olfactory receptor family 4 subfamily A member 47

decreases expression

Rifampin results in decreased expression of OR4A47 mRNA

NCBI chr 3:75,873,971...75,874,900
Ensembl chr 3:75,871,362...75,879,648

G

prolyl 4-hydroxylase subunit beta

decreases expression

Rifampin results in decreased expression of P4HB mRNA

NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500

G

poly (ADP-ribose) polymerase 1

multiple interactions

Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

paired box 7

decreases expression

Rifampin results in decreased expression of PAX7 mRNA

NCBI chr 5:151,996,368...152,098,023
Ensembl chr 5:151,999,092...152,097,979

G

phosphoenolpyruvate carboxykinase 1

multiple interactions
increases expression

[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]
Rifampin results in increased expression of PCK1 mRNA

PMID:24204015 PMID:34689256

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

PCNA clamp associated factor

increases expression

Rifampin results in increased expression of PCLAF mRNA

NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994
Ensembl chr 8:66,420,587...66,432,994

G

PDGFA associated protein 1

decreases expression

Rifampin results in decreased expression of PDAP1 mRNA

NCBI chr12:9,470,652...9,480,880
Ensembl chr12:9,470,574...9,535,374

G

phosphodiesterase 4D

decreases expression

Rifampin results in decreased expression of PDE4D mRNA

NCBI chr 2:40,014,933...41,529,190
Ensembl chr 2:40,019,933...41,525,884

G

paternally expressed 3

increases expression

Rifampin results in increased expression of PEG3 mRNA

NCBI chr 1:67,097,874...67,124,692
Ensembl chr 1:67,097,904...67,124,671

G

protein inhibitor of activated STAT, 1

multiple interactions

Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]

NCBI chr 8:63,338,150...63,451,670
Ensembl chr 8:63,338,150...63,438,905

G

paired immunoglobin-like type 2 receptor alpha

decreases expression

Rifampin results in decreased expression of PILRA mRNA

NCBI chr12:17,787,169...17,798,149
Ensembl chr12:17,787,127...17,798,094

G

phosphatidylinositol-5-phosphate 4-kinase type 2 alpha

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA

NCBI chr17:81,496,669...81,668,180
Ensembl chr17:81,496,670...81,668,029

G

polycystin 2 like 1, transient receptor potential cation channel

decreases expression

Rifampin results in decreased expression of PKD2L1 mRNA

NCBI chr 1:243,032,891...243,070,031
Ensembl chr 1:243,032,913...243,070,031

G

pyruvate kinase L/R

increases expression

Rifampin results in increased expression of PKLR mRNA

NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870

G

plasminogen activator, tissue type

decreases expression

Rifampin results in decreased expression of PLAT mRNA

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

paraoxonase 1

increases expression

Rifampin results in increased expression of PON1 mRNA

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

cytochrome p450 oxidoreductase

increases activity

Rifampin results in increased activity of POR protein

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

POU class 2 homeobox 1

decreases expression

Rifampin results in decreased expression of POU2F1 mRNA

NCBI chr13:78,120,617...78,263,306
Ensembl chr13:78,130,685...78,263,363

G

peroxisome proliferator activated receptor alpha

multiple interactions

[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARA protein

PMID:16292757 PMID:36347327

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

[Isoniazid co-treated with Rifampin] results in decreased expression of PPARG protein; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA alternative form; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]; Rifampin results in increased expression of and affects the localization of PPARG protein
Rifampin results in increased expression of PPARG mRNA

PMID:27806127 PMID:33412187 PMID:36347327

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions

[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [PPARGC1A protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]

PMID:16857725 PMID:21292004 PMID:25069801

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein kinase, DNA-activated, catalytic subunit

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A14 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA; PRKDC gene mutant form results in increased susceptibility to [Rifampin co-treated with Phenytoin co-treated with Monocrotaline]

NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952

G

protein arginine methyltransferase 1

multiple interactions

PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]

NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345

G

prune exopolyphosphatase 1

decreases expression

Rifampin results in decreased expression of PRUNE1 mRNA

NCBI chr 2:182,830,575...182,859,972
Ensembl chr 2:182,830,578...182,859,336

G

PC4 and SRSF1 interacting protein 1

increases expression

Rifampin results in increased expression of PSIP1 mRNA

NCBI chr 5:97,847,010...97,879,280
Ensembl chr 5:97,847,015...97,879,257

G

PSMC3 interacting protein

increases expression

Rifampin results in increased expression of PSMC3IP mRNA

NCBI chr10:86,024,281...86,027,928
Ensembl chr10:86,023,950...86,027,423

G

RAD50 double strand break repair protein

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA

NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396

G

RIC8 guanine nucleotide exchange factor B

decreases expression

Rifampin results in decreased expression of RIC8B mRNA

NCBI chr 7:18,746,716...18,843,264
Ensembl chr 7:18,748,641...18,842,372

G

ring finger protein 6

decreases expression

Rifampin results in decreased expression of RNF6 mRNA

NCBI chr12:8,816,797...8,826,870
Ensembl chr12:8,816,833...8,826,847

G

Ras-related GTP binding B

decreases expression

Rifampin results in decreased expression of RRAGB mRNA

NCBI chr X:18,184,619...18,234,639
Ensembl chr X:18,184,992...18,234,639

G

R-spondin 3

decreases expression

Rifampin results in decreased expression of RSPO3 mRNA

NCBI chr 1:28,283,914...28,368,661
Ensembl chr 1:28,283,914...28,367,061

G

RT1 class II, locus Bb

affects expression

Rifampin affects the expression of HLA-DQB1 mRNA

NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597

G

RT1 class II, locus DMa

increases expression

Rifampin results in increased expression of HLA-DMA mRNA

NCBI chr20:4,707,028...4,710,432
Ensembl chr20:4,707,028...4,710,432

G

RT1 class Ib, locus M3, gene 1

affects expression

Rifampin affects the expression of HLA-G mRNA

NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117

G

retinoid X receptor alpha

multiple interactions

1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]
[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]
[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]

PMID:12370413 PMID:16292757 PMID:16632523 PMID:21315811 PMID:25069801

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

scavenger receptor class B, member 1

decreases expression

Rifampin results in decreased expression of SCARB1 mRNA; Rifampin results in decreased expression of SCARB1 protein

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

stearoyl-CoA desaturase

increases expression

Rifampin results in increased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

septin 8

increases expression

Rifampin results in increased expression of SEPTIN8 mRNA

NCBI chr10:37,684,649...37,713,704
Ensembl chr10:37,684,639...37,713,174

G

serpin family A member 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA

NCBI chr 6:122,999,970...123,009,083
Ensembl chr 6:122,999,900...123,009,082

G

serpin family B member 1A

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA

NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102

G

serpin family B member 8

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA

NCBI chr13:23,626,936...23,650,277
Ensembl chr13:23,626,945...23,650,835

G

serpin family B member 9

multiple interactions
increases expression

[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA
Rifampin results in increased expression of SERPINB9 mRNA

PMID:21127053 PMID:24552687

NCBI chr17:31,420,118...31,443,237
Ensembl chr17:31,420,125...31,443,230

G

serpin family E member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA

PMID:21127053 PMID:21224054

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

sideroflexin 1

decreases expression

Rifampin results in decreased expression of SFXN1 mRNA

NCBI chr17:10,486,250...10,522,640
Ensembl chr17:10,486,271...10,522,529

G

serum/glucocorticoid regulated kinase 2

multiple interactions
increases expression

[Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]
Rifampin results in increased expression of SGK2 mRNA

PMID:21127053 PMID:24204015

NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480

G

salt-inducible kinase 2

decreases expression

Rifampin results in decreased expression of SIK2 mRNA

NCBI chr 8:51,225,543...51,325,343
Ensembl chr 8:51,225,543...51,325,415

G

solute carrier family 10 member 1

decreases expression
multiple interactions

Rifampin results in decreased expression of SLC10A1 mRNA
Rifampin results in decreased expression of SLC10A1 protein
[tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 mRNA; [tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 protein; tanshinone inhibits the reaction [Rifampin results in decreased expression of SLC10A1 protein]
[Rifampin co-treated with Isoniazid] results in decreased expression of SLC10A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1

PMID:16837569 PMID:25886055 PMID:33307820 PMID:35835356

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 13 member 5

increases expression

Rifampin results in increased expression of SLC13A5 mRNA; Rifampin results in increased expression of SLC13A5 protein

PMID:25628225 PMID:27199754

NCBI chr10:56,866,249...56,891,189
Ensembl chr10:56,866,249...56,890,945

G

solute carrier family 15 member 1

decreases expression

Rifampin results in decreased expression of SLC15A1 mRNA

NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545

G

solute carrier family 16, member 12

increases expression
decreases expression

Rifampin results in increased expression of SLC16A12 mRNA
Rifampin results in decreased expression of SLC16A12 mRNA

PMID:24552687 PMID:27199754

NCBI chr 1:232,184,004...232,262,170
Ensembl chr 1:232,185,907...232,262,141

G

solute carrier family 17 member 1

decreases expression

Rifampin results in decreased expression of SLC17A1 mRNA

NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304

G

solute carrier family 1 member 2

decreases expression

Rifampin results in decreased expression of SLC1A2 mRNA

NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498

G

solute carrier family 20 member 2

decreases expression

Rifampin results in decreased expression of SLC20A2 mRNA

NCBI chr16:69,460,850...69,551,418
Ensembl chr16:69,460,462...69,521,711

G

solute carrier family 22 member 1

decreases expression
multiple interactions

Rifampin results in decreased expression of SLC22A1 mRNA; Rifampin results in decreased expression of SLC22A1 protein
[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]

PMID:26920453 PMID:27199754

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22, member 25

decreases expression

Rifampin results in decreased expression of SLC22A9 mRNA

NCBI chr 1:205,338,698...205,498,486
Ensembl chr 1:205,338,699...205,433,085

G

solute carrier family 22 member 7

decreases expression

Rifampin results in decreased expression of SLC22A7 mRNA

PMID:16837569 PMID:27199754

NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921

G

solute carrier family 23 member 2

increases expression

Rifampin results in increased expression of SLC23A2 mRNA

NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343

G

solute carrier family 23, member 3

decreases expression

Rifampin results in decreased expression of SLC23A3 mRNA

NCBI chr 9:76,622,621...76,633,188
Ensembl chr 9:76,622,800...76,631,366

G

solute carrier family 25 member 22

increases expression

Rifampin results in increased expression of SLC25A22 mRNA

NCBI chr 1:196,528,471...196,536,398
Ensembl chr 1:196,528,472...196,536,331

G

solute carrier family 25, member 34

decreases expression

Rifampin results in decreased expression of SLC25A34 mRNA

NCBI chr 5:153,932,081...153,936,854

G

solute carrier family 25, member 40

decreases expression

Rifampin results in decreased expression of SLC25A40 mRNA

NCBI chr 4:25,631,447...25,676,454
Ensembl chr 4:25,589,360...25,676,472

G

solute carrier family 26 member 2

decreases expression

Rifampin results in decreased expression of SLC26A2 mRNA

NCBI chr18:54,648,276...54,666,627
Ensembl chr18:54,652,951...54,666,626

G

solute carrier family 26 member 4

decreases expression

Rifampin results in decreased expression of SLC26A4 mRNA

NCBI chr 6:48,107,575...48,153,762
Ensembl chr 6:48,107,588...48,145,703

G

solute carrier family 27 member 1

increases expression

Rifampin results in increased expression of SLC27A1 mRNA

NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,278,984...18,296,063

G

solute carrier family 27 member 2

increases expression

Rifampin results in increased expression of SLC27A2 mRNA

NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208

G

solute carrier family 27 member 3

decreases expression

Rifampin results in decreased expression of SLC27A3 mRNA

NCBI chr 2:175,853,241...175,857,909
Ensembl chr 2:175,853,241...175,857,909

G

solute carrier family 27 member 5

increases expression

Rifampin results in increased expression of SLC27A5 mRNA

NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172

G

solute carrier family 29 member 1

increases expression

Rifampin results in increased expression of SLC29A1 mRNA

NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203

G

solute carrier family 29 member 4

increases expression

Rifampin results in increased expression of SLC29A4 mRNA

NCBI chr12:11,853,540...11,884,660
Ensembl chr12:11,853,540...11,874,834

G

solute carrier family 2 member 12

increases expression

Rifampin results in increased expression of SLC2A12 mRNA

NCBI chr 1:22,803,068...22,862,204
Ensembl chr 1:22,804,418...22,860,971

G

solute carrier family 2 member 2

multiple interactions
decreases expression

NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein]
Rifampin results in decreased expression of SLC2A2 mRNA; Rifampin results in decreased expression of SLC2A2 protein

PMID:26616219 PMID:27199754 PMID:34689256

NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933

G

solute carrier family 30, member 10

decreases expression

Rifampin results in decreased expression of SLC30A10 mRNA

NCBI chr13:96,998,143...97,048,076
Ensembl chr13:96,998,143...97,009,103

G

solute carrier family 38, member 2

decreases expression

Rifampin results in decreased expression of SLC38A2 mRNA

NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436

G

solute carrier family 3 member 1

decreases expression

Rifampin results in decreased expression of SLC3A1 mRNA

NCBI chr 6:9,608,169...9,641,881
Ensembl chr 6:9,608,178...9,641,907

G

solute carrier family 46, member 3

increases expression

Rifampin results in increased expression of SLC46A3 mRNA

NCBI chr12:7,140,610...7,157,093
Ensembl chr12:7,140,668...7,157,092

G

solute carrier family 47 member 1

increases expression

Rifampin results in increased expression of SLC47A1 mRNA

NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637

G

solute carrier family 51 member A

increases expression

Rifampin results in increased expression of SLC51A mRNA

NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485

G

SLC51 subunit beta

increases expression

Rifampin results in increased expression of SLC51B mRNA

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

solute carrier family 5 member 11

increases expression

Rifampin results in increased expression of SLC5A11 mRNA

NCBI chr 1:177,735,511...177,795,193
Ensembl chr 1:177,756,561...177,795,193

G

solute carrier family 5 member 12

increases expression

Rifampin results in increased expression of SLC5A12 mRNA

NCBI chr 3:97,179,326...97,228,405
Ensembl chr 3:97,179,326...97,228,405

G

solute carrier family 6 member 12

increases expression

Rifampin results in increased expression of SLC6A12 mRNA

NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750

G

solute carrier family 6 member 20a

increases expression

Rifampin results in increased expression of SLC6A20 mRNA

NCBI chr 8:123,282,325...123,322,609
Ensembl chr 8:123,281,472...123,322,573

G

solute carrier family 6 member 9

increases expression

Rifampin results in increased expression of SLC6A9 mRNA

NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728

G

solute carrier family 7 member 11

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

solute carrier family 9 member A8

increases expression

Rifampin results in increased expression of SLC9A8 mRNA

NCBI chr 3:156,147,855...156,198,497
Ensembl chr 3:156,148,104...156,198,471

G

solute carrier organic anion transporter family, member 1a4

multiple interactions
decreases activity

Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin]
Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of epyrifenacil metabolite]
Rifampin results in decreased activity of SLCO1A4 protein

PMID:11883641 PMID:34619012

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family member 1B2

multiple interactions
decreases activity
decreases expression

Rifampin inhibits the reaction [SLCO1B3 protein results in increased import of cyanoginosin LR]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of epyrifenacil metabolite]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of estradiol-17 beta-glucuronide]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of fexofenadine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Ursodeoxycholic Acid metabolite]
Rifampin inhibits the reaction [SLCO1B2 protein results in increased uptake of epyrifenacil metabolite]
Rifampin results in decreased activity of SLCO1B3 protein
Rifampin results in decreased expression of SLCO1B3 mRNA

PMID:17369605 PMID:18180276 PMID:21256917 PMID:21430235 PMID:27199754 More...

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

solute carrier organic anion transporter family, member 1c1

decreases activity
multiple interactions

Rifampin results in decreased activity of SLCO1B1 protein
[Rifampin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate

NCBI chr 4:174,466,621...174,513,290
Ensembl chr 4:174,466,631...174,513,289

G

solute carrier organic anion transporter family, member 2a1

multiple interactions

Rifampin inhibits the reaction [decitabine results in increased expression of SLCO2A1 mRNA]

NCBI chr 8:103,588,916...103,672,546
Ensembl chr 8:103,588,916...103,672,546

G

solute carrier organic anion transporter family, member 2b1

increases expression
decreases expression
multiple interactions

Rifampin results in increased expression of SLCO2B1 mRNA
Rifampin results in decreased expression of SLCO2B1 mRNA; Rifampin results in decreased expression of SLCO2B1 protein
Rifampin inhibits the reaction [Dextran Sulfate results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [Lipopolysaccharides results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein]

PMID:21430235 PMID:27199754 PMID:38423481

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

solute carrier organic anion transporter family, member 4C1

increases expression

Rifampin results in increased expression of SLCO4C1 mRNA

NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:97,178,861...97,229,715

G

SMAD family member 9

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA

NCBI chr 2:138,956,326...139,006,315
Ensembl chr 2:138,986,471...139,006,307

G

synuclein alpha

multiple interactions
increases sumoylation

Rifampin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SNCA protein modified form]; UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein]

PMID:17280646 PMID:28132806

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

small nucleolar RNA, H/ACA box 71C

decreases expression

Rifampin results in decreased expression of SNORA71C mRNA

NCBI chr 3:147,017,736...147,017,867
Ensembl chr 3:147,017,736...147,017,867

G

suppressor of cytokine signaling 3

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

sorbin and SH3 domain containing 1

decreases expression

Rifampin results in decreased expression of SORBS1 mRNA

NCBI chr 1:239,107,882...239,330,276
Ensembl chr 1:239,108,777...239,330,169

G

spectrin, beta, erythrocytic

increases expression

Rifampin results in increased expression of SPTB mRNA

NCBI chr 6:95,310,342...95,437,221
Ensembl chr 6:95,310,326...95,437,118

G

sequestosome 1

increases expression

Rifampin results in increased expression of SQSTM1 protein

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

signal transducer and activator of transcription 5A

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA

NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866

G

serine threonine kinase 39

increases expression

Rifampin results in increased expression of STK39 mRNA

NCBI chr 3:52,913,583...53,179,060
Ensembl chr 3:52,913,585...53,179,060

G

sulfotransferase family 1E member 1

multiple interactions

[NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]

NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275

G

sulfotransferase family 2A member 1

multiple interactions

[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

small ubiquitin-like modifier 1

increases expression

Rifampin results in increased expression of SUMO1 protein

NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761

G

small ubiquitin-like modifier 3

multiple interactions

Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]

NCBI chr20:11,010,140...11,020,850
Ensembl chr20:11,007,148...11,020,877
Ensembl chr20:11,007,148...11,020,877

G

Sad1 and UNC84 domain containing 1

decreases expression

Rifampin results in decreased expression of SUN1 mRNA

NCBI chr12:15,396,378...15,441,277
Ensembl chr12:15,396,381...15,441,571

G

thymus, brain and testes associated

decreases expression

Rifampin results in decreased expression of TBATA mRNA

NCBI chr20:29,118,055...29,135,124
Ensembl chr20:29,118,070...29,135,109

G

transcription factor EC

increases expression

Rifampin results in increased expression of TFEC mRNA

NCBI chr 4:45,106,129...45,180,236
Ensembl chr 4:45,107,641...45,180,236

G

thrombospondin type 1 domain containing 4

increases expression

Rifampin results in increased expression of THSD4 mRNA

NCBI chr 8:60,384,636...60,984,419
Ensembl chr 8:60,386,875...61,024,995

G

tight junction protein 1

affects localization
decreases expression

Rifampin affects the localization of TJP1 protein
Rifampin results in decreased expression of TJP1 mRNA

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tight junction protein 2

decreases expression

Rifampin results in decreased expression of TJP2 mRNA

NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295

G

toll-like receptor 1

increases expression

Rifampin results in increased expression of TLR1 mRNA

NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125

G

transmembrane protein 120B

decreases expression

Rifampin results in decreased expression of TMEM120B mRNA

NCBI chr12:33,447,441...33,487,257
Ensembl chr12:33,446,660...33,487,200

G

transmembrane protein 145

increases expression

Rifampin results in increased expression of TMEM145 mRNA

NCBI chr 1:80,891,888...80,901,615
Ensembl chr 1:80,891,927...80,901,611

G

transmembrane protein 88

increases expression

Rifampin results in increased expression of TMEM88 mRNA

NCBI chr10:54,118,752...54,120,447
Ensembl chr10:54,118,752...54,120,447

G

tumor necrosis factor

decreases expression

Rifampin results in decreased expression of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 10b

multiple interactions

[Rifampin co-treated with Cobicistat] results in increased expression of TNFRSF10B mRNA

NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467

G

TNF superfamily member 10

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNFRSF1A-associated via death domain

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA

NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638

G

tsukushi, small leucine rich proteoglycan

increases expression

Rifampin results in increased expression of TSKU mRNA

PMID:24552687 PMID:27177772

NCBI chr 1:152,660,259...152,671,682
Ensembl chr 1:152,656,693...152,672,588

G

ubiquitin-conjugating enzyme E2I

multiple interactions

UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein]

NCBI chr10:14,277,749...14,294,681
Ensembl chr10:69,701,618...69,702,443
Ensembl chr10:69,701,618...69,702,443

G

UDP-glucose 6-dehydrogenase

multiple interactions
increases expression

[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA
Rifampin results in increased expression of UGDH mRNA

NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354

G

UDP glucuronosyltransferase family 1 member A1

affects expression
increases expression
multiple interactions

Rifampin affects the expression of UGT1A1 mRNA
Rifampin results in increased expression of UGT1A1 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of UGT1A1 mRNA

PMID:15104253 PMID:15771232 PMID:15849716 PMID:18098064 PMID:22126990 More...

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases expression
multiple interactions

Rifampin results in increased expression of UGT1A3 mRNA
pimecrolimus inhibits the reaction [Rifampin results in increased expression of UGT1A3 mRNA]

PMID:25313206 PMID:29356861

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A6

increases expression

Rifampin results in increased expression of UGT1A6 mRNA

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

increases expression

Rifampin results in increased expression of UGT1A9 mRNA; Rifampin results in increased expression of UGT1A9 protein

NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

ubiquitin like with PHD and ring finger domains 2

decreases expression

Rifampin results in decreased expression of UHRF2 mRNA

NCBI chr 1:227,814,639...227,877,907
Ensembl chr 1:227,814,963...227,877,904

G

uracil-DNA glycosylase

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA

NCBI chr12:42,485,276...42,494,217
Ensembl chr12:42,485,276...42,494,206

G

ubiquitin specific peptidase 17-like a2

decreases expression

Rifampin results in decreased expression of USP17L2 mRNA

NCBI chr 1:159,151,417...159,155,192
Ensembl chr 1:159,151,432...159,155,192

G

vascular endothelial growth factor A

increases expression

Rifampin results in increased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial growth factor D

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA

NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295

G

vitamin K epoxide reductase complex, subunit 1

affects response to substance

VKORC1 alternative form affects the susceptibility to Rifampin

NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008

G

von Willebrand factor A domain containing 1

decreases expression

Rifampin results in decreased expression of VWA1 mRNA

NCBI chr 5:166,377,451...166,382,784
Ensembl chr 5:166,377,455...166,382,637

G

X-linked inhibitor of apoptosis

increases expression

Rifampin results in increased expression of XIAP protein

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

G

X-ray repair cross complementing 4

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA

NCBI chr 2:20,948,464...21,197,705
Ensembl chr 2:20,951,200...21,197,808

G

zinc finger CCHC-type containing 13

decreases expression

Rifampin results in decreased expression of ZCCHC13 mRNA

NCBI chr X:68,643,568...68,644,671
Ensembl chr X:68,643,549...68,665,131

G

zinc finger protein 11

decreases expression

Rifampin results in decreased expression of ZNF546 mRNA

NCBI chr12:27,028,067...27,040,846
Ensembl chr12:27,028,115...27,041,365

G

zinc finger protein 451

decreases expression

Rifampin results in decreased expression of ZNF451 mRNA

NCBI chr 9:35,985,441...36,040,991
Ensembl chr 9:35,985,443...36,040,652

G

zinc finger protein 46

decreases expression

Rifampin results in decreased expression of ZNF436 mRNA

NCBI chr 5:148,519,398...148,529,903
Ensembl chr 5:148,520,855...148,529,459

G

zinc finger protein 462

decreases expression

Rifampin results in decreased expression of ZNF462 mRNA

NCBI chr 5:69,670,085...69,810,729
Ensembl chr 5:69,670,328...69,810,327

G

zinc finger protein 658

decreases expression

Rifampin results in decreased expression of ZNF782 mRNA

NCBI chr 1:93,992,467...94,005,689
Ensembl chr 1:93,992,469...94,005,687

G

zinc finger protein 873

increases expression

Rifampin results in increased expression of ZNF441 mRNA

NCBI chr 7:7,926,951...7,959,822
Ensembl chr 7:7,926,957...7,951,803
Ensembl chr 7:7,926,957...7,951,803

rifaximin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ABCB1A mRNA
rifaximin results in increased expression of ABCB1 mRNA

PMID:21141967 PMID:22790967

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

actin alpha 2, smooth muscle

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ACTA2 mRNA

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

apolipoprotein A4

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of APOA4 mRNA

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

C-C motif chemokine ligand 3

multiple interactions

[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

CD36 molecule

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CD36 protein

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

complement factor D

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CFD mRNA

NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053

G

cell death-inducing DFFA-like effector c

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CIDEC mRNA

NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173

G

collagen type I alpha 1 chain

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression

Rifaximin results in increased expression of CYP3A4 mRNA

PMID:21141967 PMID:27506419

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7B1 protein

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

diacylglycerol O-acyltransferase 2

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of DGAT2 mRNA

NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428

G

fatty acid binding protein 2

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of FABP2 protein

NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089

G

interferon gamma

multiple interactions

[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

[rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

lymphotoxin alpha

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of LTA mRNA

NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859

G

myeloperoxidase

multiple interactions

[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of NR1H4 protein

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases activity
increases expression
increases response to substance

4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; 4,4'-hexafluorisopropylidene diphenol metabolite inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased abundance of Triglycerides; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ABCB1A mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ACTA2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of APOA4 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CD36 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CFD mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CIDEC mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of COL1A1 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP3A11 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7A1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7B1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of DGAT2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of FABP2 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of LTA mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of NR1H4 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of PPARG mRNA; [Rifaximin binds to and results in increased activity of NR1I2 protein] which results in decreased susceptibility to Trinitrobenzenesulfonic Acid; bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; Rifaximin binds to and results in increased activity of NR1I2 protein
[Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
rifaximin results in increased expression of NR1I2 mRNA
NR1I2 results in increased susceptibility to rifaximin

PMID:21599020 PMID:22291955 PMID:22790967 PMID:27506419 PMID:30408883

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

peroxisome proliferator-activated receptor gamma

multiple interactions

[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

transforming growth factor, beta 1

multiple interactions

[rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

rubitecan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

increases expression

rubitecan results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions
increases expression

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of AIFM1 protein
rubitecan results in increased expression of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

androgen receptor

multiple interactions

rubitecan binds to and results in decreased activity of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of BAX protein
rubitecan results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of BCL2 protein
rubitecan results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
increases expression

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP3 protein
rubitecan results in increased expression of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases expression

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP8 protein
rubitecan results in increased expression of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases expression
multiple interactions

rubitecan results in increased expression of CASP9 protein
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin D1

multiple interactions
decreases expression

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CCND1 protein
rubitecan results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

multiple interactions
decreases expression

Phosphatidylcholines promotes the reaction [rubitecan results in decreased expression of CCNE1 protein]

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin dependent kinase 2

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1A protein
rubitecan results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression
multiple interactions

rubitecan results in increased expression of CDKN1B protein
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

estrogen receptor 1

multiple interactions

rubitecan binds to and results in decreased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

rubitecan binds to and results in decreased activity of ESR2 protein

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

progesterone receptor

multiple interactions

rubitecan binds to and results in decreased activity of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

tumor protein p53

multiple interactions
increases expression

Phosphatidylcholines inhibits the reaction [rubitecan results in increased expression of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

simvastatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

Simvastatin results in decreased expression of A2M mRNA

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

ATP binding cassette subfamily A member 1

decreases expression
increases expression

Simvastatin results in decreased expression of ABCA1; Simvastatin results in decreased expression of ABCA1 mRNA
Simvastatin results in increased expression of ABCA1 mRNA
Simvastatin results in increased expression of ABCA1 mRNA; Simvastatin results in increased expression of ABCA1 protein

PMID:16282522 PMID:18270459 PMID:19383813 PMID:19461118 PMID:21241519 More...

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity
decreases expression

Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Simvastatin results in decreased activity of ABCB11 protein
Simvastatin results in decreased expression of ABCB11 mRNA

PMID:20829430 PMID:23956101 PMID:24014644 PMID:27765674

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions
affects response to substance
decreases activity
increases transport

ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; Simvastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]
ABCB1 polymorphism affects the susceptibility to Simvastatin
Simvastatin analog results in decreased activity of ABCB1 protein
ABCB1 protein results in increased transport of Simvastatin

PMID:15616150 PMID:16321621 PMID:19802823 PMID:19891551

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

increases expression
decreases expression

Simvastatin results in increased expression of ABCB4 mRNA
Simvastatin results in decreased expression of ABCB4 mRNA

PMID:21241519 PMID:27765674

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

multiple interactions
decreases activity
affects response to substance
decreases expression

ABCC2 protein binds to and results in increased uptake of Simvastatin analog; Simvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Simvastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM]
Simvastatin analog results in decreased activity of ABCC2 protein
ABCC2 polymorphism affects the susceptibility to Simvastatin
Simvastatin results in decreased expression of ABCC2 mRNA

PMID:15616150 PMID:22186618 PMID:23562342 PMID:27765674

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions
increases nitrosation

artemisinin inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; parthenolide inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased nitrosation of ABCC3 protein]

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 1

decreases expression

Simvastatin results in decreased expression of ABCG1 mRNA

PMID:19383813 PMID:22120639

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 5

increases expression

Simvastatin results in increased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

decreases expression

Simvastatin results in decreased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-CoA acyltransferase 2

decreases expression
multiple interactions

Simvastatin results in decreased expression of ACAA2 mRNA
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of ACAA2 mRNA

NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA carboxylase beta

increases expression

Simvastatin results in increased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

aggrecan

multiple interactions
increases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]

PMID:18628692 PMID:19912653

NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627

G

angiotensin converting enzyme 2

decreases expression

Simvastatin results in decreased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

actin alpha 2, smooth muscle

decreases expression
multiple interactions

Simvastatin results in decreased expression of ACTA2 protein
Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA]

PMID:15677772 PMID:15855201

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

actin, beta

increases expression

Simvastatin results in increased expression of ACTB mRNA

NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877

G

actinin alpha 4

increases expression

Simvastatin results in increased expression of ACTN4 mRNA

NCBI chr 1:84,182,783...84,251,867
Ensembl chr 1:84,182,788...84,251,847

G

adiponectin, C1Q and collagen domain containing

multiple interactions

Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of ADIPOQ mRNA]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of ADIPOQ protein]
carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]]; Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]

PMID:17641834 PMID:29071762

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adenosine A2B receptor

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B protein]

NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772

G

adrenoceptor beta 1

increases expression

Simvastatin results in increased expression of ADRB1 mRNA; Simvastatin results in increased expression of ADRB1 protein

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

alpha-fetoprotein

increases expression

Simvastatin results in increased expression of AFP mRNA

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

advanced glycosylation end product-specific receptor

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein]
Simvastatin results in decreased expression of AGER protein

NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078

G

angiotensinogen

multiple interactions
decreases expression

[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]]
Simvastatin results in decreased expression of AGT mRNA
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA]

PMID:17513949 PMID:18400235 PMID:18475152 PMID:19100119 PMID:19225232 More...

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

decreases expression

Simvastatin results in decreased expression of AGTR1 mRNA

PMID:17513949 PMID:18475152

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

aldo-keto reductase family 1, member C1

increases expression

Simvastatin results in increased expression of AKR1C1 mRNA

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C3

decreases expression

Simvastatin results in decreased expression of AKR1C3 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

aldo-keto reductase family 1, member D1

decreases expression

Simvastatin results in decreased expression of AKR1D1 mRNA

NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372

G

AKT serine/threonine kinase 1

decreases expression
multiple interactions
decreases activity
increases phosphorylation
decreases phosphorylation

Simvastatin results in decreased expression of AKT1 mRNA; Simvastatin results in decreased expression of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein; [Simvastatin co-treated with Metformin] results in decreased phosphorylation of AKT1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of AKT1 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]
Simvastatin inhibits the reaction [Glucose results in decreased expression of AKT1 protein modified form]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein
Simvastatin results in decreased activity of AKT1 protein
Simvastatin results in increased phosphorylation of AKT1 protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein]

PMID:12438947 PMID:17327694 PMID:17335931 PMID:18004065 PMID:18031796 More...

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 3 family, member A1

increases expression

Simvastatin results in increased expression of ALDH3A1 mRNA

NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681

G

ALK receptor tyrosine kinase

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA

NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034

G

arachidonate 5-lipoxygenase activating protein

increases expression

Simvastatin results in increased expression of ALOX5AP mRNA

NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986

G

alkaline phosphatase, intestinal

increases expression

Simvastatin results in increased expression of ALPI mRNA

NCBI chr 9:87,773,411...87,776,877
Ensembl chr 9:87,773,411...87,776,877

G

alkaline phosphatase, biomineralization associated

increases expression
affects expression
multiple interactions

Simvastatin results in increased expression of ALPL mRNA
Simvastatin affects the expression of ALPL mRNA
Hydroxychloroquine affects the reaction [Simvastatin affects the expression of ALPL mRNA]

PMID:20417880 PMID:28975700

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

angiopoietin 1

increases expression

Simvastatin results in increased expression of ANGPT1; Simvastatin results in increased expression of ANGPT1 mRNA; Simvastatin results in increased expression of ANGPT1 protein

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin 2

multiple interactions

Simvastatin inhibits the reaction [Streptozocin results in increased expression of ANGPT2 protein]

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804

G

angiopoietin-like 3

decreases expression

Simvastatin results in decreased expression of ANGPTL3 mRNA

NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957

G

angiopoietin-like 4

increases expression

Simvastatin results in increased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin repeat family A member 2

increases expression

Simvastatin results in increased expression of ANKRA2 mRNA

NCBI chr 2:29,612,867...29,623,748
Ensembl chr 2:29,612,925...29,623,730

G

alanyl aminopeptidase, membrane

increases expression

Simvastatin results in increased expression of ANPEP mRNA

NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789

G

annexin A1

increases expression

Simvastatin results in increased expression of ANXA1 protein

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

annexin A3

decreases expression

Simvastatin results in decreased expression of ANXA3 mRNA
Simvastatin results in decreased expression of ANXA3 protein

PMID:14973129 PMID:17428261

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

amine oxidase, copper containing 1

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of AOC1 mRNA]

NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840

G

adipocyte plasma membrane associated protein

decreases expression

Simvastatin results in decreased expression of APMAP protein

NCBI chr 3:139,409,021...139,437,296
Ensembl chr 3:139,409,022...139,437,341

G

apolipoprotein A1

multiple interactions
increases expression
decreases expression

MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]
Polystyrenes analog promotes the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Simvastatin promotes the reaction [Polystyrenes analog results in increased expression of APOA1 mRNA]
Simvastatin results in increased expression of APOA1 mRNA; Simvastatin results in increased expression of APOA1 protein
[Niacin co-treated with Ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein; [Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; Niacin promotes the reaction [[Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein]; Simvastatin results in increased expression of and results in increased secretion of APOA1 protein
Simvastatin results in decreased expression of APOA1 mRNA; Simvastatin results in decreased expression of APOA1 protein

PMID:8289597 PMID:8461338 PMID:12048122 PMID:12633795 PMID:18270459 More...

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A2

decreases expression

Simvastatin results in decreased expression of APOA2 mRNA

NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355

G

apolipoprotein A4

multiple interactions
increases expression
decreases expression

Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein]
Simvastatin results in increased expression of APOA4 protein
Polystyrenes analog promotes the reaction [Simvastatin results in decreased expression of APOA4 protein]; Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOA4 protein]
Simvastatin results in decreased expression of APOA4 mRNA; Simvastatin results in decreased expression of APOA4 protein

PMID:8289597 PMID:8461338 PMID:18224302 PMID:25055962

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein B

multiple interactions
affects response to substance
decreases expression
decreases secretion

[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB]
APOB polymorphism affects the susceptibility to Simvastatin
Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOB protein]
Simvastatin results in decreased expression of APOB mRNA; Simvastatin results in decreased expression of APOB protein
Simvastatin results in decreased secretion of APOB protein

PMID:1627634 PMID:8289597 PMID:8461338 PMID:9512650 PMID:10498134 More...

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C1

decreases expression

Simvastatin results in decreased expression of APOC1 mRNA

NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375

G

apolipoprotein C3

decreases expression

Simvastatin results in decreased expression of APOC3 mRNA

NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583

G

apolipoprotein E

decreases expression
affects response to substance
multiple interactions

Simvastatin results in decreased expression of APOE; Simvastatin results in decreased expression of APOE mRNA
APOE affects the susceptibility to Simvastatin
Polystyrenes analog inhibits the reaction [Simvastatin results in decreased expression of APOE protein]
APOE polymorphism affects the susceptibility to Simvastatin
Simvastatin results in decreased expression of APOE mRNA; Simvastatin results in decreased expression of APOE protein

PMID:8289597 PMID:8461338 PMID:11849659 PMID:11947894 PMID:12901521 More...

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

apolipoprotein F

decreases expression

Simvastatin results in decreased expression of APOF mRNA

NCBI chr 7:700,688...702,130
Ensembl chr 7:700,762...701,946

G

apolipoprotein M

decreases expression
increases expression
multiple interactions

Simvastatin results in decreased expression of APOM mRNA
Simvastatin results in increased expression of APOM mRNA; Simvastatin results in increased expression of APOM protein
T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM protein]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM protein]

PMID:21729290 PMID:22160096

NCBI chr20:3,690,950...3,693,550
Ensembl chr20:3,688,413...3,693,550

G

amyloid beta precursor protein

multiple interactions
decreases activity

oblimersen inhibits the reaction [Simvastatin results in decreased activity of APP protein alternative form]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein]
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein]

PMID:17241114 PMID:28734741

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

Rho GTPase activating protein 29

decreases expression

Simvastatin results in decreased expression of ARHGAP29 mRNA

NCBI chr 2:210,060,036...210,132,572
Ensembl chr 2:210,071,199...210,132,028

G

Rho GTPase activating protein 4

increases expression

Simvastatin results in increased expression of ARHGAP4 mRNA

NCBI chr X:151,636,071...151,651,528
Ensembl chr X:151,632,454...151,651,128

G

Rho/Rac guanine nucleotide exchange factor 2

increases expression

Simvastatin results in increased expression of ARHGEF2 mRNA

NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355

G

argininosuccinate synthase 1

decreases expression

Simvastatin results in decreased expression of ASS1 mRNA

NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903

G

activating transcription factor 2

increases phosphorylation

Simvastatin results in increased phosphorylation of ATF2 protein

NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236

G

activating transcription factor 3

increases expression

Simvastatin results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 6

increases expression

Simvastatin results in increased expression of ATF6 mRNA; Simvastatin results in increased expression of ATF6 protein

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

ATM serine/threonine kinase

multiple interactions

Simvastatin results in increased phosphorylation of and results in increased activity of ATM protein

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

increases expression

Simvastatin results in increased expression of ATP2A2 mRNA; Simvastatin results in increased expression of ATP2A2 protein

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

ATPase H+ transporting V1 subunit E1

increases expression

Simvastatin results in increased expression of ATP6V1E1 mRNA

NCBI chr 4:154,022,358...154,044,486
Ensembl chr 4:154,022,358...154,044,584

G

aurora kinase A

decreases expression

Simvastatin results in decreased expression of AURKA mRNA

NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390

G

axin 2

affects expression

Simvastatin affects the expression of AXIN2 mRNA

NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231

G

Axl receptor tyrosine kinase

decreases expression

Simvastatin results in decreased expression of AXL mRNA

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

BCL2-associated agonist of cell death

multiple interactions
decreases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]
IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]

PMID:12438947 PMID:27734117

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

affects localization
increases expression

Simvastatin affects the localization of BAX protein
Simvastatin results in increased expression of BAX mRNA; Simvastatin results in increased expression of BAX protein

PMID:12557325 PMID:17901590 PMID:20045437 PMID:25300705

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

multiple interactions
affects localization
increases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BBC3 protein]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 mRNA]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 protein]
Simvastatin affects the localization of BBC3 protein
Simvastatin results in increased expression of BBC3 mRNA; Simvastatin results in increased expression of BBC3 protein

PMID:17428261 PMID:20045437 PMID:21199873 PMID:37956312

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

multiple interactions
decreases expression
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of BCL2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter]
Simvastatin results in decreased expression of BCL2 mRNA; Simvastatin results in decreased expression of BCL2 protein
Simvastatin results in increased expression of BCL2 protein
Simvastatin results in increased expression of BCL2 mRNA; Simvastatin results in increased expression of BCL2 protein

PMID:17241114 PMID:17277159 PMID:17901590 PMID:18031796 PMID:18521906 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]
Simvastatin results in decreased expression of BCL2L1 protein

PMID:17277159 PMID:18521906 PMID:20060890

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

brain-derived neurotrophic factor

increases expression
multiple interactions

Simvastatin results in increased expression of BDNF
Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of BDNF mRNA]

PMID:18047562 PMID:20851742

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

bone gamma-carboxyglutamate protein

increases expression
increases secretion
multiple interactions

Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA
Simvastatin results in increased secretion of BGLAP protein
[Simvastatin co-treated with Dexamethasone] results in increased expression of BGLAP
Simvastatin results in increased expression of BGLAP protein
CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA]
Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA; Simvastatin results in increased expression of BGLAP protein

PMID:12914771 PMID:14601315 PMID:14973129 PMID:15953866 PMID:17252541 More...

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

basic helix-loop-helix family, member a15

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of BHLHA15 mRNA

NCBI chr12:10,420,465...10,424,641
Ensembl chr12:10,420,467...10,424,713

G

baculoviral IAP repeat-containing 2

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]
Simvastatin results in decreased expression of BIRC2 protein

PMID:17277159 PMID:18521906 PMID:19343037

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

multiple interactions

Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]

PMID:17277159 PMID:19343037

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

multiple interactions
decreases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC5 protein]
Simvastatin results in decreased expression of BIRC5 mRNA; Simvastatin results in decreased expression of BIRC5 protein

PMID:17277159 PMID:20464445

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

bone morphogenetic protein 1

increases expression

Simvastatin results in increased expression of BMP1 mRNA

NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776

G

bone morphogenetic protein 2

increases secretion
multiple interactions
increases expression

Simvastatin results in increased secretion of BMP2 protein
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BMP2 mRNA]
Simvastatin results in increased expression of BMP2; Simvastatin results in increased expression of BMP2 mRNA
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]
Simvastatin results in increased expression of BMP2 mRNA; Simvastatin results in increased expression of BMP2 protein

PMID:10814523 PMID:11162604 PMID:12914771 PMID:16470222 PMID:17252541 More...

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein receptor type 2

affects expression
increases expression
increases stability

Simvastatin affects the expression of BMPR2 mRNA
Simvastatin results in increased expression of BMPR2 protein
Simvastatin results in increased stability of BMPR2 mRNA

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

BCL2 interacting protein 3

increases expression

Simvastatin results in increased expression of BNIP3 mRNA

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

complement C5a receptor 1

decreases expression

Simvastatin results in decreased expression of C5AR1 mRNA

NCBI chr 1:76,948,622...76,959,826

G

calcium voltage-gated channel subunit alpha1 C

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C protein]
Simvastatin results in decreased expression of CACNA1C mRNA; Simvastatin results in decreased expression of CACNA1C protein

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

calcium voltage-gated channel subunit alpha1 H

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H protein]
Simvastatin results in decreased expression of CACNA1H mRNA; Simvastatin results in decreased expression of CACNA1H protein

NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376

G

calbindin 1

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in decreased expression of CALB1 mRNA]

NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431

G

calbindin 2

decreases expression

Simvastatin results in decreased expression of CALB2 protein

NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438

G

caldesmon 1

decreases expression

Simvastatin results in decreased expression of CALD1 mRNA; Simvastatin results in decreased expression of CALD1 protein

NCBI chr 4:63,265,781...63,446,938
Ensembl chr 4:63,265,942...63,446,932

G

calmodulin-like 3

increases expression

Simvastatin results in increased expression of CALML3 mRNA

NCBI chr17:66,419,844...66,423,083
Ensembl chr17:66,419,882...66,423,175

G

calpain 1

increases expression

Simvastatin results in increased expression of CAPN1 mRNA

PMID:18664198 PMID:19253821

NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177

G

capping actin protein of muscle Z-line subunit alpha 1

decreases expression

Simvastatin results in decreased expression of CAPZA1 protein

NCBI chr 2:192,319,696...192,364,755
Ensembl chr 2:192,319,702...192,364,480

G

capping actin protein of muscle Z-line subunit alpha 2

decreases expression

Simvastatin results in decreased expression of CAPZA2 protein

NCBI chr 4:45,978,142...46,014,032
Ensembl chr 4:45,977,807...46,013,864

G

caspase 1

decreases activity
multiple interactions

Simvastatin results in decreased activity of CASP1 protein
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of CASP1 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]

PMID:16054375 PMID:30408459 PMID:35762198

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 12

multiple interactions

Simvastatin results in increased cleavage of and results in increased activity of CASP12 protein

NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037

G

caspase 3

multiple interactions
increases activity
increases cleavage
increases expression
decreases activity

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of CASP3 protein modified form]; Simvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein
[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein; [Lipopolysaccharides co-treated with Simvastatin] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein]
carvacrol inhibits the reaction [Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]]; PD 150606 inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of CASP3 mRNA]; Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]; Simvastatin results in decreased expression of and results in decreased activity of CASP3 protein; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein; Verapamil inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]
Simvastatin results in increased expression of CASP3 mRNA; Simvastatin results in increased expression of CASP3 protein
Simvastatin results in decreased activity of CASP3 protein

PMID:11868908 PMID:12557325 PMID:12962723 PMID:14527821 PMID:15200425 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 6

multiple interactions

Simvastatin results in increased cleavage of and results in increased activity of CASP6 protein

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caspase 7

multiple interactions
increases activity

Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP7 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP7 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP7 protein

PMID:19253821 PMID:20045437 PMID:20427495

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

increases activity
multiple interactions
increases cleavage

Simvastatin results in increased activity of CASP8 protein
Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP8 protein]
Simvastatin results in increased cleavage of CASP8 protein
Simvastatin results in increased cleavage of and results in increased activity of CASP8 protein

PMID:12962723 PMID:15705602 PMID:20464445 PMID:20883752 PMID:21910007

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases cleavage
decreases activity
increases activity

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased activity of CASP9 protein]; DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP9 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP9 protein

PMID:12438947 PMID:12962723 PMID:15705602 PMID:16470222 PMID:19253821 More...

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases expression
increases activity
multiple interactions

Simvastatin results in decreased expression of CAT mRNA
Simvastatin results in increased activity of CAT protein
carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein]]; Simvastatin inhibits the reaction [Diazepam results in decreased activity of CAT protein]; Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein]

PMID:17479860 PMID:20883752 PMID:27111380 PMID:29071762

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA]
Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein]
Simvastatin results in decreased expression of CAV1 protein
Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV1 protein]

PMID:16698853 PMID:18224302 PMID:19816600

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

caveolin 2

multiple interactions

Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV2 protein]

NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244

G

cystathionine beta synthase

multiple interactions

Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein]

NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764

G

C-C motif chemokine ligand 2

multiple interactions
decreases expression
decreases response to substance
affects expression

[Simvastatin co-treated with Ramipril] results in decreased expression of CCL2 protein; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin results in decreased expression of and results in decreased secretion of CCL2 protein
Simvastatin results in decreased expression of CCL2 mRNA; Simvastatin results in decreased expression of CCL2 protein
Simvastatin results in decreased susceptibility to CCL2 protein
Simvastatin affects the expression of CCL2 mRNA

PMID:12117737 PMID:12818400 PMID:15184351 PMID:15781755 PMID:15824212 More...

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

decreases expression

Simvastatin results in decreased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 3

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA]
Simvastatin results in decreased expression of CCL3 mRNA

PMID:16321392 PMID:16414398

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA]

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

increases expression
decreases expression

Simvastatin results in increased expression of CCL5 mRNA
Simvastatin results in decreased expression of CCL5 mRNA
Simvastatin results in decreased expression of CCL5 protein

PMID:17112859 PMID:17183729 PMID:17449418

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA]
Simvastatin results in decreased expression of CCN1 mRNA

PMID:17428261 PMID:20191585

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cellular communication network factor 2

multiple interactions
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein]
Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 protein]
Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]
Simvastatin results in decreased expression of CCN2 mRNA; Simvastatin results in decreased expression of CCN2 protein

PMID:15200425 PMID:15298857 PMID:15677772 PMID:19080365 PMID:19099753 More...

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin A2

decreases expression
multiple interactions

Simvastatin results in decreased expression of CCNA2 mRNA
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein]

PMID:17428261 PMID:26577051

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin D1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]
Simvastatin results in decreased expression of CCND1 mRNA; Simvastatin results in decreased expression of CCND1 protein

PMID:17277159 PMID:17428261 PMID:20878096

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

multiple interactions
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein]

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

C-C motif chemokine receptor 1

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]
Simvastatin results in decreased expression of CCR1 mRNA

PMID:16321392 PMID:16414398

NCBI chr 8:123,556,286...123,561,841

G

C-C motif chemokine receptor 2

multiple interactions
decreases expression

[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]
Simvastatin results in decreased expression of CCR2 mRNA; Simvastatin results in decreased expression of CCR2 protein

PMID:15781755 PMID:16321392 PMID:16414398 PMID:16781696 PMID:17449418

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 4

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]

NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056

G

C-C motif chemokine receptor 5

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]
Simvastatin results in decreased expression of CCR5 mRNA
Simvastatin results in decreased expression of CCR5 protein

PMID:16321392 PMID:17112859 PMID:17449418

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

CD14 molecule

decreases expression

Simvastatin results in decreased expression of CD14 mRNA

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

CD151 molecule (Raph blood group)

decreases expression

Simvastatin results in decreased expression of CD151 mRNA

NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753

G

CD24 molecule

increases expression

Simvastatin results in increased expression of CD24 mRNA

NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662

G

CD27 molecule

decreases expression

Simvastatin results in decreased expression of CD27 mRNA

NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592

G

CD2-associated protein

increases expression

Simvastatin results in increased expression of CD2AP mRNA

NCBI chr 9:18,086,744...18,182,744
Ensembl chr 9:18,086,984...18,182,199

G

CD40 molecule

decreases expression
multiple interactions

Simvastatin results in decreased expression of CD40 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]

PMID:16387846 PMID:17169357 PMID:17507688

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

CD40 ligand

decreases expression
increases expression
multiple interactions

Simvastatin results in decreased expression of CD40LG protein; Simvastatin results in decreased expression of CD40LG protein modified form
Simvastatin results in increased expression of CD40LG protein
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]

PMID:17169357 PMID:18269829 PMID:21330348

NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306

G

CD44 molecule

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CD44 protein]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter]
Simvastatin results in decreased expression of CD44 mRNA; Simvastatin results in decreased expression of CD44 protein

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

Cd80 molecule

decreases expression

Simvastatin results in decreased expression of CD80 mRNA

NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030

G

CD83 molecule

decreases expression

Simvastatin results in decreased expression of CD83 protein

NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083

G

CD86 molecule

decreases expression

Simvastatin results in decreased expression of CD86 protein

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cell division cycle 25B

affects expression

Simvastatin affects the expression of CDC25B mRNA; Simvastatin affects the expression of CDC25B protein

NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272

G

cell division cycle 42

decreases activity

Simvastatin results in decreased activity of CDC42 protein

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

cell division cycle 45

decreases expression

Simvastatin results in decreased expression of CDC45 mRNA

NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619

G

cell division cycle 6

decreases expression

Simvastatin results in decreased expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cadherin 5

increases expression

Simvastatin results in increased expression of CDH5 mRNA; Simvastatin results in increased expression of CDH5 protein

NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368

G

cyclin-dependent kinase 1

decreases expression
multiple interactions

Simvastatin results in decreased expression of CDK1 mRNA; Simvastatin results in decreased expression of CDK1 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein]

PMID:17428261 PMID:20878096 PMID:26577051

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

multiple interactions
decreases activity
decreases expression

[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; [Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein
Simvastatin results in decreased activity of CDK2 protein
Simvastatin results in decreased expression of CDK2 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein]

PMID:10412745 PMID:17928568 PMID:18804536 PMID:20878096 PMID:26577051

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression
decreases activity

Simvastatin results in decreased expression of CDK4 protein
Simvastatin results in decreased activity of CDK4 protein

PMID:18804536 PMID:20878096

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 5

increases expression

Simvastatin results in increased expression of CDK5

NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of CDKN1A protein]; Simvastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein]
Simvastatin results in increased expression of CDKN1A mRNA; Simvastatin results in increased expression of CDKN1A protein

PMID:15625077 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18625202 More...

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression

[Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein
Simvastatin results in increased expression of CDKN1B mRNA; Simvastatin results in increased expression of CDKN1B protein

PMID:12963647 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18804536 More...

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 1C

increases expression

Simvastatin results in increased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

cyclin-dependent kinase inhibitor 2A

increases expression

Simvastatin results in increased expression of CDKN2A protein

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cyclin dependent kinase inhibitor 2D

increases expression

Simvastatin results in increased expression of CDKN2D mRNA; Simvastatin results in increased expression of CDKN2D protein

NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674

G

chromatin licensing and DNA replication factor 1

decreases expression

Simvastatin results in decreased expression of CDT1 mRNA

NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659

G

CCAAT/enhancer binding protein zeta

multiple interactions

Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter]

NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600

G

carboxylesterase 1D

multiple interactions

Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 mRNA]; Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 protein]
Simvastatin inhibits the reaction [CES1 protein results in increased hydrolysis of remdesivir]

PMID:33383043 PMID:34774545

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

CASP8 and FADD-like apoptosis regulator

multiple interactions
decreases expression
increases expression

Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein]
Simvastatin results in decreased expression of CFLAR protein; Simvastatin results in decreased expression of CFLAR protein alternative form
Simvastatin results in increased expression of CFLAR mRNA; Simvastatin results in increased expression of CFLAR protein

PMID:17277159 PMID:18521906 PMID:19262002 PMID:21910007

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

CF transmembrane conductance regulator

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR protein]

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

choline O-acetyltransferase

multiple interactions

Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA]

NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093

G

cholinergic receptor, muscarinic 5

multiple interactions

Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA]

NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions
increases phosphorylation
increases expression

artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of CHUK protein]
Simvastatin results in increased expression of CHUK mRNA

PMID:18463201 PMID:19262002

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

class II, major histocompatibility complex, transactivator

multiple interactions

Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein]

NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440

G

creatine kinase, M-type

multiple interactions
decreases expression
increases secretion

[Clarithromycin co-treated with Simvastatin] results in increased expression of CKM protein
Simvastatin results in decreased expression of CKM protein
carvacrol inhibits the reaction [Simvastatin results in increased secretion of CKM protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]

PMID:8611662 PMID:19252767 PMID:29071762 PMID:35762198

NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720

G

chloride voltage-gated channel 3

multiple interactions
decreases expression

Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein]
Simvastatin results in decreased expression of CLCN3 protein

NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119

G

claudin 18

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 protein]

NCBI chr 8:100,246,499...100,265,797
Ensembl chr 8:100,247,633...100,273,351

G

claudin 4

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 protein]

NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436

G

collagen type XI alpha 1 chain

increases expression

Simvastatin results in increased expression of COL11A1 mRNA

NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853

G

collagen type XII alpha 1 chain

increases expression

Simvastatin results in increased expression of COL12A1 mRNA

NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686

G

collagen type XIII alpha 1 chain

decreases response to substance

COL13A1 SNP results in decreased susceptibility to Simvastatin

NCBI chr20:29,783,965...29,924,116
Ensembl chr20:29,783,965...29,924,032

G

collagen type I alpha 1 chain

multiple interactions
decreases expression
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter]; Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter]
Simvastatin results in increased expression of COL1A1 mRNA

PMID:10412775 PMID:14973129 PMID:16274305 PMID:16575855 PMID:17252541 More...

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type II alpha 1 chain

multiple interactions
increases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]

PMID:18628692 PMID:19912653

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

collagen type III alpha 1 chain

increases expression
decreases expression

Simvastatin results in increased expression of COL3A1 mRNA
Simvastatin results in decreased expression of COL3A1 mRNA

PMID:10412775 PMID:16274305 PMID:16414398 PMID:17183729

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type IV alpha 1 chain

decreases expression

Simvastatin results in decreased expression of COL4A1 mRNA

NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412

G

collagen type V alpha 1 chain

increases expression

Simvastatin results in increased expression of COL5A1 mRNA

NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588

G

collagen type VI alpha 2 chain

increases expression

Simvastatin results in increased expression of COL6A2 mRNA

NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564

G

collagen type VII alpha 1 chain

increases expression

Simvastatin results in increased expression of COL7A1 mRNA

NCBI chr 8:109,604,877...109,637,249
Ensembl chr 8:109,604,861...109,637,252

G

coronin 1A

decreases expression

Simvastatin results in decreased expression of CORO1A protein

NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534

G

cAMP responsive element binding protein 1

multiple interactions

Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

C-reactive protein

decreases expression
multiple interactions

Simvastatin results in decreased expression of CRP protein
[Ezetimibe co-treated with Simvastatin] results in decreased expression of CRP protein; [Simvastatin co-treated with Ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in increased expression of CRP protein]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]; Simvastatin inhibits the reaction [ethinyl estradiol-desogestrel combination results in increased expression of CRP protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein]

PMID:15184351 PMID:15824212 PMID:17105841 PMID:18023360 PMID:18420099 More...

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

citrate synthase

multiple interactions
increases activity

[Simvastatin co-treated with Lipopolysaccharides] results in increased activity of CS protein
Simvastatin results in increased activity of CS protein

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

chondroitin sulfate proteoglycan 4

increases expression

Simvastatin results in increased expression of CSPG4 mRNA

NCBI chr 8:57,264,962...57,300,010
Ensembl chr 8:57,264,962...57,300,010

G

cardiotrophin 1

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein]

PMID:16534557 PMID:18400235 PMID:19100119

NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335

G

cytotoxic T-lymphocyte-associated protein 4

decreases expression

Simvastatin results in decreased expression of CTLA4 mRNA

NCBI chr 9:62,318,874...62,325,978
Ensembl chr 9:62,319,312...62,324,963

G

catenin alpha-like 1

decreases expression

Simvastatin results in decreased expression of CTNNAL1 mRNA

NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431

G

catenin beta 1

multiple interactions
increases expression

CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein]
Simvastatin inhibits the reaction [Glucose results in decreased expression of CTNNB1 protein]
Simvastatin results in increased expression of CTNNB1 protein

PMID:18004065 PMID:22058016

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin L

increases expression

Simvastatin results in increased expression of CTSL mRNA

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cathepsin S

multiple interactions

Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS protein]

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

cortactin

affects localization
multiple interactions

Simvastatin affects the localization of CTTN protein
Simvastatin affects the reaction [F2 affects the localization of CTTN protein]

NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164

G

C-X3-C motif chemokine receptor 1

decreases expression

Simvastatin results in decreased expression of CX3CR1 mRNA

NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014

G

C-X-C motif chemokine ligand 10

multiple interactions
decreases expression

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL10 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL10 protein]
Simvastatin results in decreased expression of CXCL10 mRNA; Simvastatin results in decreased expression of CXCL10 protein

PMID:15187114 PMID:16414398 PMID:17449418 PMID:22305382

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 12

increases expression

Simvastatin results in increased expression of CXCL12

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 16

decreases expression

Simvastatin results in decreased expression of CXCL16 mRNA

NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592

G

C-X-C motif chemokine ligand 2

decreases expression

Simvastatin results in decreased expression of CXCL2 mRNA; Simvastatin results in decreased expression of CXCL2 protein

PMID:21330348 PMID:21441352

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

decreases expression

Simvastatin results in decreased expression of CXCL1 mRNA; Simvastatin results in decreased expression of CXCL1 protein

PMID:21330348 PMID:21441352

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine ligand 6

decreases expression

Simvastatin results in decreased expression of CXCL5 mRNA

NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093

G

C-X-C motif chemokine receptor 2

decreases expression

Simvastatin results in decreased expression of CXCR2 mRNA

NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425

G

C-X-C motif chemokine receptor 4

decreases expression
increases expression

Simvastatin results in decreased expression of CXCR4 mRNA
Simvastatin results in increased expression of CXCR4

PMID:16414398 PMID:19591934

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome b-245 alpha chain

affects response to substance

CYBA gene SNP affects the susceptibility to Simvastatin

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome b-245 beta chain

multiple interactions

Simvastatin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11A1 mRNA; [Simvastatin co-treated with resveratrol] results in decreased expression of CYP11A1 mRNA

PMID:24524197 PMID:25055962

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 11, subfamily b, polypeptide 2

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B1 mRNA

NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004

G

cytochrome P450, family 11, subfamily b, polypeptide 3

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B2 mRNA

NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression
multiple interactions

Simvastatin results in decreased expression of CYP17A1 mRNA
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP17A1 mRNA; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; resveratrol promotes the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; Simvastatin promotes the reaction [resveratrol results in decreased expression of CYP17A1 mRNA]

PMID:21918126 PMID:24524197 PMID:25055962

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

Simvastatin results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Simvastatin results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions

Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP27A1 mRNA]

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

Simvastatin results in increased expression of CYP2B6 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily c, polypeptide 79

decreases activity

Simvastatin results in decreased activity of CYP2C8 protein

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects response to substance

CYP2D6 polymorphism affects the susceptibility to Simvastatin

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 39, subfamily a, polypeptide 1

decreases expression

Simvastatin results in decreased expression of CYP39A1 mRNA

NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
decreases activity
decreases expression
affects metabolic processing
increases expression
increases metabolic processing
affects response to substance

Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]
Simvastatin results in decreased expression of CYP3A4 mRNA; Simvastatin results in decreased expression of CYP3A4 protein
CYP3A4 protein affects the metabolism of Simvastatin
Simvastatin results in increased expression of CYP3A4 mRNA
CYP3A4 protein results in increased metabolism of Simvastatin
[Simvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Simvastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; telaprevir inhibits the reaction [CYP3A4 protein results in increased metabolism of Simvastatin]

PMID:12505310 PMID:15650881 PMID:16011971 PMID:17041008 PMID:19802823 More...

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

affects response to substance

CYP3A5 polymorphism affects the susceptibility to Simvastatin

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 46, subfamily a, polypeptide 1

decreases expression

Simvastatin results in decreased expression of CYP46A1 mRNA

NCBI chr 6:127,247,543...127,274,765
Ensembl chr 6:127,243,315...127,274,760

G

cytochrome P450, family 51

increases expression

Simvastatin results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]; Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 protein]

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

DBF4-CDC7 kinase regulatory subunit

decreases expression

Simvastatin results in decreased expression of DBF4 mRNA

NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066

G

D-box binding PAR bZIP transcription factor

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of DBP mRNA]

NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745

G

doublecortin

increases expression

Simvastatin results in increased expression of DCX

NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476

G

dimethylarginine dimethylaminohydrolase 1

decreases expression

Simvastatin results in decreased expression of DDAH1 mRNA

NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339

G

diacylglycerol O-acyltransferase 1

increases expression
increases activity

Simvastatin results in increased expression of DGAT1 mRNA
Simvastatin results in increased activity of DGAT1 protein

NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299

G

24-dehydrocholesterol reductase

increases expression

Simvastatin results in increased expression of DHCR24
Simvastatin results in increased expression of DHCR24 mRNA; Simvastatin results in increased expression of DHCR24 protein

PMID:21987590 PMID:25055962

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

7-dehydrocholesterol reductase

affects response to substance
multiple interactions
affects expression

DHCR7 mutant form affects the susceptibility to Simvastatin
Hydroxychloroquine affects the reaction [Simvastatin affects the expression of DHCR7 mRNA]; Simvastatin promotes the reaction [DHCR7 results in increased chemical synthesis of Cholesterol]
Simvastatin inhibits the reaction [DHCR7 mutant form results in increased abundance of 7-dehydrocholesterol]
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of DHCR7 mRNA

PMID:15896653 PMID:16446309 PMID:19365639 PMID:25055962 PMID:28975700

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

diablo, IAP-binding mitochondrial protein

affects localization
multiple interactions

Simvastatin affects the localization of DIABLO protein
DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein]

NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387

G

dickkopf WNT signaling pathway inhibitor 1

multiple interactions

DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA]

NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202

G

delta like canonical Notch ligand 4

increases expression

Simvastatin results in increased expression of DLL4 mRNA

NCBI chr 3:106,317,114...106,327,004
Ensembl chr 3:106,316,986...106,326,931

G

dynamin 1-like

affects localization
increases expression

Simvastatin affects the localization of DNM1L protein
Simvastatin results in increased expression of DNM1L protein

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

dopamine receptor D1

multiple interactions
increases expression

SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein]
Simvastatin results in increased expression of DRD1 mRNA; Simvastatin results in increased expression of DRD1 protein

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

increases expression

Simvastatin results in increased expression of DRD2 mRNA; Simvastatin results in increased expression of DRD2 protein

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dentin sialophosphoprotein

increases expression

Simvastatin results in increased expression of DSPP mRNA

NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672

G

dual specificity phosphatase 1

decreases expression

Simvastatin results in decreased expression of DUSP1 mRNA; Simvastatin results in decreased expression of DUSP1 protein

NCBI chr10:16,680,478...16,683,275

G

E2F transcription factor 1

decreases expression

Simvastatin results in decreased expression of E2F1 mRNA

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

ELL associated factor 2

decreases response to substance

EAF2 SNP results in decreased susceptibility to Simvastatin

NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610

G

endothelin 1

decreases secretion
multiple interactions
decreases expression

Simvastatin results in decreased secretion of EDN1 protein
Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDN1 mRNA]
Simvastatin results in decreased expression of EDN1 mRNA; Simvastatin results in decreased expression of EDN1 protein
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 protein]; Simvastatin results in increased expression of and results in increased secretion of EDN1 protein

PMID:16375908 PMID:18390205 PMID:19099753 PMID:20369390 PMID:20644009 More...

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type A

multiple interactions

Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDNRA mRNA]

PMID:19505368 PMID:22022327

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

epidermal growth factor receptor

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

decreases expression

Simvastatin results in decreased expression of EGR1 protein

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

eukaryotic translation initiation factor 4E binding protein 1

decreases phosphorylation
multiple interactions

Simvastatin results in decreased phosphorylation of EIF4EBP1 protein
IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein]

PMID:22144680 PMID:27734117

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

enolase 1

decreases expression

Simvastatin results in decreased expression of ENO1 protein

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336

G

ectonucleoside triphosphate diphosphohydrolase 1

multiple interactions

Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein]

NCBI chr 1:239,425,515...239,552,323
Ensembl chr 1:239,425,430...239,552,317

G

Eph receptor A3

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA3 mRNA

NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900

G

Eph receptor A8

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA8 mRNA

NCBI chr 5:149,166,107...149,193,515
Ensembl chr 5:149,166,697...149,193,399

G

erythropoietin

multiple interactions

Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPO protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPO mRNA]

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

erythropoietin receptor

multiple interactions

Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPOR protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPOR mRNA]

NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257

G

coagulation factor II, thrombin

multiple interactions
decreases activity

Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein]; Simvastatin affects the reaction [F2 affects the localization of CTTN protein]; Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein]

PMID:12067895 PMID:14630613

NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486

G

coagulation factor III, tissue factor

multiple interactions
decreases expression
increases expression
affects response to substance
decreases activity

geranylgeraniol inhibits the reaction [Simvastatin results in decreased expression of F3]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of F3 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of F3]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein]
Simvastatin results in decreased expression of F3; Simvastatin results in decreased expression of F3 mRNA; Simvastatin results in decreased expression of F3 protein
Simvastatin results in increased expression of F3 mRNA; Simvastatin results in increased expression of F3 protein
F3 polymorphism affects the susceptibility to Simvastatin
Simvastatin results in decreased activity of F3 protein

PMID:9081680 PMID:10830219 PMID:12753293 PMID:12818400 PMID:15824212 More...

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid synthase

increases expression

Simvastatin results in increased expression of FASN mRNA

PMID:11728391 PMID:12056585

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

F-box protein 32

increases expression
multiple interactions

Simvastatin results in increased expression of FBXO32 mRNA; Simvastatin results in increased expression of FBXO32 protein
FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]

PMID:19001041 PMID:25300705 PMID:27734117 PMID:33034787

NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436

G

farnesyl diphosphate farnesyl transferase 1

increases expression
increases activity
multiple interactions

Simvastatin results in increased expression of FDFT1 protein
Simvastatin results in increased activity of FDFT1 protein
resveratrol inhibits the reaction [Simvastatin results in increased expression of FDFT1 mRNA]

PMID:8517861 PMID:12518039 PMID:23386644

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

increases expression
multiple interactions

Simvastatin results in increased expression of FDPS mRNA
resveratrol inhibits the reaction [Simvastatin results in increased expression of FDPS mRNA]

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

fibroblast growth factor 19

multiple interactions

Simvastatin inhibits the reaction [Dietary Fats results in increased expression of FGF19 mRNA]

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

fibroblast growth factor 2

increases expression

Simvastatin results in increased expression of FGF2

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

FKBP prolyl isomerase 1A

decreases expression

Simvastatin results in decreased expression of FKBP1A mRNA

NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743

G

FKBP prolyl isomerase 4

increases expression

Simvastatin results in increased expression of FKBP4 mRNA

NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833

G

flotillin 1

decreases expression

Simvastatin results in decreased expression of FLOT1 protein

NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978

G

Fms related receptor tyrosine kinase 1

multiple interactions
increases expression

Simvastatin inhibits the reaction [Streptozocin results in increased expression of FLT1 mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased expression of FLT1 protein]
Simvastatin results in increased expression of FLT1 mRNA

PMID:19109527 PMID:20821229

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

fibronectin 1

decreases expression
increases expression

Simvastatin results in decreased expression of FN1 mRNA
Simvastatin results in increased expression of FN1 mRNA

PMID:10412775 PMID:15855201 PMID:16274305 PMID:16414398

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
decreases localization
decreases expression

farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of FOS mRNA]
Simvastatin results in decreased localization of FOS protein
FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FOS protein]
Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA]

PMID:12753293 PMID:12963647 PMID:15187114 PMID:16005304 PMID:19100119

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Simvastatin results in increased expression of FOSL1 protein

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

FOS like 2, AP-1 transcription factor subunit

multiple interactions

Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]

NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034

G

forkhead box O1

affects localization
decreases phosphorylation
increases phosphorylation
multiple interactions
decreases localization

Simvastatin affects the localization of FOXO1 protein
Simvastatin results in decreased phosphorylation of FOXO1 protein
Simvastatin results in increased phosphorylation of FOXO1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased localization of FOXO1 protein]
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of FOXO1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of and affects the localization of FOXO1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of and affects the localization of FOXO1 protein]

PMID:12438947 PMID:18826357 PMID:19001041 PMID:33034787

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

forkhead box O3

multiple interactions
increases phosphorylation
decreases expression
decreases phosphorylation
affects localization

Acetylcysteine inhibits the reaction [Simvastatin results in increased phosphorylation of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein]
Simvastatin results in decreased expression of FOXO3 protein
Simvastatin results in decreased phosphorylation of FOXO3 protein

PMID:19001041 PMID:20883752 PMID:27734117

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

forkhead box P3

increases expression
multiple interactions
affects methylation
decreases expression

Simvastatin results in increased expression of FOXP3
IL2 affects the reaction [Simvastatin results in increased expression of FOXP3]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of FOXP3]
Simvastatin affects the methylation of FOXP3 promoter
Simvastatin results in decreased expression of FOXP3 mRNA

PMID:20408897 PMID:20491794 PMID:22305382

NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838

G

follistatin

multiple interactions

FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of MTOR protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 protein]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 protein]; FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD2 protein]; FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD3 protein]

NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571

G

frizzled class receptor 2

increases expression

Simvastatin results in increased expression of FZD2 mRNA

NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

[Simvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glyceraldehyde-3-phosphate dehydrogenase

decreases expression

Simvastatin results in decreased expression of GAPDH mRNA

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

GATA binding protein 6

increases expression

Simvastatin results in increased expression of GATA6 mRNA; Simvastatin results in increased expression of GATA6 protein

NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532

G

GDP dissociation inhibitor 2

decreases expression

Simvastatin results in decreased expression of GDI2 protein

NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366

G

glial cell derived neurotrophic factor

increases expression

Simvastatin results in increased expression of GDNF

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

GDNF family receptor alpha 1

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of GFRA1 mRNA

NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473

G

gap junction protein, alpha 1

multiple interactions

GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Simvastatin affects the localization of and results in decreased phosphorylation of GJA1 protein

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

gap junction protein, beta 2

increases expression

Simvastatin results in increased expression of GJB2 mRNA

NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177

G

galactosidase, beta 1

multiple interactions

Simvastatin inhibits the reaction [Coal Ash results in increased expression of GLB1 protein]

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

glutathione peroxidase 1

decreases expression
multiple interactions

Simvastatin results in decreased expression of GPX1 mRNA
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of GPX1 mRNA]

PMID:20883752 PMID:28734741

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 2

increases expression

Simvastatin results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glycogen synthase kinase 3 beta

increases expression
multiple interactions

Simvastatin results in increased expression of GSK3B
Simvastatin inhibits the reaction [Glucose results in decreased phosphorylation of and results in increased activity of GSK3B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of GSK3B protein]
Simvastatin results in increased expression of GSK3B protein modified form

PMID:18004065 PMID:18047562 PMID:19461118

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione S-transferase pi 1

multiple interactions

Simvastatin inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

H2A.X variant histone

increases phosphorylation

Simvastatin results in increased phosphorylation of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

hes family bHLH transcription factor 5

increases expression

Simvastatin results in increased expression of HES5 mRNA

NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001

G

hypoxia inducible factor 1 subunit alpha

increases expression
multiple interactions
decreases expression

Simvastatin results in increased expression of HIF1A protein
HIF1A mutant form inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]
Simvastatin results in decreased expression of HIF1A mRNA

PMID:18356691 PMID:21844074

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

high mobility group box 1

multiple interactions

Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholecalciferol] results in increased expression of HMGB1 mRNA]
[Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein]

PMID:20519084 PMID:25412314

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases response to substance
affects response to substance
increases activity
multiple interactions
increases expression
decreases activity

HMGCR exon alternative form results in decreased susceptibility to Simvastatin
HMGCR intron polymorphism affects the susceptibility to Simvastatin; HMGCR polymorphism affects the susceptibility to Simvastatin
Simvastatin results in increased activity of HMGCR protein
[HMGCR intron polymorphism affects the expression of HMGCR exon alternative form] which results in decreased susceptibility to Simvastatin; [MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to Simvastatin; [Simvastatin co-treated with Ezetimibe] results in increased expression of HMGCR mRNA; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; Resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin affects the reaction [Hydroxychloroquine affects the expression of HMGCR mRNA]; Simvastatin results in increased expression of and results in increased activity of HMGCR protein
Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA]
Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of HMGCR protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin results in increased expression of and results in decreased activity of HMGCR protein; Simvastatin results in increased expression of and results in increased activity of HMGCR protein
Simvastatin results in increased expression of HMGCR mRNA; Simvastatin results in increased expression of HMGCR protein

PMID:1627634 PMID:8517861 PMID:8593127 PMID:9512650 PMID:10357840 More...

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

heme oxygenase 1

multiple interactions
increases stability
decreases expression
increases activity
increases expression
increases response to substance

[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]]
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; tin protoporphyrin IX inhibits the reaction [Simvastatin results in increased expression of HMOX1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased stability of HMOX1 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]
Simvastatin results in decreased expression of HMOX1 mRNA
Simvastatin results in increased activity of HMOX1 protein
Simvastatin results in increased expression of HMOX1 mRNA; Simvastatin results in increased expression of HMOX1 protein
HMOX1 gene mutant form results in increased susceptibility to Simvastatin

PMID:16375908 PMID:16414398 PMID:16628357 PMID:17928392 PMID:18073186 More...

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

HNF1 homeobox A

increases expression

Simvastatin results in increased expression of HNF1A mRNA

NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104

G

HRas proto-oncogene, GTPase

multiple interactions
decreases activity

Farnesol inhibits the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased prenylation of HRAS protein]; Simvastatin results in decreased prenylation of and results in decreased localization of HRAS protein
Simvastatin results in decreased activity of HRAS

PMID:11914545 PMID:12477733 PMID:18625914 PMID:19360310

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

multiple interactions

[Simvastatin co-treated with resveratrol] results in decreased expression of HSD3B1 mRNA

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

heat shock transcription factor 1

affects localization

Simvastatin affects the localization of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

heat shock protein 90 alpha family class A member 1

increases expression

Simvastatin results in increased expression of HSP90AA1 protein

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein family A (Hsp70) member 4

increases expression

Simvastatin results in increased expression of HSPA4 protein

NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001

G

heat shock protein family A (Hsp70) member 5

increases expression

Simvastatin results in increased expression of HSPA5 mRNA; Simvastatin results in increased expression of HSPA5 protein

PMID:18664198 PMID:19253821

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

decreases expression

Simvastatin results in decreased expression of HSPA8 protein

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

HtrA serine peptidase 2

affects localization

Simvastatin affects the localization of HTRA2 protein

NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095

G

integrin-binding sialoprotein

increases expression

Simvastatin results in increased expression of IBSP mRNA

NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693

G

intercellular adhesion molecule 1

multiple interactions
decreases expression

farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Simvastatin affects the expression of and affects the secretion of ICAM1 protein; Simvastatin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of ICAM1 protein modified form]
Simvastatin results in decreased expression of ICAM1 mRNA; Simvastatin results in decreased expression of ICAM1 protein; Simvastatin results in decreased expression of ICAM1 protein modified form

PMID:10946302 PMID:12615677 PMID:14602771 PMID:15234187 PMID:16054375 More...

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inhibitor of DNA binding 1

increases expression

Simvastatin results in increased expression of ID1 mRNA

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

isopentenyl-diphosphate delta isomerase 1

increases expression

Simvastatin results in increased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

indoleamine 2,3-dioxygenase 1

increases expression

Simvastatin results in increased expression of IDO1

NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730

G

interferon gamma

multiple interactions
increases expression
increases secretion

IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of PTGS2]; Simvastatin inhibits the reaction [IFNG results in increased expression of STAT1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA]
Simvastatin results in increased expression of IFNG mRNA
Simvastatin results in increased secretion of IFNG protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased phosphorylation of STAT1 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]; Simvastatin promotes the reaction [IFNG results in increased expression of PTGS2]

PMID:11219190 PMID:16321392 PMID:17507688 PMID:18453621 PMID:19589242 More...

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

multiple interactions

[Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK3 protein]

PMID:17327694 PMID:27734117

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 1 receptor

decreases expression
increases expression
multiple interactions

Simvastatin results in decreased expression of IGF1R; Simvastatin results in decreased expression of IGF1R mRNA; Simvastatin results in decreased expression of IGF1R protein
Simvastatin results in increased expression of IGF1R protein alternative form
[Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]

PMID:17158816 PMID:17327694 PMID:18489904 PMID:27734117

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

insulin-like growth factor binding protein 6

increases expression

Simvastatin results in increased expression of IGFBP6 mRNA

NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:133,276,234...133,280,966

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions
decreases expression
increases phosphorylation

artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of IKBKB protein]
Simvastatin results in decreased expression of IKBKB mRNA

PMID:17277159 PMID:18463201

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 10

increases expression
multiple interactions

Simvastatin results in increased expression of IL10
Simvastatin results in increased expression of IL10 mRNA; Simvastatin results in increased expression of IL10 protein
Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein]
1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of IL10 protein]]; [Lipopolysaccharides co-treated with Simvastatin] results in increased expression of and results in increased secretion of IL10 protein; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of IL10 protein]

PMID:15883752 PMID:20491794 PMID:21925249 PMID:25674200 PMID:33774062

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12B

multiple interactions
increases expression

FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; JUN promotes the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B protein]; Simvastatin promotes the reaction [Pam(3)CSK(4) peptide results in increased expression of IL12B protein]; Simvastatin promotes the reaction [resiquimod results in increased expression of IL12B protein]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 13

decreases expression

Simvastatin results in decreased expression of IL13 mRNA; Simvastatin results in decreased expression of IL13 protein

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 16

multiple interactions

[Lipopolysaccharides co-treated with Simvastatin] results in increased expression of IL16 mRNA

NCBI chr 1:137,617,702...137,718,022
Ensembl chr 1:137,617,944...137,718,130

G

interleukin 17A

multiple interactions
decreases expression
decreases secretion

IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL17A mRNA]

PMID:18453621 PMID:21856936

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 17F

decreases secretion

Simvastatin results in decreased secretion of IL17F protein

NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482

G

interleukin 18

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]]; Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]
Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL18 protein]

PMID:18660453 PMID:27377765

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 alpha

multiple interactions

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NFKBIA protein modified form]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]; Simvastatin inhibits the reaction [IL1A results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]

PMID:15705589 PMID:15728660

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
decreases expression
decreases secretion

1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]]; Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B mRNA]; Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA]
farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Simvastatin affects the reaction [IL1B protein results in increased activity of MMP2 protein]; Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [IL1B protein results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE mRNA]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of VCAM1 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
Simvastatin results in decreased expression of IL1B mRNA; Simvastatin results in decreased expression of IL1B protein
Simvastatin results in decreased secretion of IL1B protein

PMID:10946302 PMID:12829860 PMID:15883752 PMID:16054375 PMID:17075836 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 2

decreases expression

Simvastatin results in decreased expression of IL1R2 mRNA

NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725

G

interleukin 1 receptor-like 1

decreases expression

Simvastatin results in decreased expression of IL1RL1 mRNA

NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256

G

interleukin 2

multiple interactions

IL2 affects the reaction [Simvastatin results in increased expression of FOXP3]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 20 receptor subunit beta

increases expression

Simvastatin results in increased expression of IL20RB mRNA

NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942

G

interleukin 21

decreases expression
decreases secretion

Simvastatin results in decreased expression of IL21 mRNA
Simvastatin results in decreased secretion of IL21 protein

PMID:18453621 PMID:21856936

NCBI chr 2:120,117,105...120,127,012
Ensembl chr 2:120,119,444...120,126,996

G

interleukin 22

decreases secretion

Simvastatin results in decreased secretion of IL22 protein

NCBI chr 7:53,801,206...53,805,673
Ensembl chr 7:53,801,206...53,806,186

G

interleukin 23 subunit alpha

decreases expression

Simvastatin results in decreased expression of IL23A mRNA

PMID:18453621 PMID:22305382

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 25

decreases expression

Simvastatin results in decreased expression of IL25 mRNA

NCBI chr15:28,408,766...28,412,157
Ensembl chr15:28,408,842...28,411,893

G

interleukin 27

increases expression
multiple interactions
increases secretion

Simvastatin results in increased expression of IL27 mRNA
IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]
Simvastatin results in increased secretion of IL27 protein

NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582

G

interleukin 2 receptor subunit alpha

affects expression
decreases expression

Simvastatin affects the expression of IL2RA protein
Simvastatin results in decreased expression of IL2RA mRNA

PMID:16387846 PMID:18453621

NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697

G

interleukin 4

multiple interactions
increases expression
increases secretion
decreases expression

IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]
Simvastatin results in increased expression of IL4 mRNA
Simvastatin results in increased secretion of IL4 protein
Simvastatin results in decreased expression of IL4 mRNA; Simvastatin results in decreased expression of IL4 protein

PMID:17169357 PMID:18453621

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 4 receptor

decreases expression

Simvastatin results in decreased expression of IL4R mRNA
Simvastatin results in decreased expression of IL4RA mRNA

PMID:16414398 PMID:18453621

NCBI chr 1:180,115,061...180,139,981
Ensembl chr 1:180,115,120...180,139,980

G

interleukin 6

multiple interactions
increases expression
decreases expression
decreases secretion
affects secretion

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL6 mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Simvastatin results in decreased expression of and results in decreased secretion of IL6 protein
Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]
Simvastatin results in increased expression of IL6 mRNA
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]
Simvastatin results in decreased expression of IL6 mRNA; Simvastatin results in decreased expression of IL6 protein
Simvastatin results in decreased secretion of IL6 protein
Simvastatin affects the secretion of IL6 protein

PMID:12117737 PMID:15665042 PMID:15883752 PMID:16387846 PMID:16424782 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit alpha

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INHA mRNA

NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248

G

insulin induced gene 2

decreases expression

Simvastatin results in decreased expression of INSIG2 mRNA

NCBI chr13:32,472,390...32,500,139
Ensembl chr13:32,473,742...32,494,923

G

insulin-like 3

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INSL3 mRNA

NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560

G

interferon regulatory factor 1

multiple interactions

Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA]

NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166

G

interferon regulatory factor 4

decreases expression
multiple interactions

Simvastatin results in decreased expression of IRF4 protein
Simvastatin results in decreased expression of IRF4 mRNA; Simvastatin results in decreased expression of IRF4 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of IRF4 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of IRF4 protein]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IRF4 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IRF4 protein]

PMID:21856936 PMID:33034787

NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070

G

insulin receptor substrate 1

multiple interactions

Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein]

NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122

G

integrin subunit alpha L

affects binding
multiple interactions
decreases expression

Simvastatin binds to [ITGAL protein binds to ITGB2 protein]
Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGAL]
Simvastatin results in decreased expression of ITGAL mRNA

PMID:12615677 PMID:15041742 PMID:16828882

NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732

G

integrin subunit alpha M

decreases expression
multiple interactions

Simvastatin results in decreased expression of ITGAM mRNA; Simvastatin results in decreased expression of ITGAM protein
Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein]

PMID:16414398 PMID:21330348 PMID:21441352

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 1

decreases expression

Simvastatin results in decreased expression of ITGB1 mRNA; Simvastatin results in decreased expression of ITGB1 protein

PMID:17428261 PMID:21874229

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

integrin subunit beta 2

affects binding
multiple interactions
decreases expression

Simvastatin binds to [ITGAL protein binds to ITGB2 protein]
Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein]
Simvastatin inhibits the reaction [TNF results in increased expression of ITGB2]
Simvastatin results in decreased expression of ITGB2 mRNA

PMID:12615677 PMID:15041742 PMID:21330348

NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600

G

integrin subunit beta 3 binding protein

decreases expression

Simvastatin results in decreased expression of ITGB3BP mRNA

NCBI chr 5:114,460,217...114,525,538
Ensembl chr 5:114,460,221...114,525,704

G

integrin subunit beta 4

affects expression
increases expression

Simvastatin affects the expression of ITGB4 mRNA; Simvastatin affects the expression of ITGB4 protein
Simvastatin results in increased expression of ITGB4 mRNA; Simvastatin results in increased expression of ITGB4 protein

PMID:14630613 PMID:19110722

NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012

G

integrin subunit beta like 1

decreases expression

Simvastatin results in decreased expression of ITGBL1 mRNA

NCBI chr15:100,780,184...101,041,734
Ensembl chr15:100,780,184...101,041,733

G

Janus kinase 1

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]

NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926

G

Janus kinase 2

multiple interactions
decreases expression
decreases phosphorylation

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein]
Simvastatin results in decreased expression of JAK2 mRNA
Simvastatin results in decreased phosphorylation of JAK2 protein

PMID:16414398 PMID:16534557 PMID:18400235 PMID:19100119

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases phosphorylation
decreases localization
decreases expression

pyrazolanthrone inhibits the reaction [Simvastatin results in increased phosphorylation of JUN protein]
JUN promotes the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of JUN protein]
Simvastatin results in decreased localization of JUN protein
Simvastatin results in decreased expression of JUN mRNA

PMID:12753293 PMID:12963647 PMID:15187114 PMID:15488325 PMID:17125918

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

potassium voltage-gated channel subfamily H member 2

decreases localization
decreases activity
multiple interactions

Simvastatin results in decreased localization of KCNH2 protein
Simvastatin results in decreased activity of KCNH2 protein
Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein]

PMID:21525004 PMID:30086269

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

kinase insert domain receptor

increases expression
multiple interactions

Simvastatin results in increased expression of KDR mRNA; Simvastatin results in increased expression of KDR protein
Simvastatin inhibits the reaction [Streptozocin results in increased expression of KDR mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased expression of KDR protein]

PMID:15572054 PMID:19109527 PMID:20821229

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

KIT proto-oncogene receptor tyrosine kinase

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of KIT mRNA

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

KLF transcription factor 10

multiple interactions

[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA]

NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994

G

KLF transcription factor 16

increases expression

Simvastatin results in increased expression of KLF16 mRNA

NCBI chr 7:9,138,503...9,148,322
Ensembl chr 7:9,138,503...9,148,317

G

KLF transcription factor 2

increases expression
multiple interactions
decreases expression

Simvastatin results in increased expression of KLF2 mRNA
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of KLF2 mRNA]
Simvastatin results in decreased expression of KLF2 mRNA

PMID:17428261 PMID:20493886 PMID:20737288 PMID:22305382

NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944

G

KLF transcription factor 6

increases expression

Simvastatin results in increased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

killer cell lectin like receptor B1

decreases expression

Simvastatin results in decreased expression of KLRF1 mRNA

NCBI chr 4:162,456,294...162,474,989
Ensembl chr 4:162,456,294...162,474,989

G

KRAS proto-oncogene, GTPase

decreases prenylation

Simvastatin results in decreased prenylation of KRAS protein

NCBI chr 4:178,185,418...178,218,484

G

keratin 13

increases expression

Simvastatin results in increased expression of KRT13 mRNA

NCBI chr10:85,051,887...85,056,099
Ensembl chr10:85,051,889...85,056,084

G

keratin 15

increases expression

Simvastatin results in increased expression of KRT15 mRNA

NCBI chr10:85,066,797...85,070,614
Ensembl chr10:85,066,802...85,171,799

G

keratin 17

increases expression

Simvastatin results in increased expression of KRT17 mRNA

NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392

G

LBH regulator of WNT signaling pathway

increases expression

Simvastatin results in increased expression of LBH mRNA

NCBI chr 6:22,569,238...22,593,056
Ensembl chr 6:22,568,834...22,593,079

G

lipopolysaccharide binding protein

decreases expression

Simvastatin results in decreased expression of LBP mRNA

NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586

G

lecithin cholesterol acyltransferase

increases activity
decreases expression

Simvastatin results in increased activity of LCAT protein
Simvastatin results in decreased expression of LCAT mRNA

PMID:21241519 PMID:25055962

NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231

G

low density lipoprotein receptor

multiple interactions
affects response to substance
increases expression
increases activity

[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Simvastatin co-treated with Ezetimibe] results in increased expression of LDLR mRNA; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB]
LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin; LDLR mutant form affects the susceptibility to Simvastatin
Simvastatin results in increased expression of LDLR mRNA
Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA]
Simvastatin results in increased activity of LDLR protein
Simvastatin results in increased expression of LDLR mRNA; Simvastatin results in increased expression of LDLR protein

PMID:1627634 PMID:8457250 PMID:8593127 PMID:9633944 PMID:10208479 More...

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

lymphoid enhancer binding factor 1

increases expression

Simvastatin results in increased expression of LEF1 mRNA

NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794

G

leptin

multiple interactions
decreases expression
decreases secretion

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; GGTI 298 inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; GGTI 298 inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]
Simvastatin results in decreased expression of LEP mRNA; Simvastatin results in decreased expression of LEP mRNA alternative form
Simvastatin inhibits the reaction [Poloxamer results in increased secretion of LEP protein]

PMID:19254925 PMID:29071762

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

leptin receptor

affects response to substance

LEPR polymorphism affects the susceptibility to Simvastatin

PMID:14625131 PMID:18854995

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

luteinizing hormone subunit beta

multiple interactions

Simvastatin promotes the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in decreased expression of LHB protein]; Simvastatin promotes the reaction [ethinyl estradiol-desogestrel combination results in decreased expression of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

LIF, interleukin 6 family cytokine

multiple interactions

[Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

lipopolysaccharide-induced TNF factor

decreases expression

Simvastatin results in decreased expression of LITAF mRNA

NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763

G

lysyl oxidase

decreases expression

Simvastatin results in decreased expression of LOX mRNA

NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477

G

lipoprotein lipase

decreases expression
increases expression

Simvastatin results in decreased expression of LPL
Simvastatin results in increased expression of LPL protein

PMID:2009092 PMID:19216230

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

LDL receptor related protein 6

decreases expression

Simvastatin results in decreased expression of LRP6 mRNA

NCBI chr 4:167,269,856...167,400,364
Ensembl chr 4:167,270,353...167,400,497

G

leucine rich repeat containing 2

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of LRRC2 mRNA

NCBI chr 8:110,936,119...110,969,189
Ensembl chr 8:110,938,165...110,969,185

G

lymphotoxin beta

decreases expression

Simvastatin results in decreased expression of LTB mRNA

NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381

G

mitotic arrest deficient 2 like 1

decreases expression

Simvastatin results in decreased expression of MAD2L1 mRNA

NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470

G

microtubule-associated protein 1 light chain 3 beta

increases expression
multiple interactions

Simvastatin results in increased expression of MAP1LC3B protein
[Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form; Chloroquine promotes the reaction [[Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form]

PMID:23817226 PMID:25412314

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen-activated protein kinase kinase kinase 14

decreases expression

Simvastatin results in decreased expression of MAP3K14 mRNA

NCBI chr10:88,165,349...88,215,558
Ensembl chr10:88,165,351...88,215,523

G

mitogen activated protein kinase kinase kinase 7

multiple interactions

Simvastatin results in decreased activity of [MAP3K7 protein co-treated with TAB1 protein]

NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597

G

mitogen activated protein kinase 1

multiple interactions
decreases activity
increases phosphorylation
decreases phosphorylation

[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; MAPK1 promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of NFE2L2 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of NQO1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
Simvastatin results in decreased activity of MAPK1 protein
Simvastatin results in increased phosphorylation of MAPK1 protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK1 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of MAPK1 protein
Simvastatin results in decreased phosphorylation of MAPK1 protein
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK1 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein

PMID:17169357 PMID:17327694 PMID:17428261 PMID:17928392 PMID:18047562 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

multiple interactions
decreases expression

Simvastatin results in increased phosphorylation of and results in increased activity of MAPK14 protein
Simvastatin results in decreased expression of MAPK14 mRNA

PMID:16414398 PMID:17928392

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
decreases activity
increases phosphorylation
decreases phosphorylation

[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK3 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
Simvastatin results in decreased activity of MAPK3 protein
Simvastatin results in increased phosphorylation of MAPK3 protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK3 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of MAPK3 protein
Simvastatin results in decreased phosphorylation of MAPK3 protein
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK3 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein

PMID:17169357 PMID:17327694 PMID:17428261 PMID:17928392 PMID:18047562 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions
increases activity

farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]
Simvastatin results in increased activity of MAPK8 protein

PMID:15187114 PMID:18047562 PMID:18310456

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

increases activity

Simvastatin results in increased activity of MAPK9 protein

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

microtubule-associated protein tau

affects expression

Simvastatin affects the expression of MAPT

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

myoglobin

multiple interactions

Simvastatin inhibits the reaction [Poloxamer results in increased secretion of MB protein]

NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383

G

minichromosome maintenance complex component 4

decreases expression

Simvastatin results in decreased expression of MCM4 mRNA

NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144

G

malate dehydrogenase 1

decreases expression

Simvastatin results in decreased expression of MDH1 protein

NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925

G

MDM2 proto-oncogene

increases phosphorylation
multiple interactions

Simvastatin results in increased phosphorylation of MDM2 protein
Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]]

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

MER proto-oncogene, tyrosine kinase

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of MERTK mRNA

NCBI chr 3:115,939,351...116,045,141
Ensembl chr 3:115,939,351...116,046,554

G

microRNA 221

decreases expression

Simvastatin results in decreased expression of MIR221

NCBI chr X:3,429,465...3,429,573
Ensembl chr X:3,429,465...3,429,573

G

marker of proliferation Ki-67

decreases expression

Simvastatin results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 1

multiple interactions
decreases expression
decreases secretion
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP1]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of MMP1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of MMP1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased secretion of MMP1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of MMP1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of MMP1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased secretion of MMP1 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]
Simvastatin results in decreased secretion of MMP1 mRNA; Simvastatin results in decreased secretion of MMP1 protein
Simvastatin results in increased expression of MMP1 mRNA

PMID:17303772 PMID:17428261 PMID:18625914 PMID:31260663

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 10

increases expression

Simvastatin results in increased expression of MMP10 mRNA

NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748

G

matrix metallopeptidase 12

increases expression

Simvastatin results in increased expression of MMP12 mRNA

NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611

G

matrix metallopeptidase 13

increases expression
multiple interactions

Simvastatin results in increased expression of MMP13 mRNA
Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]

PMID:16274305 PMID:17428261 PMID:31260663

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 2

decreases activity
increases activity
multiple interactions
decreases expression

Simvastatin results in decreased activity of MMP2 protein
Simvastatin results in increased activity of MMP2 protein
Simvastatin inhibits the reaction [Monocrotaline results in increased expression of MMP2 mRNA]; Simvastatin results in decreased expression of and results in decreased activity of MMP2 protein
Simvastatin affects the reaction [IL1B protein results in increased activity of MMP2 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP2 protein]
Simvastatin results in decreased expression of MMP2 mRNA
Simvastatin results in decreased expression of MMP2 protein

PMID:15210533 PMID:17038636 PMID:17158816 PMID:17169357 PMID:18309148 More...

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 28

increases expression

Simvastatin results in increased expression of MMP28 mRNA

NCBI chr10:68,241,138...68,264,866
Ensembl chr10:68,241,138...68,264,866

G

matrix metallopeptidase 3

decreases expression
multiple interactions

Simvastatin results in decreased expression of MMP3 mRNA
Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]

PMID:16414398 PMID:31260663

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 8

multiple interactions

Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP8 mRNA]

NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520

G

matrix metallopeptidase 9

multiple interactions
increases activity
decreases activity
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of MMP9 protein]; Simvastatin promotes the reaction [TNF results in increased expression of MMP9 mRNA]
Simvastatin results in increased activity of MMP9 protein
Simvastatin results in decreased activity of MMP9 protein
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of MMP9 protein]
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of MMP9 mRNA]; Simvastatin results in decreased expression of and results in decreased activity of MMP9 protein
Simvastatin results in decreased expression of MMP9 protein
Simvastatin results in decreased expression of MMP9 mRNA; Simvastatin results in decreased expression of MMP9 protein

PMID:15107580 PMID:15210533 PMID:15537504 PMID:15728660 PMID:16002570 More...

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions
decreases expression
decreases activity

Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein]
Simvastatin results in decreased expression of MPO protein
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein]
Simvastatin results in decreased activity of MPO protein
1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]

PMID:15665042 PMID:17038636 PMID:21764683 PMID:33774062

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

muscle RAS oncogene homolog

multiple interactions

Simvastatin inhibits the reaction [Glucose results in increased activity of MRAS protein]; Simvastatin inhibits the reaction [Smoke analog results in increased activity of MRAS protein]

PMID:18569938 PMID:19299917

NCBI chr 8:99,944,036...100,006,771
Ensembl chr 8:99,944,036...99,996,408

G

mitochondrial ribosomal protein S31

decreases response to substance

MRPS31 SNP results in decreased susceptibility to Simvastatin

NCBI chr16:69,601,349...69,621,609
Ensembl chr16:69,601,349...69,630,654

G

myostatin

multiple interactions
increases expression

5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Simvastatin results in increased expression of and results in increased secretion of MSTN protein
Simvastatin results in increased expression of MSTN mRNA; Simvastatin results in increased expression of MSTN protein

NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933

G

metallothionein 1

increases expression

Simvastatin results in increased expression of MT1A mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

methylenetetrahydrofolate reductase

multiple interactions
increases expression
affects response to substance

Homocysteine inhibits the reaction [Simvastatin results in increased expression of MTHFR protein modified form]; Simvastatin promotes the reaction [Homocysteine results in increased expression of MTHFR protein]
MTHFR affects the susceptibility to Simvastatin
MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 mRNA]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 protein]

NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797

G

mechanistic target of rapamycin kinase

decreases phosphorylation
multiple interactions

Simvastatin results in decreased phosphorylation of MTOR protein
FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of MTOR protein]

PMID:22144680 PMID:33034787

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC mRNA]; Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MUC5AC mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MUC5AC protein]
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]]; Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]

PMID:19024099 PMID:20359552

NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475

G

mevalonate diphosphate decarboxylase

increases expression

Simvastatin results in increased expression of MVD mRNA

NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971

G

mevalonate kinase

increases expression
multiple interactions

Simvastatin results in increased expression of MVK mRNA
[MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to Simvastatin; MVK gene mutant form promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]

PMID:12477733 PMID:25055962

NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882

G

myosin binding protein H

increases expression

Simvastatin results in increased expression of MYBPH mRNA

NCBI chr13:45,653,156...45,660,893
Ensembl chr13:45,653,234...45,660,893

G

myosin heavy chain 10

decreases expression

Simvastatin results in decreased expression of MYH10 protein

NCBI chr10:53,393,901...53,525,174
Ensembl chr10:53,394,389...53,525,165

G

myosin heavy chain 6

increases expression

Simvastatin results in increased expression of MYH6 mRNA

NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720

G

N-myc downstream regulated 1

decreases expression

Simvastatin results in decreased expression of NDRG1 protein

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

nuclear factor of activated T-cells 3

multiple interactions
decreases localization
increases localization

Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter]
Simvastatin results in decreased localization of NFATC3 protein alternative form
Simvastatin results in increased localization of NFATC3 protein

NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150

G

NFE2 like bZIP transcription factor 2

increases localization
multiple interactions
increases expression

Simvastatin results in increased localization of NFE2L2 protein
NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]]
Mevalonic Acid affects the reaction [Simvastatin results in increased localization of NFE2L2 protein]
Simvastatin results in increased expression of NFE2L2 mRNA
MAPK1 promotes the reaction [Simvastatin results in increased expression of NFE2L2 mRNA]; Simvastatin results in increased expression of and affects the localization of NFE2L2 protein

PMID:17928392 PMID:18787804 PMID:30513525

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions
increases localization
decreases localization
decreases activity
decreases expression

artemisinin inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; artemisinin inhibits the reaction [Simvastatin results in increased localization of NFKB1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; parthenolide inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; parthenolide inhibits the reaction [Simvastatin results in increased localization of NFKB1 protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of and results in increased activity of NFKB1 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of NFKB1 protein]; Simvastatin results in increased localization of and results in increased activity of NFKB1 protein
Simvastatin results in decreased localization of NFKB1 protein
Simvastatin results in decreased activity of NFKB1 protein
Simvastatin results in decreased expression of NFKB1 mRNA
Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]

PMID:12753293 PMID:17038636 PMID:17277159 PMID:18463201 PMID:21465237 More...

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions
increases phosphorylation

artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of NFKBIA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of NFKBIA protein]
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]]
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; Simvastatin inhibits the reaction [IL1A results in decreased expression of NFKBIA protein modified form]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of NFKBIA protein]

PMID:15705589 PMID:17075836 PMID:17178392 PMID:17277159 PMID:18073186 More...

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

neuroligin 3

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NLGN3 mRNA]

NCBI chr X:66,427,926...66,457,378
Ensembl chr X:66,429,458...66,451,876

G

NLR family, pyrin domain containing 3

multiple interactions

Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of NLRP3 mRNA]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]

PMID:30408459 PMID:35762198

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

noggin

multiple interactions

NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]

NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339

G

nitric oxide synthase 2

multiple interactions
increases expression
decreases expression

Simvastatin promotes the reaction [Doxorubicin results in increased expression of NOS2 protein]
Simvastatin results in increased expression of NOS2 mRNA; Simvastatin results in increased expression of NOS2 protein
Homocysteine affects the reaction [Simvastatin results in increased expression of NOS2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 mRNA]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]; Simvastatin promotes the reaction [Homocysteine results in increased expression of NOS2 mRNA]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]
Simvastatin results in decreased expression of NOS2 mRNA; Simvastatin results in decreased expression of NOS2 protein

PMID:10188333 PMID:11470468 PMID:15705589 PMID:16414398 PMID:17729120 More...

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

increases expression
multiple interactions
increases phosphorylation
decreases expression

Simvastatin results in increased expression of NOS3; Simvastatin results in increased expression of NOS3 mRNA; Simvastatin results in increased expression of NOS3 protein
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of NOS3 mRNA]; Simvastatin inhibits the reaction [Smoke analog affects the expression of NOS3 mRNA]; Simvastatin results in increased expression of and results in increased phosphorylation of and results in increased activity of NOS3 protein
Simvastatin results in increased phosphorylation of NOS3 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of NOS3 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Nifedipine promotes the reaction [Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]; Simvastatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]; Simvastatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]]; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]]
Simvastatin results in decreased expression of NOS3 mRNA
Simvastatin results in decreased expression of NOS3 mRNA; Simvastatin results in decreased expression of NOS3 protein

PMID:10188333 PMID:11470468 PMID:11947894 PMID:12379581 PMID:12406854 More...

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

notch receptor 1

increases cleavage
increases expression

Simvastatin results in increased cleavage of NOTCH1 protein
Simvastatin results in increased expression of NOTCH1 mRNA

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

notch receptor 4

increases expression

Simvastatin results in increased expression of NOTCH4 mRNA

NCBI chr20:4,160,362...4,184,466
Ensembl chr20:4,160,445...4,184,465

G

NPC1 like intracellular cholesterol transporter 1

decreases expression

Simvastatin results in decreased expression of NPC1L1 mRNA

NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113

G

NPHS2 stomatin family member, podocin

increases expression

Simvastatin results in increased expression of NPHS2 mRNA

NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313

G

natriuretic peptide A

decreases expression

Simvastatin results in decreased expression of NPPA mRNA

PMID:16029635 PMID:16534557

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide B

decreases expression

Simvastatin results in decreased expression of NPPB; Simvastatin results in decreased expression of NPPB protein

PMID:16628357 PMID:21124329

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

MAPK1 promotes the reaction [Simvastatin results in increased expression of NQO1 mRNA]
Simvastatin results in increased expression of NQO1 mRNA; Simvastatin results in increased expression of NQO1 protein

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 0, group B, member 1

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of NR0B1 mRNA

NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NR1D1 mRNA]

NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705

G

nuclear receptor subfamily 1, group H, member 3

decreases expression

Simvastatin results in decreased expression of NR1H3 mRNA

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Simvastatin affects the reaction [Dietary Fats affects the expression of NR1H4 mRNA]; Simvastatin affects the reaction [Dietary Fats affects the expression of NR1H4 protein]

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

increases activity
multiple interactions

Simvastatin results in increased activity of NR1I2 protein
[Simvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose; [Simvastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose]; Simvastatin promotes the reaction [NR1I2 protein binds to SGK2 promoter]

PMID:15802384 PMID:17041008 PMID:24204015

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

increases activity

Simvastatin results in increased activity of NR1I3 protein

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor subfamily 4, group A, member 3

multiple interactions

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of NR4A3 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of NR4A3 mRNA]

NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733

G

neuropilin 1

decreases response to substance

NRP1 SNP results in decreased susceptibility to Simvastatin

NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633

G

NAD(P) dependent steroid dehydrogenase-like

decreases expression

Simvastatin results in decreased expression of NSDHL mRNA

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

neurotrophic receptor tyrosine kinase 1

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of NTRK1 mRNA

NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of NTRK2 mRNA

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

occludin

increases expression

Simvastatin results in increased expression of OCLN

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

oxidized low density lipoprotein receptor 1

decreases expression

Simvastatin results in decreased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

oxysterol binding protein-like 1A

decreases expression

Simvastatin results in decreased expression of OSBPL1A mRNA

NCBI chr18:3,904,006...4,094,635
Ensembl chr18:3,904,006...4,094,585

G

oncostatin M

multiple interactions

Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA]; Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein]

NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313

G

prolyl 4-hydroxylase subunit beta

decreases expression

Simvastatin results in decreased expression of P4HB mRNA

NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500

G

poly (ADP-ribose) polymerase 1

multiple interactions
decreases cleavage
increases cleavage

[Simvastatin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; Mevalonic Acid inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; pifithrin inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of PARP1 protein modified form]; Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]
Simvastatin results in decreased cleavage of PARP1 mRNA
Simvastatin inhibits the reaction [Glucose results in increased activity of PARP1 protein]
IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]

PMID:16054375 PMID:18004065 PMID:20045437 PMID:20464445 PMID:21910007 More...

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

proliferating cell nuclear antigen

decreases expression

Simvastatin results in decreased expression of PCNA mRNA; Simvastatin results in decreased expression of PCNA protein

PMID:17428261 PMID:18824851

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

proprotein convertase subtilisin/kexin type 9

multiple interactions

[Simvastatin co-treated with Ezetimibe] results in increased expression of PCSK9 mRNA

NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688

G

phosphodiesterase 4B

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of PDE4B mRNA]

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

platelet derived growth factor subunit A

decreases expression

Simvastatin results in decreased expression of PDGFA mRNA

NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497

G

platelet derived growth factor subunit B

decreases expression
multiple interactions
decreases activity

Simvastatin results in decreased expression of PDGFB protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased activity of PDGFB protein]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of PDGFB mRNA]
Simvastatin results in decreased expression of PDGFB mRNA

PMID:8231022 PMID:10412745 PMID:10412775 PMID:15728660 PMID:16373842

NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984

G

platelet derived growth factor receptor alpha

decreases expression

Simvastatin results in decreased expression of PDGFRA mRNA

NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335

G

platelet derived growth factor receptor beta

decreases expression
multiple interactions

Simvastatin results in decreased expression of PDGFRB mRNA
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of PDGFRB mRNA

PMID:10412775 PMID:28263720

NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843

G

pyruvate dehydrogenase kinase 2

increases expression

Simvastatin results in increased expression of PDK2 mRNA

NCBI chr10:79,972,550...79,987,074
Ensembl chr10:79,972,556...79,987,085

G

pyruvate dehydrogenase kinase 4

increases expression

Simvastatin results in increased expression of PDK4 mRNA

PMID:19001041 PMID:19262002

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

platelet and endothelial cell adhesion molecule 1

increases expression

Simvastatin results in increased expression of PECAM1 mRNA

NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116

G

prohibitin 2

decreases expression

Simvastatin results in decreased expression of PHB2 protein

NCBI chr 4:157,517,662...157,522,268
Ensembl chr 4:157,517,577...157,522,272

G

phosphatidylinositol glycan anchor biosynthesis, class C

decreases expression

Simvastatin results in decreased expression of PIGC mRNA

NCBI chr13:74,343,619...74,346,148
Ensembl chr13:74,296,854...74,346,211

G

paired-like homeodomain 2

decreases expression

Simvastatin results in decreased expression of PITX2 mRNA

NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293

G

protein kinase, membrane associated tyrosine/threonine 1

decreases expression

Simvastatin results in decreased expression of PKMYT1 mRNA

NCBI chr10:12,748,221...12,758,995
Ensembl chr10:12,748,237...12,758,995

G

phospholipase A2 group IIA

multiple interactions

Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of PLA2G2A protein]

NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014

G

phospholipase A2 group VII

multiple interactions

Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PLA2G7 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G7 mRNA]

NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476

G

plasminogen activator, tissue type

multiple interactions
increases expression
increases activity
decreases expression

geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT mRNA]; geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PLAT mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PLAT]; Simvastatin inhibits the reaction [TNF results in decreased expression of PLAT]
Simvastatin results in increased expression of PLAT; Simvastatin results in increased expression of PLAT mRNA; Simvastatin results in increased expression of PLAT protein
Simvastatin results in increased activity of PLAT protein
Simvastatin results in decreased expression of PLAT mRNA

PMID:12371961 PMID:12753293 PMID:16414398

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

plasminogen activator, urokinase

decreases expression

Simvastatin results in decreased expression of PLAU mRNA

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

phospholipase C, gamma 2

increases expression

Simvastatin results in increased expression of PLCG2 mRNA

NCBI chr19:45,547,416...45,683,930
Ensembl chr19:45,547,416...45,683,930

G

polo-like kinase 2

decreases expression

Simvastatin results in decreased expression of PLK2 mRNA

NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947

G

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3

decreases expression

Simvastatin results in decreased expression of PLOD3 mRNA

NCBI chr12:19,676,384...19,686,945
Ensembl chr12:19,676,386...19,686,960

G

plexin D1

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of PLXND1 mRNA

NCBI chr 4:149,002,786...149,043,097
Ensembl chr 4:149,002,784...149,043,244

G

phorbol-12-myristate-13-acetate-induced protein 1

affects localization
multiple interactions
increases expression

Simvastatin affects the localization of PMAIP1 protein
pifithrin inhibits the reaction [Simvastatin results in increased expression of PMAIP1 mRNA]
Simvastatin results in increased expression of PMAIP1 mRNA; Simvastatin results in increased expression of PMAIP1 protein

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

phosphomevalonate kinase

increases expression

Simvastatin results in increased expression of PMVK mRNA

NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364

G

protein-O-mannosyltransferase 1

increases expression

Simvastatin results in increased expression of POMT1 mRNA

NCBI chr 3:15,520,717...15,538,579
Ensembl chr 3:15,520,481...15,538,581

G

paraoxonase 1

multiple interactions
increases expression

farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; PON1 gene polymorphism affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 gene SNP affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 protein affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]; Simvastatin results in increased expression of and results in increased activity of PON1 protein; Squalene inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]

PMID:14500290 PMID:15690306 PMID:16238680

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

increases expression
multiple interactions

Simvastatin results in increased expression of PPARA mRNA
PPARA mutant form inhibits the reaction [Simvastatin results in increased expression of SCARB1]; Simvastatin promotes the reaction [TNF results in increased expression of PPARA]
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARA mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARA protein]; Simvastatin promotes the reaction [Zymosan results in increased expression of PPARA]

PMID:15234187 PMID:18981156 PMID:19001041 PMID:20835264 PMID:21323892

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

multiple interactions
decreases expression

[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein]
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARG mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARG protein]
Simvastatin results in decreased expression of PPARG

PMID:15781755 PMID:19216230 PMID:20835264

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 1, regulatory subunit 12A

multiple interactions

geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein]

NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425

G

protein phosphatase 1, regulatory (inhibitor) subunit 14A

multiple interactions

geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R14A protein]

NCBI chr 1:84,583,127...84,590,743
Ensembl chr 1:84,586,627...84,590,671

G

DNA primase subunit 1

decreases expression

Simvastatin results in decreased expression of PRIM1 mRNA

NCBI chr 7:446,342...462,526
Ensembl chr 7:431,805...462,526

G

protein kinase AMP-activated catalytic subunit alpha 1

increases expression

Simvastatin results in increased expression of PRKAA1 mRNA

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

presenilin 1

increases expression

Simvastatin results in increased expression of PSEN1 mRNA

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

platelet-activating factor receptor

decreases expression

Simvastatin results in decreased expression of PTAFR mRNA

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

phosphatase and tensin homolog

increases expression

Simvastatin results in increased expression of PTEN mRNA; Simvastatin results in increased expression of PTEN protein

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin E synthase

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGES protein]
Simvastatin results in decreased expression of PTGES protein

NCBI chr 3:14,177,892...14,189,236

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression
decreases expression

JTE 013 inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of PTGS2]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]]; Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]; Suramin inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]
Simvastatin results in increased expression of PTGS2 mRNA
Simvastatin promotes the reaction [IFNG results in increased expression of PTGS2]
Simvastatin results in decreased expression of PTGS2 protein
Simvastatin inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein]

PMID:17038636 PMID:17277159 PMID:17901590 PMID:18612546 PMID:19225232 More...

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine kinase 2

decreases activity

Simvastatin results in decreased activity of PTK2 protein

NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783

G

paxillin

multiple interactions
affects localization
decreases phosphorylation

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein]
Simvastatin affects the localization of PXN protein
Simvastatin results in decreased phosphorylation of PXN protein

NCBI chr12:41,060,791...41,107,952
Ensembl chr12:41,060,791...41,107,931

G

Rac family small GTPase 1

multiple interactions
affects localization
increases expression
decreases activity
decreases expression
increases activity

Cholesterol inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RAC1 protein]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]]; Simvastatin affects the localization of and results in decreased activity of RAC1 protein; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased prenylation of RAC1 protein]
Simvastatin affects the localization of RAC1 protein
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of RAC1 protein]
Simvastatin results in decreased activity of RAC1 protein
Simvastatin results in decreased expression of RAC1
Simvastatin results in increased activity of RAC1 protein

PMID:16698853 PMID:17169357 PMID:17303772 PMID:17513949 PMID:18625914 More...

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

Rac family small GTPase 2

affects localization
decreases activity

Simvastatin affects the localization of RAC2 protein
Simvastatin results in decreased activity of RAC2 protein

PMID:17169357 PMID:20045437

NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720

G

Rac family small GTPase 3

affects localization

Simvastatin affects the localization of RAC3 protein

NCBI chr10:106,002,808...106,005,243
Ensembl chr10:105,993,087...106,005,260

G

Rac GTPase-activating protein 1

decreases expression

Simvastatin results in decreased expression of RACGAP1 mRNA

NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831

G

Raf-1 proto-oncogene, serine/threonine kinase

decreases activity
multiple interactions

Simvastatin results in decreased activity of RAF1 protein
Simvastatin inhibits the reaction [Streptozocin results in increased expression of RAF1 protein]

PMID:18569938 PMID:19360310

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

G

RAP1A, member of RAS oncogene family

decreases prenylation
multiple interactions
decreases geranoylation
decreases expression

Simvastatin results in decreased prenylation of RAP1A protein
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased geranoylation of RAP1A protein]; Simvastatin results in decreased geranoylation of and results in decreased prenylation of RAP1A protein
Simvastatin results in decreased expression of RAP1A protein alternative form

PMID:20018177 PMID:22120639 PMID:25578243 PMID:37956312

NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501

G

RAS protein-specific guanine nucleotide-releasing factor 1

affects phosphorylation
affects localization

Simvastatin affects the phosphorylation of RASGRF1 protein
Simvastatin affects the localization of RASGRF1 protein

NCBI chr 8:90,445,154...90,574,274
Ensembl chr 8:90,445,154...90,574,269

G

RB transcriptional corepressor 1

decreases phosphorylation

Simvastatin results in decreased phosphorylation of RB1 protein

PMID:17928568 PMID:18804536

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases localization
decreases localization
decreases expression

artemisinin inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; artemisinin inhibits the reaction [Simvastatin results in increased localization of RELA protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; parthenolide inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; parthenolide inhibits the reaction [Simvastatin results in increased localization of RELA protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Simvastatin inhibits the reaction [TNF results in increased localization of RELA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of and results in increased activity of RELA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of RELA protein]; Simvastatin results in increased localization of and results in increased activity of RELA protein
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]]; Simvastatin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of RELA protein]
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; Homocysteine inhibits the reaction [Simvastatin results in decreased expression of RELA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]]
Simvastatin results in decreased localization of RELA protein
Simvastatin results in decreased expression of RELA mRNA; Simvastatin results in decreased expression of RELA protein

PMID:12753293 PMID:15705589 PMID:16414398 PMID:17038636 PMID:17075836 More...

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ret proto-oncogene

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of RET mRNA

NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176

G

resistin

multiple interactions

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]

NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620

G

replication factor C subunit 5

decreases expression

Simvastatin results in decreased expression of RFC5 mRNA

NCBI chr12:39,207,484...39,217,041
Ensembl chr12:39,207,484...39,217,312

G

regulator of G-protein signaling 2

increases expression

Simvastatin results in increased expression of RGS2 mRNA

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

ras homolog family member A

multiple interactions
decreases activity
decreases expression
increases expression
increases localization
affects localization
decreases prenylation

farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]]; geranylgeraniol inhibits the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased activity of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased localization of RHOA protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; RHOA inhibits the reaction [Simvastatin results in increased expression of SCARB1]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; Simvastatin affects the localization of and results in decreased activity of RHOA protein; Simvastatin inhibits the reaction [geranylgeranyl pyrophosphate affects the localization of RHOA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]; Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]; Simvastatin results in decreased localization of and results in decreased activity of RHOA protein; Simvastatin results in increased localization of and results in decreased prenylation of RHOA protein
geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of RHOA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of RHOA]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein]; Simvastatin results in decreased geranoylation of and results in decreased prenylation of RHOA protein
Simvastatin results in decreased expression of RHOA; Simvastatin results in decreased expression of RHOA protein
Simvastatin results in increased expression of RHOA mRNA
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]
Simvastatin results in increased expression of RHOA protein
Simvastatin affects the localization of RHOA protein
Simvastatin results in decreased prenylation of RHOA protein

PMID:12477733 PMID:14630613 PMID:15200425 PMID:16005304 PMID:16470222 More...

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

ras homolog family member C

increases expression

Simvastatin results in increased expression of RHOC mRNA

NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306

G

receptor interacting serine/threonine kinase 1

multiple interactions

[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]; [Simvastatin co-treated with Metformin] results in increased expression of RIPK1 protein; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]; RIPK3 protein affects the reaction [necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]]

NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824

G

receptor-interacting serine-threonine kinase 3

multiple interactions

[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]; RIPK3 protein affects the reaction [necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]]

NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121

G

RAR-related orphan receptor C

multiple interactions
decreases expression

IFNG affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL27 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL4 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of RORC mRNA]

NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907

G

ribosomal protein L39

increases expression

Simvastatin results in increased expression of RPL39 mRNA

NCBI chr X:116,327,216...116,330,211
Ensembl chr18:6,326,330...6,326,692
Ensembl chr X:6,326,330...6,326,692

G

ribosomal protein S10

increases expression

Simvastatin results in increased expression of RPS10 mRNA

NCBI chr20:5,694,313...5,698,922
Ensembl chr20:5,694,313...5,699,044
Ensembl chr 6:5,694,313...5,699,044

G

ribosomal protein S6

multiple interactions
decreases phosphorylation

IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6 protein]

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

ribosomal protein S6 kinase B1

multiple interactions
decreases phosphorylation

FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]

PMID:27734117 PMID:33034787

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

RT1 class Ia, locus A2

affects expression

Simvastatin affects the expression of HLA-E mRNA

NCBI chr20:4,870,939...4,910,183

G

RT1 class II, locus Bb

affects expression

Simvastatin affects the expression of HLA-DQB1 mRNA

NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597

G

RT1 class I, locus CE5

affects expression

Simvastatin affects the expression of HLA-F mRNA

NCBI chr20:3,403,418...3,479,476

G

RT1 class II, locus Da

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]

NCBI chr20:4,513,464...4,518,457
Ensembl chr20:4,512,911...4,518,455

G

RT1 class II, locus DMa

decreases expression

Simvastatin results in decreased expression of RT1-DMA mRNA

NCBI chr20:4,707,028...4,710,432
Ensembl chr20:4,707,028...4,710,432

G

RUNX family transcription factor 2

increases expression
multiple interactions

Simvastatin results in increased expression of RUNX2
DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]

PMID:18310456 PMID:20381859 PMID:20417880 PMID:22058016

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

ryanodine receptor 2

increases expression

Simvastatin results in increased expression of RYR2 mRNA; Simvastatin results in increased expression of RYR2 protein

NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142

G

S100 calcium binding protein A6

increases expression
multiple interactions

Simvastatin results in increased expression of S100A6 mRNA
Simvastatin results in increased expression of and results in increased localization of S100A6 protein
Simvastatin results in increased expression of S100A6 mRNA; Simvastatin results in increased expression of S100A6 protein

PMID:14973129 PMID:17428261

NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180

G

S100 calcium binding protein A8

increases expression

Simvastatin results in increased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

increases expression

Simvastatin results in increased expression of S100A9 mRNA

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

sphingosine-1-phosphate receptor 1

increases expression

Simvastatin results in increased expression of S1PR1 mRNA

NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681

G

sphingosine-1-phosphate receptor 3

increases expression
decreases expression

Simvastatin results in increased expression of S1PR3 mRNA
Simvastatin results in decreased expression of S1PR3 mRNA

PMID:18612546 PMID:18981156

NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505

G

SREBF chaperone

affects response to substance

SCAP polymorphism affects the susceptibility to Simvastatin

NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666

G

scavenger receptor class B, member 1

multiple interactions
increases expression

PPARA mutant form inhibits the reaction [Simvastatin results in increased expression of SCARB1]; RHOA inhibits the reaction [Simvastatin results in increased expression of SCARB1]
Simvastatin results in increased expression of SCARB1; Simvastatin results in increased expression of SCARB1 mRNA; Simvastatin results in increased expression of SCARB1 protein
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of SCARB1 mRNA; Simvastatin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 mRNA]; Simvastatin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 protein]

PMID:18981156 PMID:20025956 PMID:21241519 PMID:25055962 PMID:33383043

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

syndecan 1

decreases expression

Simvastatin results in decreased expression of SDC1 mRNA

NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264

G

syndecan 4

decreases expression

Simvastatin results in decreased expression of SDC4 mRNA

NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580

G

selectin E

multiple interactions
decreases expression
affects expression

farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE mRNA]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of SELE protein modified form]
Simvastatin affects the expression of SELE protein

PMID:10946302 PMID:14602771 PMID:16740276 PMID:21994025

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

selectin P

multiple interactions
decreases expression

Simvastatin inhibits the reaction [staphylococcal alpha-toxin results in increased expression of SELP protein]
Simvastatin results in decreased expression of SELP mRNA

PMID:12379581 PMID:16414398

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

serpin family E member 1

decreases expression
multiple interactions
decreases activity
decreases secretion

Simvastatin results in decreased expression of SERPINE1 mRNA; Simvastatin results in decreased expression of SERPINE1 protein
[Simvastatin co-treated with Dexamethasone] results in increased secretion of SERPINE1 protein
Simvastatin results in decreased activity of SERPINE1 protein
Simvastatin results in decreased secretion of SERPINE1 protein

PMID:16375908 PMID:16414398 PMID:17513194 PMID:21524281

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

sestrin 2

increases expression

Simvastatin results in increased expression of SESN2 mRNA

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

sestrin 3

decreases expression

Simvastatin results in decreased expression of SESN3 mRNA

NCBI chr 8:11,133,822...11,189,436
Ensembl chr 8:11,133,678...11,185,842

G

serum/glucocorticoid regulated kinase 2

multiple interactions

[Simvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose]; Simvastatin promotes the reaction [NR1I2 protein binds to SGK2 promoter]

NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480

G

solute carrier family 10 member 1

decreases expression

Simvastatin results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 38, member 4

increases expression

Simvastatin results in increased expression of SLC38A4 mRNA

NCBI chr 7:128,142,866...128,203,000
Ensembl chr 7:128,144,807...128,202,995

G

solute carrier family 6 member 4

increases activity

Simvastatin results in increased activity of SLC6A4 protein

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

SMAD family member 1

multiple interactions
increases expression
increases phosphorylation

Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]
Simvastatin results in increased expression of SMAD1 mRNA
Simvastatin results in increased phosphorylation of SMAD1 protein

PMID:18310456 PMID:20417880

NCBI chr19:28,513,130...28,573,665
Ensembl chr19:28,513,131...28,573,651

G

SMAD family member 2

decreases phosphorylation
increases expression
increases phosphorylation
multiple interactions

Simvastatin results in decreased phosphorylation of SMAD2 protein
Simvastatin results in increased expression of SMAD2 mRNA
Simvastatin results in increased phosphorylation of SMAD2 protein
FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD2 protein]

PMID:18310456 PMID:19659652 PMID:33034787

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

SMAD family member 3

increases expression
decreases phosphorylation
increases phosphorylation
multiple interactions

Simvastatin results in increased expression of SMAD3 mRNA
Simvastatin results in decreased phosphorylation of SMAD3 protein
Simvastatin results in increased phosphorylation of SMAD3 protein
FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD3 protein]

PMID:18310456 PMID:19659652 PMID:33034787

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

SMAD family member 5

multiple interactions

Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]

NCBI chr17:7,862,332...7,891,678
Ensembl chr17:7,864,720...7,891,634

G

SMAD family member 9

multiple interactions

Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]

NCBI chr 2:138,956,326...139,006,315
Ensembl chr 2:138,986,471...139,006,307

G

sorting nexin 17

decreases expression
multiple interactions

Simvastatin results in decreased expression of SNX17 mRNA
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of SNX17 mRNA

NCBI chr 6:25,177,528...25,183,001
Ensembl chr 6:25,177,391...25,183,030

G

sterol O-acyltransferase 1

increases expression

Simvastatin results in increased expression of SOAT1 mRNA

NCBI chr13:68,552,274...68,597,529
Ensembl chr13:68,552,317...68,597,494

G

suppressor of cytokine signaling 3

increases expression

Simvastatin results in increased expression of SOCS3 mRNA

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

suppressor of cytokine signaling 4

increases expression

Simvastatin results in increased expression of SOCS4 mRNA; Simvastatin results in increased expression of SOCS4 protein

NCBI chr15:20,523,406...20,537,889
Ensembl chr15:20,523,183...20,542,494

G

suppressor of cytokine signaling 7

increases expression

Simvastatin results in increased expression of SOCS7 mRNA

NCBI chr10:82,352,159...82,388,829
Ensembl chr10:82,351,680...82,388,830

G

superoxide dismutase 2

decreases expression

Simvastatin results in decreased expression of SOD2 mRNA

PMID:16414398 PMID:20883752

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

superoxide dismutase 3

multiple interactions

Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD3 mRNA]

NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990

G

Sp1 transcription factor

multiple interactions

Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

Sp7 transcription factor

multiple interactions
increases expression

CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA]
Simvastatin results in increased expression of SP7; Simvastatin results in increased expression of SP7 mRNA; Simvastatin results in increased expression of SP7 protein

PMID:20564244 PMID:22058016

NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847

G

spondin 2

increases expression

Simvastatin results in increased expression of SPON2 mRNA

NCBI chr14:77,505,695...77,518,001
Ensembl chr14:77,511,901...77,517,996

G

secreted phosphoprotein 1

decreases expression
increases expression

Simvastatin results in decreased expression of SPP1 mRNA
Simvastatin results in increased expression of SPP1 protein

PMID:12914771 PMID:14601315 PMID:21076490 PMID:21109955 PMID:22058016

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

sequestosome 1

multiple interactions

[Simvastatin co-treated with Metformin] results in decreased expression of SQSTM1 protein; Chloroquine inhibits the reaction [[Simvastatin co-treated with Metformin] results in decreased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

increases localization
decreases expression

Simvastatin results in increased localization of SREBF1 protein
Simvastatin results in decreased expression of SREBF1 mRNA

PMID:17655842 PMID:25055962

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

sterol regulatory element binding transcription factor 2

multiple interactions
increases expression

Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]]; Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]
Simvastatin results in increased expression of SREBF2 protein modified form
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of SREBF2 mRNA]; Simvastatin results in increased activity of and results in increased localization of SREBF2 protein

PMID:12056585 PMID:14500290 PMID:20018177

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

steroidogenic acute regulatory protein

increases expression
multiple interactions

Simvastatin results in increased expression of STAR mRNA
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of STAR mRNA

PMID:24524197 PMID:25055962

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 1

multiple interactions
decreases expression
decreases activity
decreases phosphorylation

Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of STAT1 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of STAT1 mRNA]
Simvastatin results in decreased expression of STAT1 mRNA
Simvastatin results in decreased activity of STAT1 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of STAT1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of STAT1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of STAT1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of STAT1 protein]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased phosphorylation of STAT1 protein]
Simvastatin results in decreased expression of STAT1 mRNA; Simvastatin results in decreased expression of STAT1 protein
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]

PMID:16534557 PMID:17507688 PMID:18453621 PMID:19886038 PMID:21268089

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 3

decreases activity
multiple interactions
affects expression
decreases phosphorylation

Simvastatin results in decreased activity of STAT3 protein
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of STAT3 protein]
Simvastatin affects the expression of STAT3 protein
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of STAT3 protein]

PMID:16534557 PMID:17507688 PMID:18400235 PMID:18453621 PMID:19100119 More...

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

signal transducer and activator of transcription 5A

affects expression

Simvastatin affects the expression of STAT5A protein

NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866

G

signal transducer and activator of transcription 6

affects expression

Simvastatin affects the expression of STAT6 protein

NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495

G

serine/threonine kinase 11

increases phosphorylation

Simvastatin results in increased phosphorylation of STK11 protein

NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315

G

TGF-beta activated kinase 1/MAP3K7 binding protein 1

multiple interactions

Simvastatin results in decreased activity of [MAP3K7 protein co-treated with TAB1 protein]

NCBI chr 7:111,675,829...111,707,058
Ensembl chr 7:111,686,371...111,707,058

G

TRAF family member-associated NFKB activator

multiple interactions

[Lipopolysaccharides co-treated with Simvastatin] results in increased expression of TANK mRNA

NCBI chr 3:46,114,230...46,190,270
Ensembl chr 3:46,114,274...46,190,264

G

thromboxane A synthase 1

decreases expression
increases expression

Simvastatin results in decreased expression of TBXAS1 mRNA
Simvastatin results in increased expression of TBXAS1 mRNA

PMID:16414398 PMID:20659230

NCBI chr 4:67,664,963...67,837,096
Ensembl chr 4:67,665,007...67,837,096

G

TEK receptor tyrosine kinase

multiple interactions
increases expression

Simvastatin inhibits the reaction [Streptozocin results in increased expression of TEK mRNA]; Simvastatin results in increased expression of and results in increased activity of TEK protein
Simvastatin results in increased expression of TEK; Simvastatin results in increased expression of TEK mRNA

PMID:18544044 PMID:20821229

NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804

G

transferrin

multiple interactions

Simvastatin inhibits the reaction [TNF results in increased expression of TF]

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

transferrin receptor

affects expression

Simvastatin affects the expression of TFRC protein

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor, beta 1

multiple interactions
increases expression
increases activity
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein]
Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]
Simvastatin results in increased expression of TGFB1 mRNA
Simvastatin results in increased activity of TGFB1 protein
Simvastatin results in decreased expression of TGFB1 mRNA; Simvastatin results in decreased expression of TGFB1 protein

PMID:15298857 PMID:15677772 PMID:15855201 PMID:16320597 PMID:19080365 More...

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta receptor 2

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of TGFBR2 mRNA]
Simvastatin results in decreased expression of TGFBR2 mRNA

PMID:16320597 PMID:16373842

NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228

G

thrombomodulin

increases expression
multiple interactions

Simvastatin results in increased expression of THBD mRNA; Simvastatin results in increased expression of THBD protein
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of THBD mRNA]

PMID:14630613 PMID:16375908 PMID:20493886 PMID:20737288

NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193

G

thrombospondin 1

decreases expression

Simvastatin results in decreased expression of THBS1 mRNA

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

TIMP metallopeptidase inhibitor 1

multiple interactions
decreases expression

Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP1 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP1 mRNA]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of TIMP1 mRNA]

PMID:16414398 PMID:20137537 PMID:22022327

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

TIMP metallopeptidase inhibitor 2

multiple interactions
decreases expression

Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP2 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP2 mRNA]

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

G

toll-like receptor 2

increases expression
multiple interactions

Simvastatin results in increased expression of TLR2 protein
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 protein]

PMID:16387846 PMID:16443229

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

toll-like receptor 4

increases expression
decreases expression
multiple interactions

Simvastatin results in increased expression of TLR4 protein
Simvastatin results in decreased expression of TLR4 mRNA; Simvastatin results in decreased expression of TLR4 protein
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]

PMID:16387846 PMID:16443229 PMID:19166837

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

transmembrane 7 superfamily member 2

increases expression

Simvastatin results in increased expression of TM7SF2 mRNA

NCBI chr 1:203,355,930...203,360,287
Ensembl chr 1:203,355,931...203,360,270

G

tenascin C

decreases expression

Simvastatin results in decreased expression of TNC mRNA

NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624

G

tumor necrosis factor

multiple interactions
increases expression
decreases activity
decreases expression
increases secretion
decreases secretion
affects secretion

geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in decreased expression of PLAT]; Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]; Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGAL]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGB2]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of TF]; Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased localization of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased localization of RELA protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CXCL8 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of MMP9 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [TNF results in increased expression of MMP9 mRNA]; Simvastatin promotes the reaction [TNF results in increased expression of PPARA]
Simvastatin results in increased expression of TNF mRNA
1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; [Lipopolysaccharides co-treated with Simvastatin] results in increased expression of and results in increased secretion of TNF protein; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased secretion of TNF protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Acrolein results in increased secretion of TNF protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of NOS2 mRNA]
Simvastatin results in decreased activity of TNF; Simvastatin results in decreased activity of TNF protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Guanidines inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL15 mRNA]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]
Simvastatin results in decreased expression of TNF mRNA; Simvastatin results in decreased expression of TNF protein
Simvastatin results in increased secretion of TNF protein
Simvastatin results in decreased secretion of TNF protein
Simvastatin affects the secretion of TNF protein

PMID:10946302 PMID:12117737 PMID:12615677 PMID:12753293 PMID:12829860 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 11B

increases expression

Simvastatin results in increased expression of TNFRSF11B mRNA

NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538

G

TNF receptor superfamily member 1A

decreases expression

Simvastatin results in decreased expression of TNFRSF1A mRNA

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

TNF receptor superfamily member 1B

decreases expression

Simvastatin results in decreased expression of TNFRSF1B mRNA

NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206

G

TNF receptor superfamily member 4

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]
Simvastatin results in decreased expression of TNFRSF4 mRNA; Simvastatin results in decreased expression of TNFRSF4 protein

NCBI chr 5:166,606,909...166,609,599
Ensembl chr 5:166,606,909...166,609,599

G

TNF superfamily member 10

multiple interactions
increases response to substance

[Simvastatin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]
TNFSF10 protein results in increased susceptibility to Simvastatin

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 4

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]
Simvastatin results in decreased expression of TNFSF4 mRNA; Simvastatin results in decreased expression of TNFSF4 protein

NCBI chr13:73,723,329...73,746,809
Ensembl chr13:73,723,329...73,746,788

G

troponin I3, cardiac type

multiple interactions

Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein]

NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580

G

tumor protein p53

multiple interactions
increases phosphorylation
increases expression

pifithrin inhibits the reaction [Simvastatin results in increased expression of TP53 protein]; Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter]; Simvastatin results in increased expression of and results in increased phosphorylation of TP53 protein
Simvastatin results in increased phosphorylation of TP53 protein
Simvastatin results in increased expression of TP53 mRNA; Simvastatin results in increased expression of TP53 mutant form; Simvastatin results in increased expression of TP53 protein

PMID:15625077 PMID:18804536 PMID:20045437 PMID:21199873

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein, translationally-controlled 1

decreases expression

Simvastatin results in decreased expression of TPT1 protein

NCBI chr15:51,156,728...51,159,629
Ensembl chr15:51,146,154...51,159,625

G

TNFRSF1A-associated via death domain

decreases expression

Simvastatin results in decreased expression of TRADD mRNA

NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638

G

Tnf receptor-associated factor 2

decreases expression

Simvastatin results in decreased expression of TRAF2 mRNA

NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538

G

tripartite motif containing 63

increases expression
multiple interactions

Simvastatin results in increased expression of TRIM63 mRNA
FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]
Simvastatin results in increased expression of TRIM63 mRNA; Simvastatin results in increased expression of TRIM63 protein

PMID:19001041 PMID:27734117 PMID:33034787

NCBI chr 5:146,533,492...146,547,332
Ensembl chr 5:146,533,507...146,547,322

G

thioredoxin reductase 1

decreases expression

Simvastatin results in decreased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

thymidylate synthetase

decreases expression

Simvastatin results in decreased expression of TYMS mRNA; Simvastatin results in decreased expression of TYMS protein

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

vasodilator-stimulated phosphoprotein

decreases phosphorylation

Simvastatin results in decreased phosphorylation of VASP protein

NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061

G

vascular cell adhesion molecule 1

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]; Simvastatin promotes the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in decreased expression of VCAM1 protein]; Simvastatin promotes the reaction [ethinyl estradiol-desogestrel combination results in decreased expression of VCAM1 protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of VCAM1 protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of VCAM1 protein modified form]
Simvastatin results in decreased expression of VCAM1 mRNA; Simvastatin results in decreased expression of VCAM1 protein; Simvastatin results in decreased expression of VCAM1 protein modified form

PMID:10946302 PMID:14602771 PMID:15234187 PMID:17105841 PMID:17169357 More...

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vinculin

affects localization

Simvastatin affects the localization of VCL protein

NCBI chr15:3,265,776...3,355,586
Ensembl chr15:3,265,815...3,355,606

G

voltage-dependent anion channel 1

decreases expression

Simvastatin results in decreased expression of VDAC1 protein

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

G

vitamin D receptor

increases expression

Simvastatin results in increased expression of VDR mRNA

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

G

vascular endothelial growth factor A

multiple interactions
decreases expression
increases expression
increases secretion

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; HIF1A mutant form inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of VEGFA protein]
Simvastatin results in decreased expression of VEGFA protein
Simvastatin results in increased expression of VEGFA; Simvastatin results in increased expression of VEGFA mRNA
Simvastatin results in increased secretion of VEGFA protein
Simvastatin results in increased expression of VEGFA mRNA; Simvastatin results in increased expression of VEGFA protein
Simvastatin inhibits the reaction [Glucose results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of VEGFA protein]

PMID:15572054 PMID:16424782 PMID:17277159 PMID:18316203 PMID:18356691 More...

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

decreases expression

Simvastatin results in decreased expression of VIM protein

PMID:14973129 PMID:15855201

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

von Willebrand factor

increases expression

Simvastatin results in increased expression of VWF mRNA; Simvastatin results in increased expression of VWF protein

NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539

G

Wnt family member 4

multiple interactions
increases expression

Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT4 mRNA]
Simvastatin results in increased expression of WNT4 protein

NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859

G

Wnt family member 5A

multiple interactions
increases expression

Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT5A mRNA]
Simvastatin results in increased expression of WNT5A mRNA; Simvastatin results in increased expression of WNT5A protein

PMID:18004065 PMID:19968183

NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234

G

X-box binding protein 1

decreases expression

Simvastatin results in decreased expression of XBP1 protein

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

X-linked inhibitor of apoptosis

decreases expression

Simvastatin results in decreased expression of XIAP mRNA; Simvastatin results in decreased expression of XIAP protein

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

tiamulin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

tiamulin results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

troleandomycin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

Troleandomycin inhibits the reaction [ABCB1 protein results in increased secretion of fluorexon]; Troleandomycin inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]
Troleandomycin inhibits the reaction [ABCB1A protein results in increased secretion of fluorexon]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
decreases activity
increases expression
increases activity

[Troleandomycin results in decreased activity of CYP3A4 protein] which results in decreased chemical synthesis of N-desmethyltamoxifen; [Troleandomycin results in decreased activity of CYP3A4 protein] which results in decreased metabolism of Tamoxifen; Troleandomycin inhibits the reaction [CYP3A4 protein results in decreased methylation of adinazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Cholecalciferol]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of Fluoxetine]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of laquinimod]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of triflumuron]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased oxidation of Methylenebis(chloroaniline)]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased oxidation of Nifedipine]; Troleandomycin promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; Troleandomycin results in increased expression of and results in increased activity of CYP3A4 protein
Troleandomycin results in increased expression of CYP3A4 mRNA
Troleandomycin results in increased activity of CYP3A4 protein

PMID:1740010 PMID:2271712 PMID:9512926 PMID:9600717 PMID:11409940 More...

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression

Troleandomycin results in increased expression of CYP3A23-3A1 mRNA

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions
decreases activity

Troleandomycin inhibits the reaction [CYP3A5 protein affects the metabolism of Alfentanil]
Troleandomycin results in decreased activity of CYP3A5 protein

PMID:15557344 PMID:15731592

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

fibronectin 1

increases expression

Troleandomycin results in increased expression of FN1 mRNA

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

glutathione S-transferase alpha 2

increases expression

Troleandomycin results in increased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

mucosal vascular addressin cell adhesion molecule 1

multiple interactions

Troleandomycin inhibits the reaction [TNF protein results in increased expression of MADCAM1 protein]

NCBI chr 7:10,036,301...10,039,703
Ensembl chr 7:10,036,301...10,039,703

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

Troleandomycin binds to and results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

tumor necrosis factor

multiple interactions

Troleandomycin inhibits the reaction [TNF protein results in increased expression of MADCAM1 protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19890
chemical entity	19867
atom	19888
nonmetal atom	19789
carbon atom	19743
organic molecular entity	19743
semisynthetic derivative	1648
21-deoxyconcanamycin A	0
21-phosphorifampicin	0
3-aza-A-homocholest-4a-en-4-one	0
6'-O-acetylpaeoniflorin	0
6-bromoharmine	0
GM 193663	0
KT 5720	43
N(2)-methylharmine	0
N-butylharmine	0
N-ethylharmine	0
O-(chloroacetylcarbamoyl)fumagillol	10
SH-11037	0
TX-1875	0
anidulafungin	0
artemether	3
artesunate	80
azlocillin	0
caspofungin +	1
cefaloridine	485
cefalotin +	15
cefamandole +	0
cefatrizine	0
cefazedone	0
cefotiam +	2
cefoxitin	13
cefprozil	0
cephalexin +	2
clindamycin +	5
clometocillin	0
cloxacillin	5
dalbavancin	0
dihydroergotamine +	12
emodepside	0
eprinomectin component B1a +	4
eprinomectin component B1b +	4
flurithromycin	0
leucascandrolide A congener	0
oritavancin +	0
oxycodone	165
penamecillin	0
retaspimycin	0
ridaforolimus	7
rifampicin +	404
rifaximin	22
roxithromycin +	14
rubitecan	17
statin (semi-synthetic) +	807
tiamulin	1
troleandomycin	9
vinflunine	0
Path 2
Term	Annotations
CHEBI ontology	19890
subatomic particle	19867
composite particle	19888
hadron	19888
baryon	19888
nucleon	19867
atomic nucleus	19888
atom	19888
main group element atom	19806
p-block element atom	19806
carbon group element atom	19746
carbon atom	19743
organic molecular entity	19743
semisynthetic derivative	1648
21-deoxyconcanamycin A	0
21-phosphorifampicin	0
3-aza-A-homocholest-4a-en-4-one	0
6'-O-acetylpaeoniflorin	0
6-bromoharmine	0
GM 193663	0
KT 5720	43
N(2)-methylharmine	0
N-butylharmine	0
N-ethylharmine	0
O-(chloroacetylcarbamoyl)fumagillol	10
SH-11037	0
TX-1875	0
anidulafungin	0
artemether	3
artesunate	80
azlocillin	0
caspofungin +	1
cefaloridine	485
cefalotin +	15
cefamandole +	0
cefatrizine	0
cefazedone	0
cefotiam +	2
cefoxitin	13
cefprozil	0
cephalexin +	2
clindamycin +	5
clometocillin	0
cloxacillin	5
dalbavancin	0
dihydroergotamine +	12
emodepside	0
eprinomectin component B1a +	4
eprinomectin component B1b +	4
flurithromycin	0
leucascandrolide A congener	0
oritavancin +	0
oxycodone	165
penamecillin	0
retaspimycin	0
ridaforolimus	7
rifampicin +	404
rifaximin	22
roxithromycin +	14
rubitecan	17
statin (semi-synthetic) +	807
tiamulin	1
troleandomycin	9
vinflunine	0

paths to the root